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Abstract 
 
 Analyzing protein tertiary structure is an effective method to understanding 
protein function. In my thesis study, I aimed to understand how surface features 
of protein can affect the stability and specificity of enzymes. I focus on 2 proteins 
that are involved in human disease, Profilin (PFN1) and APOBEC3A (A3A). 
When these proteins are functioning correctly, PFN1 modulates actin dynamics 
and A3A inhibits retroviral replication. However, mutations in PFN1 are 
associated with amyotrophic lateral sclerosis (ALS) while the over expression of 
A3A are associated with the development of cancer. Currently, the pathological 
mechanism of PFN1 in this fatal disease is unknown and although it is known 
that the sequence context for mutating DNA vary among A3s, the mechanism for 
substrate sequence specificity is not well understood.  
 
 To understand how the mutations in Profilin could lead to ALS, I solved the 
structure of WT and 2 ALS-related mutants of PFN1. Our collaborators 
demonstrated that ALS-linked mutations severely destabilize the native 
conformation of PFN1 in vitro and cause accelerated turnover of the PFN1 
protein in cells. This mutation-induced destabilization can account for the high 
propensity of ALS-linked variants to aggregate and also provides rationale for 
their reported loss-of-function phenotypes in cell-based assays. The source of 
this destabilization was illuminated by my X-ray crystal structures of several 
PFN1 proteins. I found an expanded cavity near the protein core of the 
destabilized M114T variant. In contrast, the E117G mutation only modestly 
perturbs the structure and stability of PFN1, an observation that reconciles the 
occurrence of this mutation in the control population. These findings suggest that 
a destabilized form of PFN1 underlies PFN1-mediated ALS pathogenesis.  
 
 To characterize A3A’s substrate specificity, we solved the structure of apo 
and bound A3A. I then used a systematic approach to quantify affinity for 
substrate as a function of sequence context, pH and substrate secondary 
structure. I found that A3A preferred ssDNA binding motif is T/CTCA/G, and that 
A3A can bind RNA in a sequence specific manner. The affinity for substrate 
increased with a decrease in pH. Furthermore, A3A binds tighter to its substrate 
binding motif when in the loop region of folded nucleic acid compared to a linear 
sequence. This result suggests that the structure of DNA, and not just its 
chemical identity, modulates A3 affinity and specificity for substrate. 
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Chapter I 
 
Introduction 
  
	
	2	
I.a. Approaches to elucidating the mechanism of biological 
processes  
Core strategies for understanding any biological process can be consolidated into 
three approaches: cellular biology, molecular biology, and biochemistry (Figure I.1). 
Cellular biology focuses on the different functions of cells and organelles within a cell 
that are involved in a particular biological process in an organism. Molecular biology 
includes techniques that study the effects of gain-of-function and loss-of-function 
mutants of genes that play a role in biological processes. Biochemical approaches 
include elucidating the structure and function of biomolecules, as well as how the 
functions of these biomolecules affect biological processes.  
A comprehensive elucidation of a biological process is necessary for a solid 
foundation for determining the mechanism of disease and designing therapies. For 
instance, combining the three core approaches explained above was essential to 
understanding the causes of cancer and ALS, which will be described in more detail 
below. This thesis explains how studying the structure and function of two different 
proteins lead to a better understanding of their role in biological processes. Results from 
this thesis not only demonstrate that biochemistry is a key component to a 
comprehensive understanding of biological malfunctions that ultimately lead to disease, 
but also build a foundation from which to design new and innovated therapies for fALS 
caused by PFN1 mutants and APOBEC3-induced cancers.  
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Figure I.1: A comprehensive elucidation of a biological process. 
A combination of cellular, molecular, and biochemical approaches can be 
used to elucidate biological processes. Each approach focuses on the 
functions of cells, genes, or biomolecules involved in a particular process.  
 
	
	4	
I.b. Human Cytidine Deaminases 
I.b.1. Activity of human cytidine deaminases in the cell 
I.b.1.i. Initial elucidation of APOBEC3 activity  
The APOBEC3 (A3) family was first discovered through gene database studies 
as APOBEC1-like genes, but the function of the gene products had not yet been 
elucidated (1). Soon after, APOBEC3G gene was found to be expressed in primary 
human T cells, the target cell type for HIV, and other permissive cells. When A3G was 
over-expressed in permissive cells, A3G rendered Vif-deficient HIV non-infectious. 
Thus, APOBEC3G gene was first identified as an anti-HIV factor (2). With further HIV 
focused studies, A3G was shown to deaminate cytidines in single stranded (ss) DNA 
intermediate of replicating HIV genomes (3, 4).   
Eventually all members of the A3 family of cytidine deaminases were found to 
restrict replication of retroviruses and retrotransposons by inducing hypermutations in 
the viral genome (Fig I.2)(2, 3, 5-9). A3 enzymes deaminate the cytidines in the ssDNA 
intermediate into uridines during reverse transcription. During second strand DNA 
synthesis, adenosines are transcribed across from uridines, resulting in G to A 
hypermutations. Proteins and proviruses produced from this hyper-mutated viral 
genome will be defective, thus preventing further viral replication (10).  
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Figure I.2: APOBEC3s deaminate cytidines in ssDNA. 
A	schematic	of	G	to	A	mutation	catalyzed	by	APOBEC3s.	Gray	ribbons	represent	DNA.	
Green	nucleotides	represent	normal	progression	of	complimentary	strand	synthesis	
in	the	absence	of	A3.	Red	nucleotides	represent	nucleotide	change	in	the	presence	
of	A3	protein.	
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I.b.1.ii. Functions of APOBEC3 beyond retroviral restriction  
Besides inhibiting retroviruses and retroelements, as described above, A3s also 
restricts DNA viruses. A3s can restrict nuclear replicating ssDNA viruses such as 
adeno-associated virus (11). A3s can also restrict nuclear and dsDNA viruses such as 
hepatitis B virus, herpes viruses and HPV (12-15). 
 A3s mediate the clearance of foreign DNA from monocytes and macrophages. 
In particular, A3A, which is primarily expressed in phagocytic cells compared to other 
cell types, was found to deaminate exogenous DNA, creating a substrate for UNG2-
mediated excision while managing to leave genomic DNA intact (16, 17). A3A is also 
the most efficient at deaminating methylated cytidine compared to other deaminases 
such as A3G or AID, giving A3A the unique ability to clear methylated foreign DNA from 
the cell (18-20).  
A3G was discovered to promote double strand break (DSB) repair through 
studying cancer cells that express high levels of A3G. Poor survival rates for patients 
undergoing chemotherapy for lymphoma and glioblastoma were found to correlate with 
having cancer cells that over-expressed the A3G gene (21-23). Through studying 
lymphoma cells, A3G was found to be transiently recruited to the nucleus and 
accumulate at DSB sites after irradiation. A3G can directly promote DSB repair through 
its enzymatic activity by deaminating cytidines in resected ssDNA, which may lead to 
recruitment of repair factors such as base-excision repair proteins. A3G can also 
contribute to DSB repair through its ability to simultaneously bind two 3’ ssDNA ends, 
promoting ssDNA end joining (24). 
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I.b.1.iii.	Other members of the human APOBEC superfamily 
The APOBEC super family of human cytidine deaminases consists of APOBEC1 
(A1), APOBEC2 (A2), subfamily APOBEC3 (A3), APOBEC4 (A4) and activation induced 
cytidine deaminase (AID). Besides the A3 subfamily, A1 and AID are the most well-
studied within the APOBEC superfamily. The physiological function for the remaining 
APOBEC proteins, A2 and A4, has remained elusive. Both A2 and A4 have not yet 
been shown to be catalytically active (25-27). A2 is primarily expressed in heart and 
skeletal muscle while A4 expression in humans has not been detected (25).  
A1 modulates lipid metabolism and transport in the small intestine by editing the 
mRNA of apoB protein (28, 29). A1 deaminates specifically one cytidine in apoB mRNA, 
C6666, creating a premature stop codon yielding a truncated apoB protein. This 
truncated apoB protein is essential for proper transport of dietary lipids from the 
intestines to other locations in the body (30-32). 
AID plays an essential role in adaptive immunity, regulating antibody maturation 
and diversification in activated B cells (33). AID catalyzes the diversification in the 
sequence of immunoglobulin genes through three pathways:  somatic hypermutation, 
gene conversion, and class switch recombination (34, 35). All three pathways are the 
consequences of AID’s cytidine deaminate activity in ssDNA of antibody and 
immunoglobulin genes(36). 
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I.b.2. Consequences of mis-regulated cytidine deamination activity  
The ability of those APOBECs that deaminate cytidines in DNA, such as the 
APOBEC3 subfamily and AID, has made them a double-edged sword. If not properly 
regulated, DNA-editing APOBECs that also have access to the nucleus have the 
potential to deaminate self-genome, which may instigate cancer. In the APOBEC3 
family, A3B and A3H localizes to the nucleus, while A3A and A3G are transiently 
recruited to the nucleus (24, 37-39). When overexpressed, A3B and A3H have been 
described as a major endogenous source for mutations in various types of human 
cancer, such as breast, bladder, head and neck, cervical, and lung cancer (39-41). Like 
A3B and A3H, AID localizes to the nucleus and when overexpressed can lead to 
cancer, as seen in non-Hodgkin B cell lymphomas (42, 43). 
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Figure I.3 Functions and malfunctions of the ssDNA deaminating 
APOBECs. 
Schematic of the effects deaminating deoxycytidine into deoxyuridine 
by ssDNA APOBECs. Green arrows represent functions in the cell 
APOBEC family helps promote or inhibit. Red arrow represents the 
consequence of over-expression of A3/AID. 
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I.b.3 Enzymology of human ssDNA deaminating APOBECs 
I.b.3.i Comparison of human ssDNA-deaminating APOBEC protein structures. 
Considering the similarities of functions and mis-functions between the seven A3 
proteins and AID, the remainder of this introduction will focus on these eight proteins. 
Each protein in the A3 subfamily contains either one or two zinc-coordinating (Z) 
domains (Figure I.4.A) (44). These A3 Z domains are separated into three distinct 
phylogenetic groups (Z1, Z2, and Z3) (Figure I.4.B)(45). A3A (Z1), A3C (Z2), and A3H 
(Z3) are comprised of a single cytidine deaminase Z domain while A3B, A3D, A3F, and 
A3G contain both an N-terminal pseudo-catalytic Z domain (all Z2), and a catalytically 
active C-terminal Z domain (Z1, Z2, Z2, and Z1 respectively)(46). Adding to the 
complexity, A3H has seven haplotypes with varying stability and enzymatic efficiency 
(47). AID is a single protein that consists of one catalytically active zinc-coordinating 
domain (48). Comparing available structures of zinc-coordinating domains of human 
ssDNA deaminating APOBECs, it is clear that they share a conserved overall fold 
(Figure II.5).   
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Figure I.4: APOBEC3 family of cytidine deaminases. 
A. Schematic of the seven human APOBEC3s. N-terminal and C-terminal 
domains are shown as ovals. B. Phylogenic tree of A3 Z domains. Active 
domains are marked with an orange star. Z1 domains are in red, Z2 domains 
are in blue, and Z3 domain is in green. 
	
	
	12	
  
 
 
 
Figure I.5 Structures of all human ssDNA deaminating APOBECs 
domains determined to date.   
Cartoon representation of all human apo ssDNA deaminating APOBEC 
domain crystal or NMR structures determined. Z1 domains are shown in red, 
Z2 are in blue, and AID is in purple. Zinc is depicted as orange spheres. 
Starred (*) PDB IDs denote structures solved by the Schiffer lab. 
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I.b.3.ii The active sites of ssDNA cytidine deaminases are highly conserved. 
Although human cytidine deaminases play different roles in the cell, the 
mechanism of deaminating cytidine is conserved between these enzymes. These 
enzymes deaminate cytidine into uridine by catalyzing the exchange of the NH2 group to 
oxygen on cytidine bases (Figure I.8.A). Deamination of cytidine is carried out by a 
glutamate in the active site pocket of these proteins, along with a coordinated zinc and 
water molecule (Figure I.6 and I.7B). The coordination of zinc atom and water molecule 
in the active site results in one zinc hydroxide. 
Sequence alignment of all catalytically active domains of ssDNA deaminating 
APOBECs reveal residues necessary for catalysis such as the catalytic glutamate and 
zinc coordinating residues are 100% identical in all domains (green diamonds and 
yellow star; Figure I.6). Two residues vary within the active site cavity, and the four 
loops that surround the active site vary in sequence and length (Fig 6a), which are likely 
determinants of specificity. Putative residues responsible for substrate binding reside in 
Loops 1, 3, 5, and 7. Homology within these loops vary (red dashed boxes; Figure I.6). 
Homologous residues are displayed on the crystal structure of A3A reveal most 
identical residues are internal to protein structure (Figure I.7A). These residues may be 
important for the structural similarities found in all APOBEC domains (Figure I.5). 
surface exposed 100% identical residues comprise of functional residues such as zinc 
coordination (Figure I.7B).  
Surface representation reveal mixed homology patches of localized patches on 
the surface of A3A (Figure I.7C). These patches may play a role in conserved and non-
conserved DNA binding properties, depending on the homology present in these 
	
	14	
patches. For example, surface view of A3A active site illustrates that the cytidine 
binding pocket is perfectly lined with mostly 100% identical residues (Figure I.7D). The 
non-identical pocket residues, loop1 T31(teal; T/S/A), loop 3 A71(marine; A/V), loop 5 
I96 (teal; (T/I/L), and loop 7 Y130 (marine; Y/F) are highly conserved. The minor 
differences in chemistry within the cytidine binding pocket play a role in the differences 
seen in catalytic efficiency between APOBEC enzymes, for instance, modulating the 
stability of APOBEC cytidine interactions that could affects rate of binding or catalysis.  
Loops that line the cytidine binding pocket are the least conserved part of APOBEC 
active site (Figure I.7D). Variations in loop length and chemistry may be responsible for 
the differences in APOBEC substrate sequence specificity. Further analysis of active 
site features of A3 will be discussed in Chapter 4.  
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Figure I.6: Sequence alignment of ssDNA cytidine deaminase proteins.  
Sequence alignment of human AID, and the seven members of the APOBEC3 
subfamily. Catalytic glutamate is denoted by orange star. Zinc coordinating 
residues are denoted with green diamonds. Identical residues highlighted in 
blue, residues 80-100% identical in light blue, 60-80% in teal. Active site loops 
are denoted by horizontal red lines. Residues that make up the active site 
pocket are highlighted with red dashed boxes.
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Figure I.7: Tertiary structure analysis highlight similarities in the active 
sites of ssDNA deaminating APOBECs.  
A. Cartoon view of A3A crystal structure highlighting the conservation of active 
domains of ssDNA deaminating APOBECs shown in Fig I.6. 
B. Example that highly conserved residues are important for structural and 
function components of APOBEC proteins. Residues responsible for zinc 
coordination necessary for catalysis are 100% conserved and shown as sticks. 
C. Surface view of A3A illustrating location of conserved residues on protein 
surface. D 180 rotation of C reveals the active site of A3A highlighted with a 
light orange box. The cytidine binding pocket is highly conserved between 
APOBEC proteins. Loops proposed to be responsible for ssDNA binding, 
labeled with red circles, are not conserved. Zinc shown as light orange sphere. 
Identical residues highlighted in blue, residues 80-100% identical in marine, 60-
80% in teal. 
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I.b.3.iii Conserved mechanism of cytidine deamination 
When a cytidine is coordinated properly within the active site, the oxygen of the 
zinc hydroxide molecule can make a nucleophilic attack on the C6 carbon of the cytidine 
base. The N3 nitrogen of the base may then be protonated by the OE1 oxygen of the 
catalytic glutamate. The hydrogen from newly activated zinc hydroxide group is then 
passed to the OE2 oxygen of the catalytic glutamate, which gets transferred to the NH2 
group of the cytidine base, creating the leaving NH3 group. When ammonia is released 
from the cytidine base, the active site can be reset with the introduction of a new water 
molecule. This new water molecule allows for deprotonation by the carboxylate group of 
the catalytic glutamate to form the conserved zinc-water coordination necessary for 
another round of catalysis (Figure I.8B) (49, 50). Recognition of cytidine by the catalytic 
pocket of A3 proteins will be explored in Chapter III and the Discussion section of this 
thesis.  
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Figure I.8: Deamination reaction mechanism 
A. Schematic of deoxy-cytidine conversion to deoxy-uridine by ssDNA cytidine 
deaminases. Leaving NH2 group of cytidine base is in green, added oxygen is 
in red. Cytidine deaminase is depicted as gray cartoon.  
B. Schematic of the steps of deamination by cytidine deaminases. 
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I.b.4. Substrate specificity of human ssDNA deaminating APOBECs  
While all A3 and AID enzymes deaminate cytidines in ssDNA, and have a 
conserved catalytic site and overall fold, they have different preferences for substrate 
sequence motifs. A3s and AID prefer to deaminate the second cytidine in either CC or 
TC dinucleotide motifs (16, 51-55). Additionally, sequence analysis has determined that 
not every cognate dinucleotide motif is deaminated (39, 56-59) (Table II.1). Further 
elucidation of A3 sequence specificity will be explored in Chapter IV and in the 
Discussion section of this thesis.  
Structures of A3s alone have not led to an explanation for the differences in 
sequence specificity between A3s. Since A3s and AID active domains share an overall 
fold, major structural features cannot be responsible for differences in specificity. The 
catalytic site residues of these enzymes are also highly conserved (Figure II.7A). Thus, 
it is unclear which residues of the active site (Figure II.7B) are responsible for the 
differences in sequence specificity among AID and A3s.  
Secondary structure of substrate DNA may also play a role in A3/AID specificity. 
A3s and AID are not capable of deaminating cytidines within a duplex of DNA (60-62). 
A3s and AID can only deaminate cytidines in ssDNA near duplex DNA or in the loop 
region of hairpin DNA(51, 60).  
Environmental factors have been shown to also affect the efficiency of cytidine 
deamination. In particular, pH modulates the activity for some ssDNA deaminase 
including A3A and A3G, but not others (63-65). Whether the sequence preference for 
deamination is due to direct interaction with ssDNA substrate or other factors that inhibit 
APOBECs such as secondary structure of substrate is still not clear (58, 60, 66). 
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Chapter III, Chapter IV and the Discussion section attempts to clarify the roles of 
protein, DNA, and environmental contributions to the affinity and specificity of ssDNA 
cytidine deaminases, with a focus on A3A. 
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Table I.1. Consensus sequence for deamination activity of human AID 
and APOBEC proteins. 
	
	
 Consensus Sequence 
AID          (A/T)(A/G)C(A/C/T) 
A3A TTCA 
A3B  ATCA 
A3C TC 
A3D TC 
A3F      TTC(A/T) 
A3G   (C/T)CC(A/C/T) 
A3H TCA 
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I.b.5. Scope of thesis part 1.  
This thesis attempts to fill the gaps in the substrate sequence dependence of A3A 
affinity to ssDNA (Figure I.9). First, I investigate specific binding of A3A to ssDNA using 
biochemical data combined with analysis of a novel crystal structure of apo A3A 
(Chapter II). Next, I elucidate the structural basis and mechanism of A3A ssDNA 
recognition through analysis of the first crystal structure of A3A in complex with ssDNA. 
With this structure, I also pinpoint residues that confer A3A specificity for CC/TC motifs 
(Chapter III). Finally, I identify A3A’s ssDNA binding motif as (T/C)TC(A/G), and find 
binding affinity correlates with enzymatic activity, validate that A3A binds RNA in a 
sequence specific manner, and determine that A3A binds tighter to its substrate binding 
motif when in a loop compared to linear oligonucleotide (Chapter IV). I also discuss how 
revealing the structural and biochemical mechanism of A3A’s sequence specificity can 
be applied to the substrate recognition by other A3s, and designing cancer therapies in 
Chapter V. 
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Figure I.9: Elucidating the substrate sequence dependence of A3A 
affinity to ssDNA. 
	
	
	25	
I.c. Human Profilin 1 
I.c.1. Activity of human Profilin 1 in the cell: modulator of actin 
polymerization 
Profilin 1 (PFN1) is an evolutionary conserved protein that is expressed in all 
tissue types besides skeletal muscle (67, 68). The most well studied biochemical 
function for PFN1 is its regulation of actin polymerization (68-70).The ability to modulate 
actin dynamics, along with its ubiquitous expression, allows PFN1 to play a role in a 
variety of cellular processes such as endocytosis, membrane trafficking, cell motility, 
and neuronal growth and differentiation (71).  
In the absence of PFN-1, ATP-bound monomeric G-actin can bind to one another 
to form stable oligomers. These tetramers act as seeds for the assembly of actin 
filaments (F-actin) (Figure I.10). Toward the minus end of F-actin, actin converts the 
bound ATP into ADP. These ADP-bound actin molecules have lower affinity for F-actin 
and are released from the minus end of F-actin. G-actin released from F-actin 
eventually exchange ADP for ATP, allowing for ATP-bound G-actin to form new seeds 
or to get incorporated into the plus end of an elongating actin filament.  
PFN1 can modulate actin polymerization in three ways, all of which rely on 
PFN1’s ability to bind monomeric actin and regulated by PFN1 protein concentration 
levels in the cell. When PFN1 protein concentration levels are high, PFN1 can inhibit 
actin polymerization by binding and thus sequestering monomeric G-actin. When PFN1 
protein levels are low, PFN1 can catalyze the release of ADP from G-actin monomers, 
allowing for faster turnover of ADP-bound G-actin into ATP-bound G-actin (Figure I 
.11). At low protein levels, PFN1 can also catalyze the elongation of actin filament by 
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simultaneously binding ATP-bound G-actin and other proteins that increase the rate of 
actin filament formation.  
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Figure I.10 Actin dynamics  
ATP bound actin also called G-actin (green cartoon) oligomerizes into a stable 
tetramer. This seed tetramer allows for nucleation to occurs with the addition 
G-actin monomers.  F actin filaments are formed by the addition of more G-
actin monomers to the barbed “+ end” of nucleated actin. Within the F actin 
filament G-actin hydrolyzes ATP (orange) into ADP (Gray) releasing Pi 
(phosphate shown in orange circle). ADP bound actin (pink cartoon) is then 
released from the pointed “- end”. ADP bound actin cannot be added to F- 
Actin filament until it exchanges ADP for ATP.  
	
	28	
  
 
 
Figure I.11 PFN1 can increase actin polymerization 
PFN1 (blue cartoon) can increase the rate of actin polymerization in two ways.  
1: PFN1 can bind to ADP bound actin, increasing the rate of exchange ADP 
for ATP, allowing a faster recycling of released actin from F-actin filaments. 
2: PFN1 can also simultaneously bind G-actin and other proteins in order to  
catalyze the elongation of actin filament. 
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I.c.2. Consequences of mutant Profilin 1: Amyotrophic Lateral 
Sclerosis 
I.c.2.i. Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic Lateral Sclerosis (ALS) is an incurable and fatal neurodegenerative 
disorder. In the United States alone, 30,000 individuals are living with ALS. The lifetime 
risk is 1:1,000 and male to female ratio is 3:2. ALS is a late onset disease; its peak 
onset is at 65 years of age for both males and females. Disease progresses quickly; 
there is about a fifteen percent survival rate after 80 months from the onset of 
symptoms. To date, there are only symptomatic and supportive treatments for this 
terminal disease.   
ALS is caused by progressive death of upper and lower motor neurons (72). The 
loss of motor neurons first results in impaired motor coordination, leading to paralysis 
and eventual respiratory failure. Initial clinical phenotype can vary, but most commonly 
displayed as spasticity, muscle atrophy, and trouble speaking/swallowing.  
Patients with ALS fall under two categories: sporadic (sALS) and familial (fALS). 
Those patients with no known family history of ALS are classified as sALS and make up 
90% all known cases. Of the 10% of patients with the inherited form of ALS, only 50% 
have known genetic etiology (73).  
The first gene associated with ALS, superoxide dismutase (SOD), is the most 
prevalent and well-studied gene. Within the past decade there has been over 20 other 
genes associated ALS (74). Most recently, single point mutants of PFN1 were found to 
be associated with ALS (75). 
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I.c.2.ii.. Single point mutations in PFN1 are associated with fALS 
Mutations in PFN1 protein were recently identified in both fALS and sALS 
patients (75, 76). The four single point PFN1 mutants identified, C71G, M114T, E117G, 
and G118V, range in pathogenicity. M114T, G118V, and C71G have a high propensity 
to aggregate in mammalian cultured cells, with C71G being the most aggregation prone.  
These three mutants were also shown to inhibit axon outgrowth. Although E117G was 
initially found in fALS patients, in-cell and in-vitro studies found E117G to be more 
wildtype-like. These findings suggested that PFN1 mutants cause ALS by modulating 
cytoskeletal pathway in neuronal cells. Since C71G is the most pathogenic of these 
mutants in patients, with the biggest change in aggregation potential and highest 
decrease in axon outgrowth, structural integrity of PFN1 mutants may be the root cause 
of pathogenicity.  
fALS point mutations localize to one area of the protein and are found in surface 
exposed loops as well as buried within the core of the protein (Figure III.12). The fact 
that the most pathogenic mutant, C71G, not only shows highest aggregation potential 
but is also located in the core of the protein strengthens the hypothesis that these 
mutants may modulate structural integrity of PFN1. Although this initial hypothesis 
seems promising, the mechanism associated with PFN1-mediated ALS pathogenesis 
has yet to be elucidated. Chapter V and the Discussion section of this thesis will attempt 
to address the role of PFN1 mutants on the development of ALS. 
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Figure III.12: Location of PFN1 mutations associated with ALS. 
	
	32	
I.c.3. Scope of thesis part 2. 
This thesis attempts to fill the gaps in the structural basis of single point mutations in 
PFN1 that lead to fALS. First, I identify and characterize structural differences of fALS-
linked PFN1 mutants, by solving the crystal structures of wild type PFN1, the low 
pathogenic PFN1 mutant E117G, and a fALS-linked PFN1 mutant, M114T. Next, I 
identify and describe a deep cavity expanding into the core of PFN1 M114T, but not in 
the wild type or the E117G structures that may be the source of destabilization for this 
fALS-linked mutant and may be an important factor in fALS-linked PFN1 mutant 
pathology. Finally I present preliminary modeling of a more unstable and severe fALS-
linked PFN1 mutant, C71G, which further supports the hypothesis that perturbation in 
the core of PFN1 is a common cause of instability for fALS caused by PFN1 mutants. 
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Chapter II 
 
The ssDNA Mutator APOBEC3A Is Regulated by 
Cooperative Dimerization 
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II.a.  Abstract 
Deaminase activity mediated by the human APOBEC3 family of proteins 
contributes to genomic instability and cancer. APOBEC3A is by far the most 
active in this family and can cause rapid cell death when overexpressed, but in 
general how the activity of APOBEC3s is regulated on a molecular level is 
unclear. In this study, the biochemical and structural basis of APOBEC3A 
substrate binding and specificity is elucidated. We find that specific binding of 
single-stranded DNA is regulated by the cooperative dimerization of APOBEC3A. 
The crystal structure elucidates this homodimer as a symmetric domain swap of 
the N-terminal residues. This dimer interface provides insights into how 
cooperative protein-protein interactions may affect function in the APOBEC3 
enzymes and provides a potential scaffold for strategies aimed at reducing their 
mutation load. 
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II.b. Introduction 
Several exogenous and endogenous factors act as mutagens, contributing 
to carcinogenesis. The APOBEC3 proteins have been described as a major 
endogenous source for mutations in various types of cancer. Acting on 
chromosomal DNA, the APOBEC3 family of cytidine deaminases can introduce 
G-to-A hypermutations, as observed in clusters of APOBEC3-mediated 
mutational signatures found in breast cancer genomes (3). APOBEC3B (A3B) 
was recently identified as a direct enzymatic source for this type of clustered 
mutation (4). In addition to breast cancer, several other cancers such as bladder 
cancer, head and neck cancer, cervical cancer, and lung cancer exhibit a similar 
genomic mutation pattern (5, 6). Urothelial bladder cancer exhibits the most 
pronounced contribution of APOBEC3-mediated hypermutations to the overall 
mutation load (8). In lung cancer, APOBEC3-induced genomic instability appears 
to increase over time as the tumor progresses (9). APOBEC3A (A3A) shares the 
same genomic locus as A3B but is much more catalytically active and potentially 
linked to breast cancer (10, 11). 
APOBEC3 proteins belong to a superfamily of deaminases and catalyze a 
cytidine to uridine zinc-dependent deamination reaction (12) (13). Common 
ancestry links the seven proteins of the contiguous human APOBEC3 locus (14) 
and allows classification based on phylogeny (15). A3A, A3C, and A3H comprise 
a single, catalytically active deaminase domain, whereas A3B, A3D, A3F, and 
A3G are two-domain proteins with an N-terminal pseudocatalytic deaminase 
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domain (NTD) and a C-terminal catalytic domain (CTD). The spatial extent of the 
substrate accommodating the active site region appears to be a determinant of 
whether a deaminase domain exhibits catalytic activity or not (16). The 
APOBEC3 proteins act on ssDNA to introduce strand-coordinated G-to-A point 
mutations. These mutations not only compromise the informational integrity of 
DNA but may also lead to double strand breaks (4, 17) contributing to genomic 
damage observed in the cancer genomes (18, 19). 
Four members of the APOBEC3 family (A3D, A3F, A3G, and A3H) apply 
strong selective pressure on HIV-1 in the absence of Vif (20-32). These proteins 
are incorporated into budding virions and, upon subsequent infection of a target 
cell, introduce point mutations in the newly reverse-transcribed viral genomic 
ssDNA, leading to direct degradation of the highly mutated product (33) or 
detrimental G-to-A mutations (23, 34). 
A3G and A3F form high molecular mass complexes with polynucleotides 
that are relevant for biological function (35, 36). The four antiretroviral APOBEC3 
proteins were recently demonstrated to form multimeric complexes in living cells 
(37). Over the last few years, atomic force microscopy (AFM) studies have 
provided insights into the mechanistic details influencing this complex formation 
(38-40). The crystal structures of A3C (41), A3F-CTD (42), and A3G-CTD (43-
45), and the nuclear magnetic resonance (NMR) structures of A3G-CTD (46, 47) 
and A3A (48) have provided further insights into the structural factors influencing 
this activity. However, significant details are still missing due to the lack of 
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APOBEC3-ssDNA complex structures that could illuminate the molecular basis of 
complex formation. 
The functional oligomerization state of A3 enzymes and whether or not 
cooperativity contributes to DNA binding affinity are not clear. The two-domain 
A3G binds ssDNA both as a monomer and dimer, but the dimerization is not 
induced by ssDNA binding (39), which is consistent with the observation that 
A3G binds its substrate noncooperatively (49, 50) with high affinity (KD ~ 50–75 
nM) (49, 51, 52). 
The single-domain A3A has been reported to be monomeric in vitro, in 
solution, as detected by AFM (40), as well as in living cells monitored by 
fluorescence fluctuation spectroscopy (FFS) (37). The binding affinity of 
catalytically active A3A to ssDNA substrate, compared with A3G, is reported to 
be lower by 100-fold (2, 48) or 50-fold (53), depending on the chosen 
experimental conditions. These reports are further complicated by the 
observation that catalytically active A3A is the most potent enzyme of the A3 
family, with deamination rates up to 10-fold above those of APOBEC3G (54). 
Catalytically inactive A3A, on the other hand, dimerizes readily on the target 
ssDNA substrate (40). However, catalytically inactive A3A can bind substrates 
with similar affinity as A3G (55). The fundamental reasons for these apparent 
discrepancies are not well understood. 
In this study, we explore the structural and biochemical basis underlying 
A3A ssDNA binding activity and the direct functional impact of cooperative 
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dimerization on binding affinity. We developed a novel fluorescence anisotropy-
based high-throughput binding assay, solved a high-resolution crystal structure, 
and generated a range of A3A mutants to demonstrate that catalytically inactive 
A3A binds ssDNA with high affinity and specificity while exhibiting a high degree 
of cooperativity. Cooperative dimerization of APOBEC3A provides fundamental 
insights into the function of the entire APOBEC3 family of proteins and their 
respective roles in anti-retroviral and anti-cancer therapies. 
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II.c. Results 
II.c.1. APOBEC3A Preferentially Binds the TTC Trinucleotide 
Sequence. 
APOBEC3 enzymes recognize target deamination site cytidines within the 
context of specific trinucleotide motifs. A binding assay was developed using 
short, fluorescently labeled 15-mer oligonucleotides with single target sites for 
deamination to quantitatively assess motif specificity. A catalytically inactive 
mutant of A3A (E72A/C171A) (Figure II.1A; Table II.1) was used and the 
dissociation constant determined for several trinucleotide deamination motifs. 
This variant of A3A binds the target trinucleotide motif (5’-TTC-3’) with high 
affinity (KD = 77 ± 3 nM) and strong specificity compared with an adenine 
polynucleotide. This affinity is comparable with that reported for A3G (49). Other 
cytidine-containing trinucleotide motifs known to be substrates for A3A are bound 
with similar affinities, KD = 114 ± 4 nM for 5’-TCC-3’ and KD = 100 ± 4 nM for 5’-
CCC-3’. These data are consistent with previously reported values for 
trinucleotide motifs (53) but in our observations 5’-TTC-3’ is slightly more 
preferred with a ~20–30 nM difference in KD. 
Using substrates based on the high-affinity trinucleotide (5’ -TTC-3’) a poly 
thymidine oligomer containing two cytidine bases was identified as the tightest 
binding partner for A3A (Figure II.1B; Table II.1) with KD = 44 ± 2 nM. Varying 
the number of consecutive cytidines, ranging from one to four, did not 
significantly alter substrate affinity. An oligonucleotide consisting solely of  
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Figure II.1. APOBEC3A Binding Specifically to Trinucleotide Deamination 
Motifs 
A. Fluorescence anisotropy measurements show how introduction of a single 
TTC motif in a polyA background leads to high affinity binding. Other motifs have 
a similar effect, but TTC appears to be the preferred substrate. 
B. APOBEC3A binding to an ideal substrate consisting of a polyT oligomer 
containing a single cytidine residue. Varying the number of cytidines does not 
have any pronounced effect on APOBEC3A affinity. 
C. Difference in affinity to the target deamination site versus a polyT oligomer. 
Binding is cooperative with higher affinity to the oligomer containing the TTC 
motif (polyT_1C). APOBEC3A has the same affinity to the deaminated base 
(polyT_1U) as to the polyT background. Binding is specific to the substrate and 
not to the product. 
The error bars represent the SD calculated for each measurement point from 
three independent repeats.  
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Table II.1. ssDNA Binding Affinity and Cooperativity of APOBEC3A and 
Interface Mutants 
 
 
 
The Hill coefficient (nH) is expected to be 1 for noncooperative binding and 2 for 
cooperative binding by a dimer. A3A refers to the inactive variant E72A. Fold-
changes in KD (second column) are relative to polyT_1C substrate (bold type). 
See also Table S1 for oligomer sequences. 
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thymidine, lacking cytidine, binds to the enzyme (Figure II.1C) but the affinity is 
an order of magnitude weaker than in the presence of a single cytidine (KD = 502 
± 27 nM). 
A second parameter undergoing change upon introducing a target site is 
the Hill coefficient of the binding curve. When the substrate contains a cytidine, 
the Hill coefficient is ~2 (Figures II.1A and II.1B; Table II.1), whereas the Hill 
coefficient is ~1 in the absence of a cytidine. This difference in the Hill coefficient 
may imply that APOBEC3A is in a monomeric low-affinity state in the absence of  
a target cytidine but assumes a dimeric high-affinity state when encountering a 
deamination substrate. Such a binding mechanism would predict that the affinity 
to the product of the deamination reaction would likely also be weaker. To test 
this hypothesis, we replaced the cytidine	base with a uracil, in which case both 
the affinity and the Hill coefficient are similar to those for the all-thymidine 
oligomer (1U KD = 434 ± 35 nM, h = 0.80 ± 0.04; TTT KD = 502 ± 27nM, h = 0.96 
± 0.04) (Figure II.1C; Table II.1). 
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II.c.2. Crystal Structure of APOBEC3A. 
The crystal structure of A3A-E72A-C171A was determined to 2.85 Å 
resolution with two molecules per asymmetric unit (Figure II.2A) forming a 
homodimer. The A3A dimer crystallized in space group P6522 and refined with 
good statistics (Table II.2). 
As observed in the NMR solution structure (48), A3A has a canonical DNA 
cytosine deaminase fold, composed of five β-strands, six α-helices, and the 
catalytic zinc-binding site. The zinc atom is coordinated by direct interactions with 
H70, C101, C106, and, as the catalytic glutamic acid (E72A) is inactive, to what 
appears to be a second zinc ion which is 3.3 Å apart from and appears to 
stabilize the geometry around the catalytic zinc (Figure II.2B). This type of site 
with two zinc ions in close proximity resembles cocatalytic zinc sites, which can 
be found in class III hydrolases (56). Comparing with the NMR ensemble of 
catalytically active A3A (48) shows that the loop connecting the zinc-coordinating 
cysteine residues has moved, which is necessary to conserve the active-site 
geometry in the presence of the E72A mutation and allows recruitment of T31 to 
coordinate the second ion. This loop contains 104-WG-105, an insertion unique 
to A3A and the closely related C-terminal domain of A3B. All zinc-coordinating 
residues are located in helices α2 and α3, which also provide a structural 
backbone for the catalytic pocket. 
The crystal structure reveals that A3A forms a dimer that defines the 
asymmetric unit. This dimer is formed via a symmetric domain swap between two  
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Figure II.2. Crystal Structure of APOBEC3A 
A. Crystallographic dimer of APOBEC3A. The two monomers are in orange and 
cyan, with the metal ions at the active sites depicted as steel gray spheres and 
chloride ions at the dimerization interface shown as green spheres. 
B. Close-up view of the active site. Recruitment of a second metal via a 
threonine residue (T31) protects active site geometry in the presence of a 
mutation of the catalytic glutamate residue. 
C. Surface representation of the dimeric structure in (A) reveals a groove 
connecting both active sites via the dimer interface. 
D. SiteMap prediction (7) of putative binding sites (blue) on a wireframe 
representation of the surface in (C) matches the groove connecting both active 
sites. 
E. Electrostatic potential map, same orientation as (A) and (C). Positive (blue) 
and negative (red) charges are indicated on the surface. The groove connecting 
the two active sites is mainly positively charged. See also Figure S1 for a 
superposition of both monomers. 
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Table II.2. Crystallographic Statistics for APOBEC3A Structure 
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A3A molecules. The root-mean-square deviation (RMSD) between the two 
molecules is 0.64 Å with the largest deviations in residues 25–27, 50, and 86–87 
with Cα -Cα distances of 1.3 Å (Figure II.3). Seventeen residues that form the N-
terminal loop regions of both molecules form an intimate handshake (Figure 
II.2A) burying >1,000 Å2 acting as the dimerization interface. The dimerization 
interface is away from the active sites and coordinates three metal ions by 
residues H11 and H56 from both chains and a network of water molecules. In 
addition, the side chains of residues K30 are coordinated via a water molecule at 
the interface bridging the two molecules (Figure II.4.A). 
On the surface of the dimer (Figure II.2C), a symmetric groove 36 Å in 
length connects the active site regions of the two molecules via the dimerization 
interface. This groove has been identified as a potential ligand binding site with a 
calculated (7) pocket volume of ~800 Å3 (Figure II.2D). Based on surface 
electrostatic potential, the groove is mostly positively charged (Figure II.2E). 
Residues H16, R28, K30, H56, and K60 are prominently contributing to both the 
accessible pocket volume and charge. 
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Figure II.3. Superposition of the two monomers in the crystallographic 
dimer 
Superposition of the two monomers in the crystallographic dimer colored by  
A. the two monomers (orange and cyan) and  
B. the alpha-Carbon deviations between the two monomers increasing from dark 
to lighter shades of purple.  
Regions displaying the highest deviations are indicated by residue numbers. 
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Figure II.4. Residues Contributing to Interface Formation Are Determinants 
for Cooperativity and Affinity 
A. The dimer interface in the APOBEC3A crystal structure. Residues forming the 
dimerization interface are shown as sticks and zinc (gray), chloride (green), and 
water (red) as spheres. Side-chain oxygen and nitrogen atoms are colored red 
and green, respectively. 
B. Bar graphs show how point mutations at the highlighted sites affect KD and the 
Hill coefficient. WT represents data collected for A3A-E72A-C171A. KD (rel.) 
represents the fold change in KD relative to A3A-E72A-C171A binding polyT_1C. 
The error bars represent the SD from three independent repeats. 
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II.c.3. Assessing the Functional Significance of the 
Crystallographic Dimer. 
The crystal structure allowed us to identify and test the potential 
determinants for substrate recognition and binding. Based on the crystallographic 
dimer, we engineered a series of mutant constructs to probe whether the 
observed dimer might play a role in substrate binding. If the crystallographic 
dimer indeed corresponds to a biochemically relevant structure, then the de- 
signed mutations should affect and provide insights into substrate recognition. 
Since the crystallographic interface brings the N-terminal 17 residues in 
close proximity, we tested an N-terminally truncated version of A3A to investigate 
the potential role of the crystallographic dimer as the structure responsible for the 
observed cooperativity. Under the same experimental conditions as used above, 
the truncated protein lost the high affinity to the ideal substrate (Figure II.5), and 
protein expression yields and the construct solubility were severely 
compromised. 
In order to confirm that the active site rearrangement caused by the E72A 
mutation did not cause the observed differential substrate recognition, we 
repeated the binding experiment presented in Figure II.1C with an E72Q variant. 
A3A E72Q exhibits the same kind of marked increase in affinity and cooperativity 
upon encountering the target cytidine (Figure II.6; Table II.1). 
The crystal structure was further used to narrow down the determinants 
for dimerization and identify sites amenable to single amino acid substitutions  
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Figure II.5. N-terminally truncated mutant of APOBEC3A Binding to ideal 
substrate 
Fluorescence anisotropy measurements show that deleting the N-terminus 
(A3Ad17) impairs specific, high-affinity binding of APOBEC3A to polyT-1C 
(ideal substrate). Higher concentrations of protein used in Figure 1 were not 
possible due to instability of the A3Ad17 protein, making measurement of 
accurate Kd or hill coefficient impossible.	
	
	 60	
  
	
Figure II.6. Binding of catalytically inactive E71G APOBEC3A variant 
Fluorescence anisotropy measurements of the catalytically inactive variant 
E72Q show the same kind of substrate dependent cooperativity as observed 
for E72A.	
	
	
	 61	
based on the charge distribution and interatomic distances described above. A 
series of mutant proteins were then engineered to measure the contribution of 
these individual amino acids to cooperativity and affinity (Figure II.4). From the 
structure, two pairs of residues were identified that might contribute to dimer 
formation. H11 and H56 are the first set, which forms the base of the dimerization 
interface (Figure II.4A), and mutations at these residues not only disrupt the 
protein-protein interface but also severely affect cooperativity of binding (H11A, 
KD = 855 ± 311 nM, h = 0.7 ± 0.1; H56A, KD = 86 ± 13 nM, h = 0.9 ± 0.1). A 
second set of ionic residues, H16 and K30, closer to the surface (Figure II.4A) of 
the groove also markedly reduce cooperatively and greatly compromise affinity 
when mutated (H16A, KD = 584 ± 92 nM, h = 1.2 ± 0.2; K30E, KD = 284 ± 20 nM, 
h = 1.2 ± 0.1) and greatly compromise affinity. H56A was the only mutation 
drastically reducing cooperativity while maintaining substrate affinity. The results 
show that both sets of interactions predicted by the dimerization interface	
observed in the crystal structure are critical to cooperative DNA recognition in 
solution. 
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II.d. Discussion 
In this study, we characterized the cooperativity in specific binding of A3A 
to ssDNA substrate, determined the crystal structure of the A3A dimer, and 
engineered mutations that interrogated the functional implications of this dimer 
interface. We found that A3A recognizes substrate cooperatively and with high 
affinity and specificity. Key to this recognition is the A3A dimer that forms an 
extensive positively charged groove connecting the active sites of both 
monomers. A3A exists as a monomer and as a dimer both in solution and bound 
to substrate (40, 55) yet a functional implication for transition between those 
states was missing. The identification of this substrate-binding groove and 
mutational analysis provide key insights into the structural basis of A3A substrate 
specificity, and helps to explain the previously reported apparent discrepancies 
on A3A function. 
The contiguous and positively charged groove on the A3A surface is 
consistent with DNA recognition and binding. In fact, many residues around the 
active site region appear to be involved in substrate binding. Our structure unifies 
many of the residues previously associated with ssDNA binding to A3A (1, 2) by 
mapping them to a contiguous band on the molecular surface crossing the dimer 
interface (Figure II.7; Figure II.8). This bridges the data from the two previous 
studies where only relatively few residues identified were overlapping (Figure 
II.7, yellow); most likely the experimental conditions account for the differences 
(Figure II.7, green,  
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Figure II.7. Residues Implicated in Deamination Activity 
Shown are independently determined substrate binding surfaces by enzymatic 
activity (red) (1) or chemical shift perturbation accompanied by enzymatic activity 
(green) (2). Residues identified in both studies are colored yellow. See also 
Figure S4. 
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Figure II.8. Residues Implicated in DNA Binding 
Residues identified to be involved in DNA binding by (A) Didier Trono’s (1) and 
(B) Angela Gronenborn’s and Judith Levin’s group (2) are colored in red on the 
APOBEC3A dimeric structure. The two monomers are in cyan and orange, 
and the metal ions are indicated as spheres as in Figures 2-4. 
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(2) and red, (1)). Our crystal structure demonstrates the consistency of both 
studies in that all residues identified by either study lie within the groove. In fact, 
two residues outside the active site identified in both studies, K30 and K60, that 
bridge the dimer interface and contribute to the groove’s charge, respectively, 
affect substrate affinity and deamination (1, 2). The H56A mutant, which has a 
significant impact on dimerization and a much smaller effect on substrate affinity, 
seems to allow a separation of function and shows that high affinity can be 
achieved in the monomeric state as well. 
Although A3A can and does exist in monomeric form in solution and in the 
cell (37, 40, 55), our analysis strongly implies that the high-affinity DNA-binding 
functional form is a homodimer formed by swapping the N-terminal loop. A 
naturally occurring isoform of A3A, which lacks the initial 12 residues (57, 58), 
was described to be 5-fold less active compared with the full-length enzyme (54) 
in an in vitro deamination assay. This only modest reduction in activity could 
arise from key residues of the interface lying outside the N-terminus. 
Dimerization via the N-terminus could be communicated via K30 and H56, which 
are involved in interface formation, to neighboring residues T31 and N57 forming 
the pocket containing the catalytic site. Residues H56 and K30, which form the 
top of the groove of the dimerization interface, are also positioned to favorably 
interact with the negatively charged phosphates of the substrate and thus can not 
only	communicate dimerization, but, more specifically, dimerization on the 
substrate to the active site region. 
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The necessity for A3A to form a cooperative dimer for high-affinity binding 
effectively explains the apparent discrepancy between high enzymatic activity 
and the great variation in reported substrate affinities (2, 48, 53, 59). As we 
show, affinity drops by an order of magnitude and the Hill coefficient drops 
dramatically when binding to product is compared with substrate binding. Since 
most binding experiments to determine affinity are conducted at equilibrium and 
A3A has very fast deamination rates, experiments done with active enzyme will 
observe binding to the reaction product instead of the substrate. Weaker and 
monomeric binding to product corroborates our results (40); after incubation with 
substrate, active A3A was observed in a predominantly monomeric form, 
whereas inactive A3A would form a dimer on substrate. A recent study in which 
the catalytically deficient E72A mutant was used was also able to measure a 
similarly high affinity to the ssDNA substrate (55). In the presence of active A3A, 
substrate would quickly have been turned over to product and therefore appear 
to bind with low affinity. Taken together, the differences in binding product and 
substrate explain why binding with high affinity and in a dimeric state could only 
be observed for catalytically inactive enzyme. 
A cooperative model of APOBEC3 activity also explains the ability to 
achieve the required fidelity of substrate recognition despite high deamination 
activity. Being the most active deaminase of the APOBEC3 family, A3A also 
serves as the most effective restrictor of foreign DNA (57). Less discriminatory 
than other APOBEC3 enzymes and the only known family member reported to 
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deaminate modified cytidine residues (54, 60, 61), A3A can also be implied as an 
agent in demethylation pathways (62, 63). At the same time, the random nature 
of mutations introduced by A3A can be very detrimental to cell viability (4, 57) or 
can be the source for mutations in cancer, as has been shown for the close 
relative A3B, the catalytic domain of which shares 97% similarity with A3A. The 
cooperative model of substrate interaction for A3A can have implications on how 
the mutation load inflicted by A3A is regulated in vivo. At low concentrations and 
in the dense milieu of the cell, the enzyme would encounter a short, exposed 
ssDNA substrate mostly as monomer with only modest affinity. At higher 
concentrations and in the presence of longer stretches of foreign ssDNA, A3A 
can act with very high specificity and affinity on a target sequence, leading to the 
observed high rates of deamination. Also, the change in binding affinity toward a 
stretch of thymidine bases (KD = 502 ± 27 nM) upon introduction of a single 
cytidine (KD = 56 ± 2) could suggest a possible mechanism of substrate binding 
wherein A3A initially binds the thymidine bases with low affinity, followed by 
identifying the target cytidine and binding more tightly. 
The cooperative binding model may also provide insights into the 
evolution of the APOBEC3 domain structure. Four of the seven members of the 
human APOBEC3 protein family (A3B, A3D, A3F, and A3G) comprise two 
cytidine deaminase domains connected via a short linker. This repertoire of 
double-domain APOBEC3 proteins likely evolved during a series of gene 
duplication events from single-domain precursors (14, 64). The evolutionary 
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linkage between the members of the modern primate APOBEC3 locus can be 
understood from a prototypical set of single-domain APOBEC3 proteins, one for 
each Z domain subtype (15). In primates, A3A is the sole member comprising a 
single Z1 domain, sharing phylogenetic origin with the catalytic domains of A3B 
and A3G. Both of these enzymes possess a pseudocatalytic N-terminal Z2 
domain, which is required for efficient substrate binding but does not catalyze a 
deamination reaction (65, 66). The functional A3A dimer identified here might 
provide a reason why APOBEC3 might form two-domain fusions. With a single 
target site, one of the A3A monomers does not act on the target cytidine but is 
involved in substrate binding. The evolution of double-domain enzymes appears 
to have allowed for a separation of function between binding and catalysis 
leading to less active proteins that became more specific to their target. The 
interdomain linker region has recently been shown to have the determinants for 
processivity in A3G and A3F and alterations in the linker can impair enzyme 
function (67) . 
Damage in ssDNA was shown to be a major source for mutation clusters 
in cancer (18, 19) and can also contribute to the diversity of viral genomes (68, 
69). Targeting the activity of deaminases may have implications for novel 
strategies in the treatment of infectious diseases and cancer therapies and the 
insights into the structural mechanism of substrate binding described in this study 
could help guide efforts to alleviate the detrimental mutagenic activity of cellular 
deaminases. 
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II.e. Methods 
II.e.1.  Expression and Purification of APOBEC3A- E72A-C171A. 
Escherichia coli BL21 DE3 Star (Stratagene) cells were transformed with a 
pColdIII vector (Takara Biosciences) encoding a glutathione S-transferase 
(GST)-based construct. The E72A mutation was chosen to render the protein 
inactive and C171A to increase solubility. Expression occurred at 16 ºC for 22 hr 
in lysogeny broth medium containing 1 mM isopropyl β-D-1-
thiogalactopyranoside and 100 µg/ml ampicillin. Cells were pelleted, 
resuspended in purification buffer (50 mM Tris-HCl [pH 8.0], 300 mM NaCl, 1 mM 
DTT) and disrupted through sonication. Cellular debris was separated by 
centrifugation (45,000 x g, 30 min, 4 ºC). The fusion protein was separated using 
glutathione Sepharose (GE Healthcare). The GST tag was removed by means of 
a PreScission protease digest overnight at 4 ºC. Size-exclusion chromatography 
using a HiLoad 16/60 Superdex 75 column (GE Healthcare) was used as a final 
purification step. 
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II.e.2.  Crystallization and Structural Data Analysis of 
APOBEC3A-E72A- C171A. 
The protein solution was concentrated to 19.5 mg/ml in crystallization 
buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM DTT, 50 µM ZnCl) and 
crystals were grown at 4 ºC in crystallization solution (100 mM sodium cacodylate 
[pH 6.0], 40% 2-methyl-2,4-pentanediol, 8% PEG8000) by sitting-drop vapor 
diffusion over 3 years. 
Diffraction experiments were conducted using a rotating anode X-ray 
source (Rigaku Micromax-007 HF) and charge-coupled device detector (Rigaku 
Saturn 944) at 100 K. 
Data were indexed and scaled using the software HKL2000 (70). CC1/2 
and CC* were used to determine the data cutoff. The molecular replacement 
solution was calculated by Phaser (71) using the Protein Data Bank ID PDB: 
3V4K as a search model (44). The structure was rebuilt using phenix.autobuild 
(72). An automated pipeline (REdiii) was used for processing data from 
subsequent diffraction experiments (73). Multiple crystals were diffracted with 
exposure times between 2 and 4 min per oscillation image; only one led to 
diffraction spots beyond 3 Å. Refinement was carried out using Coot (74) and 
phenix.refine (72). Molecular graphics images were generated using PyMOL 
(Schrödinger LLC) (75). SiteMap (7) was used to identify and evaluate volumes 
of binding sites, using a fine grid to search around the Zn2+ atoms in the 
dimerization interface. 
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II.e.3.  High-Throughput DNA Binding Assay. 
Carboxytetramethylrhodamine (5’-TAMRA)-labeled ssDNA (IDT) served 
as substrate (sequences are listed in Table II.3). 10 nM of substrate was added 
to A3A-E72A-C171A in concentrations varying between 10 nM and 20 mM, and 
to a control without protein. The A3A protein concentrations were 0, 10, 25, 50, 
75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, and 750 nM; 1, 1.25, 
1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, and 20 mM. The mixtures were incubated for 1 
hr at room temperature in nonbinding 96-well plates (Greiner) in 50 mM MES 
buffer (pH 6.0), 100 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine in a total 
reaction volume of 150 ml per well. Fluorescence anisotropy was measured for 
triplicate experiments using an EnVision plate reader (PerkinElmer) equipped 
with the Optimized Tamra Acyclo Prime SNP Label detection kit, allowing 
excitation at 531 nm and detection of polarized emission at 579 nm wavelength. 
Data analysis was performed using Prism (GraphPad) performing least-square 
fitting of the measured fluorescence anisotropy values (Y) at different protein 
concentrations (X) with a single-site binding curve with Hill slope, a nonspecific 
linear term, and a constant background using the equation Y=(Bmax x X^h)/ 
(Kd^h + X^h) + NS x X + Background, where Kd is the equilibrium dissociation 
constant, h is the Hill coefficient, and Bmax is the extrapolated maximum 
anisotropy at complete binding. SD was calculated for each measurement point 
from the three independent repeats and is shown as error bars in the 
corresponding data figures. 
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Table II.3. Nucleotide sequences for ssDNA oligomers used in APOBEC3A 
binding experiments 
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Chapter III 
 
Crystal structure of APOBEC3A bound to single-
stranded DNA reveals structural basis for cytidine 
deamination and specificity 
  
 
 83 
III.a. Abstract 
Nucleic acid editing enzymes are essential components of the immune system 
that lethally mutate viral pathogens and somatically mutate immunoglobulins, and 
contribute to the diversification and lethality of cancers. Among these enzymes 
are the seven human APOBEC3 deoxycytidine deaminases, each with unique 
target sequence specificity and subcellular localization. While the enzymology 
and biological consequences have been extensively studied, the mechanism by 
which APOBEC3s recognize and edit DNA remains elusive. Here we present the 
crystal structure of a complex of a cytidine deaminase with ssDNA bound in the 
active site at 2.2 Å. This structure not only visualizes the active site poised for 
catalysis of APOBEC3A, but pinpoints the residues that confer specificity towards 
CC/TC motifs. The APOBEC3A–ssDNA complex defines the 5’–3’ directionality 
and subtle conformational changes that clench the ssDNA within the binding 
groove, revealing the architecture and mechanism of ssDNA recognition that is 
likely conserved among all polynucleotide deaminases, thereby opening the door 
for the design of mechanistic-based therapeutics. 
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III.b. Introduction 
 Apolipoprotein B messenger RNA-editing enzyme, catalytic polypeptide-like 
(APOBEC3) proteins are single-stranded DNA (ssDNA) deoxycytidine 
deaminases that are among some of the fastest evolving proteins in the human 
genome (1). APOBEC3s catalyze a cytidine (C) to uridine (U) zinc-dependent 
deamination reaction (2-5). The seven APOBEC3 enzymes are clustered on 
chromosome 22 (6). Although each APOBEC3 has a single catalytic active site, 
the human genome includes three single-domain (APOBEC3A, C and H) and 
four double-domain (APOBEC3B, D, F and D) enzymes. The double-domain 
enzymes consist of a catalytically active C-terminal domain (CTD) and an 
inactive pseudo-catalytic N-terminal domain (NTD) that can bind but not edit 
nucleic acids. Four of the seven APOBEC enzymes (APOBEC3D, APOBEC3F, 
APOBEC3G and APOBEC3H) have been implicated as HIV-1 host restriction 
factors (7-13). The APOBEC3 enzymes act on ssDNA to introduce C-to-U 
modifications that create G-to-A point mutations on the paired strand as the U is 
read as T during replication. Such mutations in ssDNA can lead to double-strand 
breaks that may result in genomic DNA damage that have been observed in 
cancer (14-20).  
In the last decade, our laboratories (21-27) along with others (28-42) have 
solved crystal and nuclear magnetic resonance (NMR) structures of single 
domains of human APOBEC3s (Figure III.1). These proteins share the same  
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Figure III.1. Sequence alignment of APOBEC3s. 
Sequence alignment of A3A: 
A. with sequences of catalytically active A3 domains whose crystal structures 
have been determined,  
B. with sequences of inactive pseudo-catalytic domains whose structures have 
been solved. 
 
 
 
 
Supplementary Fig. 1.  Sequence alignment of A3A A) with sequences of catalytically active 
A3 domains whose crystal structures have been determined, B) with sequences of inactive 
pseudo-catalytic domains whose structures have been solved.  
 
 
 
 
Suppleme tary Fig. 1.  Sequence alignm nt of A3A A) with sequences of catalytically active 
A3 domains who e cryst l structures have been det rmined, B) with sequences of inac ive 
pseudo-catalytic domains whose structures have been solved.  
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overall fold (42), deaminate cytosines in ssDNA, but vary in their substrate 
specificity, processivity, catalytic rate and ability to restrict HIV-1. All APOBEC3 
domains contain a HAEx28Cx2-4C zinc binding motif. The carboxylate group of 
the catalytic glutamic acid stabilizes the transition state and proton transfer 
during catalysis where a water coordinated by the catalytic zinc is the sole source 
of proton for the amino group and N3 atom of cytosine (2,44,45). The specificity 
of different APOBECs has been elucidated by the determination of preferred 
mutagenic hotspot sequences, 5’- CC/TC-3’ for APOBEC3A (studied here) (46), 
5’-TC-3’ for APOBEC3F and 5’-CC-3’ for APOBEC3G (10,47,48). APOBEC3G 
deaminates hotspots closer to 5’-end more efficiently than to 3’-end of ssDNA 
(28,30,32,49), but the underlying mechanism for this preference is not known. 
Several alternative ssDNA-binding models for APOBEC3G-CTD and APOBEC3A 
have been proposed (21,29,35,36). Most recently, the crystal structure of the 
inactive pseuodo-catalytic rhesus macaque APOBEC3G-NTD (rA3G-NTD) 
(Figure III.1B) in complex with poly-dT ssDNA has been reported (42). However, 
only one complete deoxythymidine (dT) was resolved in this structure bound in a 
shallow cleft far from the pseudo-catalytic zinc-binding motif. This complex did 
not reveal how substrate (dC) or product (dU) may be accommodated for 
deamination reaction. The details of ssDNA-binding and -editing mechanisms, 
and molecular basis underlying substrate nucleotide sequence specificities of 
APOBEC3 enzymes still remain elusive. 
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APOBEC3A (A3A) is a single-domain enzyme with the highest catalytic 
activity among the human APOBEC3 proteins (50). While the DNA-editing 
activity inhibiting the replication of retroelements is beneficial for genome 
stability, increased expression or defective regulation of A3A could lead to 
mutagenesis of human genome and contribute to carcinogenesis (51). The 
structure of A3A was initially determined by NMR (35) and some preference for 
DNA over RNA was suggested by chemical shift perturbation data (36). 
However, mutations of residues predicted to be involved in DNA targeting had 
variable effects on deamination activity, and the detailed mechanism by which 
A3A binds DNA substrate is still elusive (35,36).  
In this study, we determined the crystal structure of a ssDNA:deaminase 
complex, or a polynucleotide substrate bound at the active site of a catalytic 
domain APOBEC3 protein. Previously, we solved the crystal structure of the 
unliganded inactive A3A (26) and determined potent binding affinity to substrate 
ssDNA of ~60 nM, whereas the product exhibited an order of magnitude lower 
affinity. Here the crystal structure to 2.2Å of this variant of A3A in complex with 
substrate DNA oligonucleotide containing a single 5’-TC-3’ deamination target 
sequence in a polyT background is presented. The central nucleotides 
comprising the 5’-TCT-3’ motif is well ordered and bound at the active site, 
revealing the intermolecular interactions defining specificity for the bases at each 
of these three positions. The target deoxycytidine (dC0), is bound in a reaction-
competent coordination at the active site. This A3A–ssDNA structure elucidates 
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the molecular basis of nucleotide preferences in the substrate motif and provides 
key insights into the overall molecular mechanisms of DNA editing by cytidine 
deaminases. 
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III.c. Results and Discussion  
III.c.1. A3A–ssDNA co-crystal structure.  
A3A (E72A/C171A) (26) was used for co-crystallization with ssDNA. E72A 
inactivates the enzyme permitting the formation of stable complexes and C171A 
increases solubility. The crystal structure of A3A (E72A/C171A) in complex with 
ssDNA was determined by molecular replacement at 2.2Å resolution (Figure 
III.2A-C and Figure III.3). A 15-mer DNA oligonucleotide that binds A3A with    
~60 nM affinity (26) with a target deoxycytidine (5’- TTTTTTTCTTTTTTT-3’) was 
co-crystallized with A3A. The final refinement of the structure resulted in R-
factor/R-free of 0.177/0.225, respectively (Table III.1). 
There was a single A3A–ssDNA complex in the asymmetric unit and 
crystal contacts with symmetry-related complexes did not correspond to the zinc-
coordinated dimer interface we observed for the apo A3A crystal structure (26). 
The apo A3A structure included an excess of zinc (50µM ZnCl) in the 
crystallization condition, while the A3A–ssDNA complex lacked added zinc, 
which may have destablized the dimer within this crystal form. The cooperativity 
upon DNA binding we observed in solution and interrogated with site-directed 
mutagenesis (26) implicates A3A capable of binding ssDNA in the dimeric form 
at least transiently. Nevertheless, cooperativity does not seem to be essential as 
the monomeric form of A3A, with a mutation at H56A, binds substrate DNA with 
similar affinity (26). Most likely both monomer and dimer forms of A3A play a role 
in recognizing substrates in solution. 
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Figure III.2. Crystal structure of A3A in complex with substrate DNA  
A. A3A structure with a 2Fo - Fc electron density map contoured at 1σ. The 
protein is presented as a green-colored ribbon diagram and the bound DNA is in 
stick representation (carbons and phosphates, orange; nitrogens, blue; oxygens, 
red). A zinc ion at the active center is depicted as a magenta-coloured sphere. 
The side chains of zinc-coordinating residues H70, C101 and C106 are shown as 
sticks (carbons, green; nitrogens, blue; oxygen, red; sulfurs, yellow).  
DNA binding at the active site of A3A is presented in B. ribbon and C. surface 
representation.  
D. Conformational changes of residues R28, H29 and Y132 upon DNA binding 
are indicated by arrows, with side chains in stick representation (white and 
green-colored carbon for the apo (PDB code 4XXO) (26) and DNA-bound forms, 
respectively).  
Surface electrostatic potentials of E. apo and F. DNA-bound A3A are colored red 
to blue for negative and positive charges, respectively, using a scale of -5 to  
+5 kTe-1. 
 
Apolipoprotein B messenger RNA-editing enzyme, catalyticpolypeptide-like (APOBEC3) proteins are single-strandedDNA (ssDNA) deoxycytidine deaminases that are among
some of the fastest evolving proteins in the human genome1.
APOBEC3s catalyse a cytidine (C) to uridine (U) zinc-dependent
deamination reaction2–5. The seven APOBEC3 enzymes are
clustered on chromosome 22 (ref. 6). Although each APOBEC3
has a single catalytic active site, the human genome includes three
single-domain (APOBEC3A, C and H) and four double-domain
(APOBEC3B, D, F and D) enzymes. The double-domain enzymes
consist of a catalytically active C-terminal domain (CTD) and an
inactive pseudo-catalytic N-terminal domain (NTD) that can
bind but not edit nucleic acids. Four of the seven APOBEC
enzymes (APOBEC3D, APOBEC3F, APOBEC3G and
APOBEC3H) have been implicated as HIV-1 host restriction
factors7–13. The APOBEC3 enzymes act on ssDNA to introduce
C-to-U modifications that create G-to-A point mutations on the
paired strand as the U is read as T during replication. Such
mutations in ssDNA can lead to double-strand breaks that may
result in genomic DNA damage that have been observed in
cancer14–20.
In the last decade, our laboratories21–27 along with others28–42
have solved crystal and nuclear magnetic resonance (NMR)
structures of single domains of human APOBEC3s
(Supplementary Fig. 1). These proteins share the same overall
fold43, deaminate cytosines in ssDNA, but vary in their substrate
specificity, processivity, catalytic rate and ability to restrict HIV-1.
All APOBEC3 domains contain a HAEx28Cx2-4C zinc binding
motif. The carboxylate group of the catalytic glutamic acid
stabilizes the transition state and proton transfer during catalysis
where a water coordinated by the catalytic zinc is the sole source
of proton for the amino group and N3 atom of cytosine2,44,45.
The specificity of different APOBECs has been elucidated by
the determination of preferred mutagenic hotspot sequences, 50-
CC/TC-30 for APOBEC3A (studied here)46, 50-TC-30 for
APOBEC3F and 50-CC-30 for APOBEC3G10,47,48. APOBEC3G
deaminates hotspots closer to 50-end more efficiently than to 30-
end of ssDNA28,30,32,49, but the underlying mechanism for this
preference is not known. Several alternative ssDNA-binding
models for APOBEC3G-CTD and APOBEC3A have been
proposed21,29,35,36. Most recently, the crystal structure of the
inactive pseuodo-catalytic rhesus macaque APOBEC3G-NTD
(rA3G-NTD) (Supplementary Fig. 1b) in complex with poly-dT
ssDNA has been reported42. However, only one complete
deoxythymidine (dT) was resolved in this structure bound in a
shallow cleft far from the pseudo-catalytic zinc-binding motif.
This complex did not reveal how substrate (dC) or product (dU)
may be accommodated for deamination reaction. The details of
ssDNA-binding and -editing mechanisms, and molecular basis
underlying substrate nucleotide sequence specificities of
APOBEC3 enzymes still remain elusive.
APOBEC3A (A3A) is a single-domain enzyme with the highest
catalytic activity among the human APOBEC3 proteins50. While
the DNA-editing activity inhibiting the replication of retroelements
is beneficial for genome stability, increased expression or defective
regulation of A3A could lead to mutagenesis of human genome and
contribute to carcinogenesis51. The structure of A3A was initially
determined by NMR35 and some preference for DNA over RNA
was suggested by chemical shift perturbation data36. However,
mutations of residues predicted to be involved in DNA targeting
had variable effects on deamination activity, and the detailed
mechanism by which A3A binds DNA substrate is still elusive35,36.
In this study, we determined the crystal structure of a
ssDNA:deaminase complex, or a polynucleotide substrate bound
at the active site of a catalytic domain APOBEC3 protein.
Previously, we solved the crystal structure of the unliganded
inactived A3A (ref. 26) and determined potent binding affinity to
substrate ssDNA of B60 nM, whereas the product exhibited an
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Figure 1 | Crystal structure of A3A in complex with substrate DNA. (a) A3A structure with a 2Fo! Fc electron density map contoured at 1s. The protein
is presented as a green-coloured ribbon diagram and the bound DNA is in stick representation (carbons and phosphates, orange; nitrogens, blue; oxygens,
red). A zinc ion at the active centre is depicted as a magenta-coloured sphere. The side chains of zinc-coordinating residues H70, C101 and C106 are shown
as sticks (carbons, green; nitrogens, blue; oxygen, red; sulfurs, yellow). DNA binding at the active site of A3A is presented in (b) ribbon and (c) surface
representation. (d) Conformational changes of residues R28, H29 and Y132 upon DNA binding are indicated by arrows, with side chains in stick
representation (white and green-coloured carbon for the apo (PDB code 4XXO)26 and DNA-bound forms, re pectively). Surfac electrostatic potentials of
(e) apo and (f) DNA-bound A3A are coloured red to blue for negative and positive charges, respectively, using a scale of ! 5 to þ 5 kTe! 1.
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Figure III.3. Secondary structure elements of A3A  
A3A structure is shown as a ribbon diagram in green. A zinc ion at the active site 
is depicted as a magenta-colored sphere. The zinc-coordinating residues H70, 
C101 and C106 are in stick representation (carbons, green; nitrogens, blue; 
oxygens, red; sulfurs, yellow). A3A structure is comprised of helix α1 (residues 
15–22), strand β1 (32–41), strand β2 (44–47 and 53–56, with a break or “kink” in 
the strand), helix  α2 (71–82), strand β3 (89–96), helix α3 (106–116), strand β4 
(120–126), helix α4 (136– 146), strand β5 (149–152), helix α5 (155–165) and 
helix α6 (179–195). 
 
 
 
 
 
 
Supplementary Fig. 2. Secondary structure elements of A3A. A3A structure is shown as a 
ribbon diagram in green. A zinc ion at the active site is depicted as a magenta-colored sphere. 
The zinc-coordinating residues H70, C101 and C106 are in stick representation (carbons, green; 
nitrogens, blue; oxygens, red; sulfurs, yellow). A3A structure is comprised of helix !1 (residues 
15–22), strand "1 (32–41), strand "2 (44–47 and 53–56, with a break or “kink” in the strand), 
helix !2 (71–82), strand "3 (89–96), helix !3 (106–116), strand "4 (120–126), helix !4 (136–
146), strand "5 (149–152), helix !5 (155–165) and helix !6 (179–195).  
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Table III.1. Data collection and refinement statistics 
 
 
 
order of magnitude lower affinity. Here the crystal structure to
2.2 Å of this variant of A3A in complex with substrate DNA
oligonucleotide containing a single 50-TC-30 deamination target
sequence in a polyT background is presented. The central
nucleotides comprising the 50-TCT-30 motif is well ordered and
bound at the active site, revealing the intermolecular interactions
defining specificity for the bases at each of these three positions.
The target deoxycytidine (dC0), is bound in a reaction-competent
coordination at the active site. This A3A–ssDNA structure
elucidates the molecular basis of nucleotide preferences in the
substrate motif and provides key insights into the overall
molecular mechanisms of DNA editing by cytidine deaminases.
Results
A3A–ssDNA co-crystal structure. A3A (E72A/C171A)26 was
used for co-crystallization with ssDNA. E72A inactivates the
enzyme permitting the formation of stable complexes and C171A
increases solubility. The crystal structure of A3A (E72A/C171A)
in complex with ssDNA was determined by molecular
replacement at 2.2 Å resolution (Fig. 1a–c; Supplementary
Fig. 2). A 15-mer DNA oligonucleotide that binds
A3A with B60 nM affinity26 with a target deoxycytidine (50-
TTTTTTTCTTTTTTT-30) was co-crystallized with A3A. The
final refinement of the structure resulted in R-factor/R-free of
0.177/0.225, respectively (Table 1).
There was a single A3A–ssDNA complex in the asymmetric
unit and crystal contacts with symmetry-related complexes did
not correspond to the zinc-coordinated dimer interface we
observed for the apo A3A crystal structure26. The apo A3A
structure included an excess of zinc (50 mM ZnCl) in the
crystallization condition, while the A3A–ssDNA complex lacked
added zinc, which may have destablized the dimer within this
crystal form. The cooperativity upon DNA binding we observed
in solution and interrogated with site-directed mutagenesis26
implicates A3A capable of binding ssDNA in the dimeric form at
least transiently. Nevertheless, cooperativity does not seem to be
essential as the monomeric form of A3A, with a mutation at
H56A, binds substrate DNA with similar affinity26. Most likely
both monomer and dimer forms of A3A play a role in
recognizing substrates in solution.
The target deoxycytidine (dC0) and flanking deoxythymidines
(dT! 1 and dT1), as well as one additional deoxyribose at 50-end
and one phosphate at 30-end, were well ordered in the electron
density (50-sugar-dT! 1-dC0-dT1-phosphate-30; Fig. 1a). Of the
nearly 1,280 Å2 of surface area on the resolved DNA, B620 Å2 is
buried in the interface with A3A. The central cytidine (dC0) and
the preceding thymidine (dT! 1) are accommodated in a deep
groove formed by Loops 1,3,5 and 7 of A3A (Fig. 1b;
Supplementary Fig. 1a). The bound DNA adopts an irregular
conformation to encircle the side chain of H29 (Fig. 1c).
Compared to apo A3A, there are conformational changes in the
rotamers of the side chains of R28 and H29 in Loop 1, and Y132
in Loop 7, accompanied by more subtle reorganization of N57–
A72 in loop 3 (Fig. 1d; Supplementary Figs 1 and 3). The rest of
the enzyme including the active site remains essentially
unchanged. The groove significantly differs from any of the
previously suggested models for how ssDNA binds to A3s (refs
21,29,35,36) including the recent structure of the pseuodo-
catalytic A3G-NTD in complex with poly-dT ssDNA42. This
conformational change allows the groove to sequester the ssDNA
by forming a more complementary molecular surface, both in
terms of van der Waals packing and electrostatic (electropositive)
nature of the groove (Fig. 1e,f).
Recognition of the targeted cytidine. The deoxycytidine (dC0),
which is the target of deamination reaction, is well coordinated
and buried within the active site of A3A. The cytidine ring is
located directly over the hydroxyl group of the T31 side chain,
which likely hydrogen bonds to the p-orbital cloud of the base
ring and simultaneously coordinates O4 atom of the deoxyribose
(Fig. 2a). Residue Y130 contributes to the dC0 positioning by
forming a T-shaped p–p interaction with the pyrimidine ring.
The hydroxyl group of Y130 further forms a hydrogen bond with
50-phosphate of dC0 (Fig. 2b). The H70 side chain is positioned
over the N1 atom of dC0, capable of potentially forming a p–p
stacking (Fig. 2a). The backbone NH of A71 hydrogen bonds to
O2 of dC0. In addition, the carbonyl oxygen atoms of W98 and
S99 form a bifurcated hydrogen bond to NH2 of the cytosine,
which appears to both support the dC0 positioning and dictate
the specificity for cytosine over thymine.
As expected for a catalytic A3 domain, electron density that fits
a zinc ion was observed coordinating H70, C101, C106 as well as
additional density that fits a Cl! ion, with both assignments
confirmed by anomalous difference calculations. To prevent
catalysis, our A3A construct was inactivated by an E72A
mutation, which left the geometry of the active site intact
(Fig. 2a). Instead of the E72 side chain, we observe electron
density that fits a water molecule. Molecular modelling of E72
into this space shows the side chain would be positioned just
proximal to the deamination target, C4-NH2 moiety, of the
cytosine (Fig. 3) and poised for deamination reaction2. After
catalysis and subsequent release of NH3, this coordination, along
with the interactions with W98 and S99, would be unfavourable
for the product uridine. Overall, multiple interactions of the
substrate cytosine with A3A active site residues ensure the
specific recognition and geometry required for the deamination
reaction and product release.
Table 1 | Data collection and refinement statistics (molecular
replacement).
A3A/DNA complex
Data collection
Space group I222
Cell dimensions
a, b, c (Å) 56.6, 72.7, 115.0
a, b, g (!) 90.0, 90.0, 90.0
Resolution (Å) 50.00–2.20 (2.24–2.20)*
Rmerge 9.1 (52.8)
I/sI 27.9 (3.0)
Completeness (%) 98.2 (82.9)
Redundancy 13.1 (8.4)
Refinement
Resolution (Å) 50.00–2.20
No. of reflections 11,542
Rwork/Rfree 0.177/0.225
No. of atoms
Protein 1,469
Ligand/ion 71/3
Water 100
B-factors
Protein 35.8
Ligand/ion 50.9/55.1
Water 38.7
r.m.s. deviations
Bond lengths (Å) 0.011
Bond angles (!) 1.040
*Highest-resolution shell is shown in parenthesis.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15024 ARTICLE
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The target deoxycytidine (dC0) and flanking deoxythymidines (dT-1 and 
dT1), as well as one additional deoxyribose at 5’-end and one phosphate at 3’-  
end, were well ordered in the electron density (5’-sugar-dT-1-dC0-dT1-phosphate-
3’; Figure III.2A). Of the nearly 1,280 Å2 of surface area on the resolved DNA, 
~620 Å2 is buried in the interface with A3A. The central cytidine (dC0) and the 
preceding thymidine (dT-1) are accommodated in a deep groove formed by Loops 
1,3,5 and 7 of A3A (Figure III.2B and Figure III.1A). The bound DNA adopts an 
irregular conformation to encircle the side chain of H29 (Figure III.2C). 
Compared to apo A3A, there are conformational changes in the rotamers of the 
side chains of R28 and H29 in Loop 1, and Y132 in Loop 7, accompanied by 
more subtle reorganization of N57– A72 in loop 3 (Figure III.2D, Figure III.1, and 
Figure III.4). The rest of the enzyme including the active site remains essentially 
unchanged. The groove significantly differs from any of the previously suggested 
models for how ssDNA binds to A3s (21,29,35,36) including the recent structure 
of the pseuodo-catalytic A3G-NTD in complex with poly-dT ssDNA (42). This 
conformational change allows the groove to sequester the ssDNA by forming a 
more complementary molecular surface, both in terms of van der Waals packing 
and electrostatic (electropositive) nature of the groove (Figure III.2E,F). 
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Figure III.4. Comparison of bound and unbound crystal structures of A3A 
A. Distance difference matrix between apo (PDB code 4XXO) (26) and DNA-
bound form of A3A. All possible inter-C distances were calculated within the apo 
and DNA-bound form of A3A. Each distance in the apo form was subtracted from 
the corresponding distance in the DNA-bound form, and the resultant distance 
difference matrix is displayed as a contour plot (blue and red for negative and 
positive values, respectively, with a scale of -3.3 to +3.3 Å). The secondary 
structure elements of the DNA-bound A3A are indicated along the matrix; red- 
and green-colored rectangles depict α-helices and β-strands, respectively.  
 
 
 
 
 
 
Suppleme tary F g. 3.  (a) Distance diff rence matrix between apo (PDB code 4XXO)!26 and 
DNA-bound form of A3A. All possible inter-C! distances were calculated within the apo and 
DNA-bound form of A3A. Each distance in the apo form was subtracted from the corresponding 
distance in the DNA-bound form, and the resultant distance difference matrix is displayed as a 
contour plot (blue and red for negative and positive values, respectively, with a scale of -3.3 to 
+3.3 Å). The secondary structure elements of the DNA-bound A3A are indicated along the 
matrix; red- and green-colored rectangles depict !-helices and "-strands, respectively. (b) The 
distance difference matrix of selected A3A residues forming the interface with the bound DNA, 
showing the changes between apo and DNA-bound structures. The residues were grouped into 
three categories and indicated by red, green and blue; red- and green-colored residues have a 
relatively longer distance to each other when the substrate DNA binds to A3A whereas blue-
colored residues have a shorter distance to both red- and green-colored residues. The location of 
selected residues in the three groups on the A3A structure, (c) side chains displayed in stick 
representation with arrows indicating side chain conformational changes, (d) spheres indicating 
the position of C! atoms (apo gray, bound colored according to the three groups as in panel a). 
The C! position changes upon the DNA binding are depicted by arrows. DNA molecule bound 
to A3A is in stick representation (carbons and phosphates, orange; nitrogens, blue; oxygens, red) 
and three nucleotides (dT-1, dC0 and dT1) are shown.  
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Figure III.4. Comparison of bound and unbound crystal structures of A3A 
(Continued) 
B. The distance difference matrix of selected A3A residues forming the 
interface with the bound DNA, showing the changes between apo and DNA-
bound structures. The residues were grouped into three categories and 
indicated by red, green and blue; red- and green-colored residues have a 
relatively longer distance to each other when the substrate DNA binds to A3A 
whereas blue- colored residues have a shorter distance to both red- and green-
colored residues.  
 
 
 
 
 
 
 
Supplementary Fig. 3.  (a) Distance difference matrix between apo (PDB code 4XXO)!26 and 
DNA-bound form of A3A. All possible inter-C! distances were calculated within the apo and 
DNA-bound form of A3A. Each distance in the apo form was subtracted from the corresponding 
distance in the DNA-bound form, and the resultant distance difference matrix is displayed as a 
contour plot (blue and red for negative and positive values, respectively, with a scale of -3.3 to 
+3.3 Å). The secondary structure elements of the DNA-bound A3A are indicated along the 
matrix; red- and green-colored rectangles depict !-helices and "-strands, respectively. (b) The 
distance difference matrix of selected A3A residues forming the interface with the bound DNA, 
showing the changes between apo and DNA-bound structures. The residues were grouped into 
three categories and indicated by red, green and blue; red- and green-colored residues have a 
relatively longer distance to each other when the substrate DNA binds to A3A whereas blue-
colored residues have a shorter distance to both red- and green-colored residues. The location of 
selected residues in the three groups on the A3A structure, (c) side chains displayed in stick 
representation with arrows indicating side chain conformational changes, (d) spheres indicating 
the position of C! atoms (apo gray, bound colored according to the three groups as in panel a). 
The C! position changes upon the DNA binding are depicted by arrows. DNA molecule bound 
to A3A is in stick representation (carbons and phosphates, orange; nitrogens, blue; oxygens, red) 
and three nucleotides (dT-1, dC0 and dT1) are shown.  
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Figure III.4. Comparison of bound and unbound crystal structures of 
A3A (Continued) 
The location of selected residues in the three groups on the A3A structure, 
C. side chains displayed in stick representation with arrows indicating side 
chain conformational changes,  
D. spheres indicating the position of Cα atoms (apo gray, bound colored 
according to the three groups as in panel a). The Cα position changes upon 
the DNA binding are depicted by arrows. DNA molecule bound to A3A is in 
stick representation (carbons and phosphates, orange; nitrogens, blue; 
oxygens, red) and three nucleotides (dT-1, dC0, and dT1) are shown. 
 
 
 
 
 
 
 
 
Supplementary Fig. 3.  (a) Distance difference matrix between apo (PDB code 4XXO)!26 and 
DNA-bound form of A3A. All possible inter-C! di tance  wer  cal ulated with n the apo and 
DNA-bound form of A3A. Each distance in the apo form was subtracted fro  the corresponding 
distance in the DNA-bound form, and the resultant distance difference matrix is displayed as a 
contour plot (blue and red for negative and positive values, respectively, with a scale of -3.3 to 
+3.3 Å). The secondary structure elements of the DNA-bound A3A are indicated along the 
matrix; red- and green-colored rectangles depict !-helices and "-strands, respectively. (b) The 
distance difference matrix of selected A3A residues forming the interface with the bound DNA, 
showing the changes between apo and DNA-bound structures. The residues were grouped into 
three categories and indicated by red, green and blue; red- and green-colored residues have a 
relatively longer distance to each other when the substrate DNA binds to A3A whereas blue-
colored residues have a shorter distance to both red- and green-colored residues. The location of 
selected residues in the three groups on the A3A structure, (c) side chains displayed in stick 
representation with arrows indicating side chain conformational changes, (d) spheres indicating 
the position of C! atoms (apo gray, bound colored according to the three groups as in panel a). 
The C! position changes upon the DNA binding are depicted by arrows. DNA molecule bound 
to A3A is in stick representation (carbons and phosphates, orange; nitrogens, blue; oxygens, red) 
and three nucleotides (dT-1, dC0 and dT1) are shown.  
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III.c.2. Recognition of the targeted cytidine.  
The deoxycytidine (dC0), which is the target of deamination reaction, is 
well coordinated and buried within the active site of A3A. The cytidine ring is 
located directly over the hydroxyl group of the T31 side chain, which likely 
hydrogen bonds to the π-orbital cloud of the base ring and simultaneously 
coordinates O4 atom of the deoxyribose (Figure III.5A). Residue Y130 
contributes to the dC0 positioning by forming a T-shaped π–π interaction with the 
pyrimidine ring. The hydroxyl group of Y130 further forms a hydrogen bond with 
5’-phosphate of dC0 (Figure III.5B). The H70 side chain is positioned over the N1 
atom of dC0, capable of potentially forming a π–π stacking (Figure III.5A). The 
backbone NH of A71 hydrogen bonds to O2 of dC0. In addition, the carbonyl 
oxygen atoms of W98 and S99 form a bifurcated hydrogen bond to NH2 of the 
cytosine, which appears to both support the dC0 positioning and dictate the 
specificity for cytosine over thymine. 
As expected for a catalytic A3 domain, electron density that fits a zinc ion 
was observed coordinating H70, C101, C106 as well as additional density that 
fits a Cl- ion, with both assignments confirmed by anomalous difference 
calculations. To prevent catalysis, our A3A construct was inactivated by an E72A 
mutation, which left the geometry of the active site intact (Figure III.5A). Instead 
of the E72 side chain, we observe electron density that fits a water molecule. 
Molecular modelling of E72 into this space shows the side chain would be 
positioned just proximal to the deamination target, C4-NH2 moiety, of the cytosine  
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Figure III.5. A3A–ssDNA atomic interactions.  
Interactions between A3A and  
A. the target nucleotide base (dC0),  
B. the DNA backbone flanking dC0  
C. nucleotide at -1 position (dT-1). 
D. Interactions between H29 side chain and the substrate DNA. Side chains of 
A3A residues (carbons green) and the DNA (carbons and phosphates orange) 
are in stick representation, with other atoms colored as in Fig.III.2b. A zinc ion 
(Zn) at the active center, the zinc-liganded chlorine (Cl) and water molecule (W) 
are indicated by spheres colored magenta, green and red, respectively. 
Estimated hydrogen bonds and π–orbital interactions are depicted by dashed 
lines colored orange and black, respectively. 
 
Specificity for pyrimidines at ! 1 position. The deoxythymidine
at the 50-side of the target (the ! 1 position; dT! 1) has extensive
van der Waals contacts with three residues from Loop 7 (Y130,
D131 and Y132) and W98 in Loop 5 (Fig. 2c). The Watson–Crick
edge of the thymine base faces these Loop 7 residues, and makes
three hydrogen bonds: O2 atom with Y132 backbone amide, N3
with the D131 side chain carboxylate and O4 with a water
molecule. In addition, the D131 side chain has a salt bridge to the
R189 side chain in helix 6, which stabilizes the overall hydrogen
bonding configuration of Loop 7 to the thymine base. This
coordination appears critical as residue 189 is conserved as a basic
residue (Arg/Lys) only in catalytically active A3 domains
(Supplementary Fig. 1; Supplementary Table 1). At the ! 1
position, deoxcytidine could form similar, but slightly rearranged,
interactions as the N3 atom lacks the proton to hydrogen bond
with D131. Indeed, although A3A has dual specificity for 50-TC-30
and 50-CC-30 (ref. 40), there is a preference for thymidine at the
! 1 position. However, Loop 7 of A3A, in particular residues
Y130 and D131, would likely preclude a larger purine base from
fitting in this position, thus defining the T/C specificity of A3A.
The conserved N57 is central to the active site geometry. N57 of
A3A is completely conserved among the catalytically active
APOBEC protein domains, while inactive pseudo-catalytic A3
domains have a conserved glycine (Supplementary Fig. 1;
Supplementary Table 1), and widely conserved among other
cytidine/cytosine deaminases from Escherichia coli through Homo
sapiens52. The structure explains this strong conservation, as N57
of A3A is central in recognizing ssDNA with three key distinct
interactions: The side chain of N57 determines the 50–30
directionality of ssDNA binding by forming a hydrogen bond
to O30 atom of dC0, which helps stabilize the geometry of the
DNA backbone and the sugar in a C20-endo conformation
(Fig. 2b; Supplementary Fig. 4a) and induces a backbone
deformation due to steric hindrance with O50 of the target dC0.
The N57 side chain forms a hydrogen bond with the backbone
NH of T31, positioning the T31 side chain to hydrogen bond to
the p-orbital cloud of the dC0 base ring, thus ensuring the
geometry of the target nucleotide within the active site (Fig. 2a;
Supplementary Fig. 4a). Finally, the N57 side chain packs against
both the deoxyribose ring of dC0, stabilizing the orientation of
sugar plane, and H70, which coordinates zinc. Although RNA
deaminase activity has been reported for A3A53,54, if the sugar
was a ribose a steric clash between the 20-OH and H70 would
occur, therefore requiring a conformational rearrangement for
RNA modification. Thus, these three pivotal interactions of N57
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(d) Interactions between H29 side chain and the substrate DNA. Side
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(Cl) and water molecule (W) are indicated by spheres coloured magenta,
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interactions are depicted by dashed lines coloured orange and black,
respectively.
dC0
H70
Y130
W98
S99
A71
Zn W
T31
E72
P100
Figure 3 | Structural model of the A3A catalytically active site. The target
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Specificity for pyrimidines at ! 1 position. The deoxythymidine
at the 50-side of the target (the ! 1 position; dT! 1) has extensive
van der Waals ontacts with three residues from Loop 7 (Y130,
D131 a d Y132) and W98 in Loop 5 (Fig. 2c). The Watson–Crick
edge of the thymine base faces these Loop 7 residues, and makes
three h drog n bonds: O2 atom with Y132 backbo e a ide, N3
with the D131 side chain carboxylate and O4 with a water
molecule. In addition, the D131 side chain has a salt bridge to the
R189 side chain in helix 6, which stabilizes the overall hydrogen
bonding configuration of Loop 7 to the thymine base. This
coordination appears critical as residue 189 is conserved as a basic
residue (Arg/Lys) only in catalytically active A3 domains
(Suppl mentary Fig. 1; Supplementary Table 1). At the ! 1
position, deoxcy dine could form similar, but slightly rearranged,
interactions as the N3 atom lacks the proton to hydrogen bond
with D131. Indeed, although A3A has dual specificity for 50-TC-30
and 50-CC-30 (ref. 40), there is a preference for thymidine at the
! 1 position. However, Loop 7 of A3A, in particular residues
Y130 and D131, would likely preclude a larger purine base from
fitting in this position, thus defining the T/C specificity of A3A.
The conserved N57 is central to the active site geometry. N57 of
A3A is completely conserved among the catalytically active
APOBEC protein domains, while inactive pseudo-catalytic A3
domains have a conserved glycine (Supplementary Fig. 1;
Supplementary Table 1), and widely conserved among other
cytidine/cytosine deaminases from Escherichia coli through Homo
sapiens52. The structure explains this strong conservation, as N57
of A3A is central in recognizing ssDNA with three key distinct
int ractions: The side chain of N57 determines the 50–30
directionality of ssDNA binding by forming a hydrogen bond
to O30 atom of dC0, which helps stabilize the geometry of the
DNA backbone and the sugar in a C20-endo conformation
(Fig. 2b; Supplementary Fig. 4a) and induces a backbone
deformation due to steric hindrance with O50 of the target dC0.
The N57 side chain forms a hydrogen bond with the backbone
NH of T31, positioning the T31 side chain to hydrogen bond to
the p-orbital cloud of the dC0 base ring, thus ensuring the
geometry of the target nucleotide within the active site (Fig. 2a;
Supplementary Fig. 4a). Finally, the N57 side chain packs against
both the deoxyribose ri g of dC0, stabilizing the orientation of
sugar plane, and H70, which coordinates zinc. Although RNA
deaminase activity has been reported for A3A53,54, if the sugar
was a ribos a steri clash between the 20-OH and H70 would
occur, therefore requiring a conformational rearrangement for
RNA modification. Thus, these three pivotal interactions of N57
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DNA backbone flanking dC0 (c) nucleotide at ! 1 position (dT! 1).
(d) Interactions between H29 side chain and the substrate DNA. Side
chains of A3A residues (carbons green) and the DNA (carbons and
phosphates orange) are in stick representation, with other atoms coloured
as in Fig. 1b. A zinc ion (Zn) at the active centre, the zinc-liganded chlorine
(Cl) and water molecule (W) are indicated by spheres coloured magenta,
green and red, respectively. Estimated hydrogen bonds and p–orbital
interactions are depicted by dashed lines coloured orange and black,
respectively.
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nucleotide base (dC0) bound at the A3A active site where the catalytic E72
side chain was modelled in instead of the alanine at this position in the
crystal structure. Zinc, the coordinated water (W), carbonyl oxygen of dC0
and carboxyl oxygen of E72 side chain were connected by dashed lines in
magenta.
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Specificity for pyrimidines at ! 1 position. The deoxythymidine
at the 50-side of the target (the ! 1 position; dT! 1) has extensive
van der Waals contacts with three residues from Loop 7 (Y130,
D131 and Y132) and W98 in Loop 5 (Fig. 2c). The Watson–Crick
edge of the thymine base faces these Loop 7 residues, and makes
three hydrogen bonds: O2 atom with Y132 backbone amide, N3
with the D131 side chain carboxylate and O4 w th a water
molecule. In addition, the D131 side chain has a salt bridge to the
R189 side chain in helix 6, which stabilizes the overall hydrogen
bonding configuration of Loop 7 to the thymine base. This
coordination appears critical as residue 189 is conserved as a basic
residue (Arg/Lys) only in catalytically active A3 domai s
(Supplementary Fig. 1; Supplementary Table 1). At the ! 1
position, deoxcytidine could form similar, but slightly rearranged,
interactions as the N3 atom lacks the proton to hydrogen bond
with D131. Indeed, although A3A has dual specificity for 50-TC-30
nd 50-CC-30 (ref. 40), there is a preference for thymidine at the
! 1 position. However, Loop 7 of A3A, in particular residues
Y130 and D 31, would likely preclude larger purine base f om
fitting in this position, thus defining the T/C specificity f A3A.
The conserved N57 is central to th active site geometry. N57 of
A3A is completely conserved among the catalytically active
APOBEC p otein domains, while inactive pseudo-catalytic A3
domains have a conserved glycine (Supplement y Fig. 1;
Supplementary Table 1), nd widely conserve among other
cytidine/cytosine deaminases from Escherichia coli through Homo
sapiens52. The structure explains this strong conservation, as N57
of A3A is central in rec gnizing ssDNA with three key istinct
interactions: The side chain of N57 determines the 50–30
directionality of ssDNA inding by formi g a hydrogen bond
to O30 atom of dC0, which helps stabilize the geometry of the
DNA backbone and the sugar in a C20-end conformation
(Fig. 2b; Supplementary Fig. 4a) and induces backbone
def rmation due t steric hin rance with O50 of the target dC0.
The N57 side chai forms a hydrogen bond with the backbone
NH of T31, positioning the T31 side chain to hydrogen bond to
the p-orbital cloud of the dC0 base ring, thus ensuring the
geometry of the target nucleotide within the active site (Fig. 2a;
Supplementary Fig. 4a). Finally, the N57 side chain packs against
both the deoxyribose ring of dC0, stabilizing the orientation of
sugar plane, and H70, which coordinates zinc. Although RNA
deaminase activity has been reported for A3A53,54, if the sugar
was a ribose a steric clash between the 20-OH and H70 would
occur, therefore requiring a conformational rearrangement for
RNA modification. Thus, these three pivotal interactions of N57
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interactions are depicted by dashed lines coloured orange and black,
respectively.
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crystal structure. Zinc, the coordinated water (W), carbonyl oxygen of dC0
and carboxyl oxygen of E72 side chain were connected by dashed lines in
magenta.
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Specificity for pyrimidines at ! 1 position. The deoxythymidine
at the 50-side of the target (t e ! 1 position; dT! 1) has extensive
van der Wa ls contacts with three residues from Loop 7 (Y130,
D131 and Y132) a d W98 in Loop 5 (Fig. 2c). Th Watson–Cri k
edge of the thymine base fac s thes Loop 7 r sidues, and makes
three hydrogen bo ds: O2 atom with Y132 backbone amide, N3
with the D131 side chain carboxylate and O4 with a water
molecule. In addition, the D131 side chain has a salt bridge to the
R189 side chain in helix 6, which stabilizes the overall hydrogen
bonding configuration of Loop 7 to the thymine base. This
coordination appears critical as resid e 189 is conserved as a basic
residue (Arg/Lys) only in catalytically active A3 domains
(Supplementary Fig. 1; Supplementary Table 1). At the ! 1
position, deoxcytidine could form similar, but slightly rearranged,
interactions as the N3 atom lacks the proton to hydrogen bond
with D131. Indeed, although A3A has dual specificity for 50-TC-30
and 50-CC-30 (ref. 40), there is a preference for thymidine at the
! 1 position. However, Loop 7 of A3A, in particular residues
Y130 and D131, would likely preclude a larger purine base from
fitting in this position, thus defining the T/C specificity of A3A.
The conserved N57 is central to he active site geometry. N57 of
A3A is completely conserved among the catalytically active
APOBEC protein domains, while inactive pseudo-catalytic A3
domains have a conserved glycine (Supplementary Fig. 1;
Supplementary Table 1), and widely conserved among other
cytidine/cytosine deaminases from Escherichia coli through Homo
sapiens52. The structure explains this strong conservation, as N57
of A3A is central in recognizing ssDNA with three key distinct
interactions: The side chain of N57 determines the 50–30
directionality of ssDNA binding by forming a hydrogen bond
to O30 atom of dC0, which helps stabilize the geometry of the
DNA backbone and the sugar in a C20-endo conformation
(Fig. 2b; Supplementary Fig. 4a) and induces a backbone
deformation due to steric hindrance with O50 of the target dC0.
The N57 side chain forms a hydrogen bond with the backbone
NH of T31, positioning the T31 side chain to hydrogen bond to
the p-orbital cloud of the dC0 base ring, thus ensuring the
geometry of the target nucleotide within the active site (Fig. 2a;
Supplementary Fig. 4a). Finally, the N57 side chain packs against
both the deoxyribose ring of dC0, stabilizing the orientation of
sugar plane, and H70, which coordinates zinc. Although RNA
deaminase activity has been reported for A3A53,54, if the sugar
was a ribose a steric clash between the 20-OH and H70 w uld
occur, therefor requiring a conform tional rearrangement for
RNA modification. Thus, these three pivotal interactio s of N57
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(d) Interactions between H29 side chain and the substrate DNA. Side
chains f A3A r sidues (carbons green) and the DNA (carbons and
phosphates orange) are in stick representation, with other atoms coloured
as in Fig. 1b. A zinc ion (Zn) at the active centre, the zinc-liganded chlorine
(Cl) and water molecule (W) are indicated by spheres coloured magenta,
green and red, respectively. Estim ted hydrogen bonds and p–orbital
interactions are depicted by dashed lines coloured orange and black,
respectively.
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crystal structure. Zinc, the coordinated water (W), carbonyl oxygen of dC0
and carboxyl oxygen of E72 side chain were connected by dashed lines in
magenta.
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(Figure III.6) and poised for deamination reaction (2). After catalysis and 
subsequent release of NH3, this coordination, along with the interactions with 
W98 and S99, would be unfavorable for the product uridine. Overall, multiple 
interactions of the substrate cytosine with A3A active site residues ensure the 
specific recognition and geometry required for the deamination reaction and 
product release. 
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Figure III.6. Structural model of the A3A catalytically active site.  
The target nucleotide base (dC0) bound at the A3A active site where the catalytic 
E72 side chain was modelled in instead of the alanine at this position in the 
crystal structure. Zinc, the coordinated water (W), carbonyl oxygen of dC0 and 
carboxyl oxygen of E72 side chain were connected by dashed lines in magenta. 
 
Specificity for pyrimidines at ! 1 position. The deoxythymidine
at the 50-side of the target (the ! 1 position; dT! 1) has extensive
van der Waals contacts with three residues from Loop 7 (Y130,
D131 and Y132) and W98 in Loop 5 (Fig. 2c). The Watson–Crick
edge of the thymine base faces these Loop 7 residues, and makes
three hydrogen bonds: O2 atom with Y132 backbone amide, N3
with the D131 side chain carboxylate and O4 with a water
molecule. In addition, the D131 side chain has a salt bridge to the
R189 side chain in helix 6, which stabilizes the overall hydrogen
bonding configuration of Loop 7 to the thymine base. This
coordination appears critical as residue 189 is conserved as a basic
residue (Arg/Lys) only in catalytically active A3 domains
(Supplementary Fig. 1; Supplementary Table 1). At the ! 1
position, deoxcytidine could form similar, but slightly rearranged,
interactions as the N3 atom lacks the proton to hydrogen bond
with D131. Indeed, although A3A has dual specificity for 50-TC-30
and 50-CC-30 (ref. 40), there is a preference for thymidine at the
! 1 position. However, Loop 7 of A3A, in particular residues
Y130 and D131, would likely preclude a larger purine base from
fitting in this position, thus defining the T/C specificity of A3A.
The conserved N57 is central to the active site geometry. N57 of
A3A is completely conserved among the catalytically active
APOBEC protein domains, while inactive pseudo-catalytic A3
domains have a conserved glycine (Supplementary Fig. 1;
Supplementary Table 1), and widely conserved among other
cytidine/cytosine deaminases from Escherichia coli through Homo
sapiens52. The structure explains this strong conservation, as N57
of A3A is central in recognizing ssDNA with three key distinct
interactions: The side chain of N57 determines the 50–30
directionality of ssDNA binding by forming a hydrogen bond
to O30 atom of dC0, which helps stabilize the geometry of the
DNA backbone and the sugar in a C20-endo conformation
(Fig. 2b; Supplementary Fig. 4a) and induces a backbone
deformation due to steric hindrance with O50 of the target dC0.
The N57 side chain forms a hydrogen bond with the backbone
NH of T31, positioning the T31 side chain to hydrogen bond to
the p-orbital cloud of the dC0 base ring, thus ensuring the
geometry of the target nucleotide within the active site (Fig. 2a;
Supplementary Fig. 4a). Finally, the N57 side chain packs against
both the deoxyribose ring of dC0, stabilizing the orientation of
sugar plane, and H70, which coordinates zinc. Although RNA
deaminase activity has been reported for A3A53,54, if the sugar
was a ribose a steric clash between the 20-OH and H70 would
occur, therefore requiring a conformational rearrangement for
RNA modification. Thus, these three pivotal interactions of N57
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Figure 2 | A3A–ssDNA atomic interactions. Stereo-view of the
interactions between A3A and (a) the target nucleotide base (dC0), (b) the
DNA backbone flanking dC0 (c) nucleotide at ! 1 position (dT! 1).
(d) Interactions between H29 side chain and the substrate DNA. Side
chains of A3A residues (carbons green) and the DNA (carbons and
phosphates orange) are in stick representation, with other atoms coloured
as in Fig. 1b. A zinc ion (Zn) at the active centre, the zinc-liganded chlorine
(Cl) and water molecule (W) are indicated by spheres coloured magenta,
green and red, respectively. Estimated hydrogen bonds and p–orbital
interactions are depicted by dashed lines coloured orange and black,
respectively.
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side chain was modelled in instead of the alanine at this position in the
cryst l structur . Zinc, the coordinat d water (W), carbo yl oxygen of dC0
and carboxyl oxygen of E72 side chain were connected by dashed lines in
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III.c.3. Specificity for pyrimidines at -1 position.  
The deoxythymidine at the 5’-side of the target (the -1position; dT-1) has 
extensive van der Waals contacts with three residues from Loop 7 (Y130, D131 
and Y132) and W98 in Loop 5 (Figure III.5C). The Watson–Crick edge of the 
thymine base faces these Loop 7 residues, and makes three hydrogen bonds: 
O2 atom with Y132 backbone amide, N3 with the D131 side chain carboxylate 
and O4 with a water molecule. In addition, the D131 side chain has a salt bridge 
to the R189 side chain in helix 6, which stabilizes the overall hydrogen bonding 
configuration of Loop 7 to the thymine base. This coordination appears critical as 
residue 189 is conserved as a basic residue (Arg/Lys) only in catalytically active 
A3 domains (Figure 1 and Table III.2). At the -1 position, deoxcytidine could 
form similar, but slightly rearranged, interactions as the N3 atom lacks the proton 
to hydrogen bond with D131. Indeed, although A3A has dual specificity for 5’-TC-
3’ and 5’-CC-3’ (40), there is a preference for thymidine at the -1 position. 
However, Loop 7 of A3A, in particular residues Y130 and D131, would likely 
preclude a larger purine base from fitting in this position, thus defining the T/C 
specificity of A3A. 
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Table III.2. Conservation of DNA coordinating residues between human A3 
domains (catalytic and inactive pseudo-catalytic) 
 
 
   *APOBEC3H not included 
!
!
!
!
!
!
Residue!(A3A!sequence)! Catalytic( Inactive(pseudo2catalytic(
Included!Domains! A3A,!A3B7CTD,!A3C,!A3D7
CTD,!A3G7CTD,!A3F7CTD!
A3B7NTD,!A3D7NTD,!A3G7NTD,!
(rA3G7NTD)!A3F7NTD!
28! Arg( Arg!(ex!A3G7NTD!Leu)!
29! His!/!Asn!/!Arg! Asn!/!Asp!/!Ser!
31! Ser!/!Thr! Val!/!Thr!
57! Asn( Gly((
70! His((Zn)( His(((Zn)(
71! Ala( Ala!/!Pro!
72! Glu((catalytic)( Glu((Zn)(
98! Trp( Trp(
99! Ser( Ser!/!Thr!/!Asn!
101! Cys((Zn)( Cys((Zn)(
106! Cys((Zn)( Cys((Zn)(
130! Tyr( Tyr(
131! Asp!/!Tyr!! Tyr(
132! Asp!/!Tyr!/!Phe! Phe!/!Tyr!
189! Arg!/!Lys! Met!/!Thr!
!
*APOBEC3H!not!included!!
 
Supplementary(Table(1.(Conservation(of(DNA(coordinating(residues(between(human(A3(
domains((catalytic(and(inactive(pseudo2catalytic)(
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III.c.4. The conserved N57 is central to the active site geometry. 
N57 of A3A is completely conserved among the catalytically active 
APOBEC protein domains, while inactive pseudo-catalytic A3 domains have a 
conserved glycine (Figure III.1 and Table III.2), and widely conserved among 
other cytidine/cytosine deaminases from Escherichia coli through Homo sapiens 
(52). The structure explains this strong conservation, as N57 of A3A is central in 
recognizing ssDNA with three key distinct interactions: The side chain of N57 
determines the 5’–3’ directionality of ssDNA binding by forming a hydrogen bond 
to O3’ atom of dC0, which helps stabilize the geometry of the DNA backbone and 
the sugar in a C2’-endo conformation (Figure III.5B and Figure 7A) and induces 
a backbone deformation due to steric hindrance with O5’ of the target dC0. The 
N57 side chain forms a hydrogen bond with the backbone NH of T31, positioning 
the T31 side chain to hydrogen bond to the π-orbital cloud of the dC0 base ring, 
thus ensuring the geometry of the target nucleotide within the active site (Figure 
III.5A and Figure 7A). Finally, the N57 side chain packs against both the 
deoxyribose ring of dC0, stabilizing the orientation of sugar plane, and H70, 
which coordinates zinc. Although RNA deaminase activity has been reported for 
A3A (53,54), if the sugar was a ribose a steric clash between the 2’-OH and H70 
would occur, therefore requiring a conformational rearrangement for RNA 
modification. Thus, these three pivotal interactions of N57 organize the enzyme 
substrate complex to be poised for catalytic turnover. 
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Figure III.7. Close-up views of the conserved asparagine and sugar 
arrangement.  
The selected amino acid residues in  
A. A3A in complex with ssDNA (this study; only dC0 is shown)  
B. DNA cytidine deaminase from bacteriophage S-TIM5 (PDB code 4P9C)(56) in 
complex with deoxyuridine monophosphate (dUMP)  
C. RNA cytidine deaminase from mouse (PDB code 2FR6) (55) in complex with 
cytidine (rC) and  
D. RNA cytidine deaminase from human (PDB code 1MQ0) (57) in complex with 
deaminase inhibitor, 1- βribofuranosyl-1,3-diazapinone (indicated by asterisk) are 
shown as a stick model (carbons for the conserved asparagine residue, green; 
carbons for others, white). The substrates are colored orange for carbons and 
phosphates. The conserved asparagine and neighboring histidine/cysteine are 
drawn with van der Waals surface. 
 
 
 
 
 
 
Supplementary Fig. 4. Close-up views of the conserved asparagine and sugar arrangement. The 
selected amino acid residues in (a) A3A in complex with ssDNA (this study; only dC0 is shown) 
(b) DNA cytidine deaminase from bacteriophage S-TIM5 (PDB code 4P9C)56!in complex with 
deoxyuridine monophosphate (dUMP) (c) RNA cytidine deaminase from mouse (PDB code 
2FR6)55 in complex with cytidine (rC) and (d) RNA cytidine deaminase from human (PDB code 
1MQ0)57  in complex with deaminase inhibitor, 1-"- ribofuranosyl-1,3-diazapinone (indicated by 
asterisk) are shown as a stick model (carbons for the conserved asparagine residue, green; 
carbons for others, white). The substrates are colored orange for carbons and phosphates.  The 
conserved asparagine and neighboring histidine/cysteine are drawn with van der Waals surface. 
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The three central interactions mediated by N57 are strictly conserved in 
the active site geometry of other cytidine deaminases (55-57), where the 
asparagine side chain (1) hydrogen bonds to substrate backbone, (2) packs to 
maintain the sugar orientation and (3) packs against the zinc-coordinating 
residue side chain (Figure III.7B-D). The RNA cytidine deaminases replace the 
zinc coordinating histidine with a relatively small amino acid, cysteine, which 
permits a ribose ring to fit (Figure III.7.C,D). This structure explains why although 
not located directly at the active site, even conservative N57Q or N57D mutations 
severely disrupt deaminase activity (29,52,58), thus our A3A–ssDNA structure 
reveals the conservation of N57 to be critical for proper orientation of the 
substrate within the active sites of cytidine deaminases. 
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III.c.5. H29 coordinates the ssDNA binding in the active site.  
H29 is the other lynchpin in ssDNA binding to A3A. H29 of A3A 
corresponding to H216 in the catalytic domain of A3G (A3G-CTD), which when 
mutated to alanine abolishes activity (21). Maximal catalytic activity occurs at pH 
5.5 for both A3G-CTD (59) and A3A (52), implying that the histidine is 
protonated. Interestingly, this His is not completely conserved in other A3s, 
where this position is sometimes an arginine or asparagine. The H216R mutation 
in A3G and H29R in A3A resulted in reduced but still significant catalytic activity 
(41,59). In the apo A3A crystal structure (26), H29 is involved in crystal contacts 
and rotated away from the active site (Figure III.2D). In the NMR structure of 
A3A the H29, side chain is solvent exposed and the rotamer is not defined in 
solution (PDB code 2M65) (35). Thus, upon ssDNA binding, the side chain of 
H29 selects a rotamer to interact extensively with the substrate, latching the 
active site to permit catalysis. Once catalysis occurs, H29 needs to rotate out of 
this position to release the deaminated product. H29 forms hydrogen bonds to 
the backbone phosphates of dT-1, dC0, and dT1, and the deoxyribose of dT1 
(Figure III.2D-F and Figure III.5D). The side chain of H29 is crucial in dT1 
recognition, with the imidazole ring positioned to form π–π interactions with the 
pyrimidine ring of dT1. This relatively non-specific stacking interaction explains 
the apparent lack of specificity at the +1 position. Thus, our structure reveals the 
unique role of H29 in positioning the substrate ssDNA with a series of 
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coordinated hydrogen bonds and stacking interactions, essentially latching the 
ssDNA and the target dC0, within the active site. 
 
  
 
 108 
III.c.6. A3A and rA3G-NTD differ in DNA binding.  
The recent structure of ssDNA bound to the inactive pseudo-catalytic 
domain rA3G-NTD (42) is not that of a substrate complex and displays a binding 
mode that is incompatible with catalysis. In contrast to our structure, the single 
base ordered in that structure is not coordinated within the binding pocket 
(Figure III.8), but rather a sugar is partially buried in the pocket. More 
specifically, comparing the A3A–ssDNA with the rA3G-NTD– ssDNA structure: 
H70, W98, S99 and Y130 in A3A (H65, W94, S95 and Y125 in rA3G-NTD) are 
conserved in the two protein’s sequences and interact with ssDNA; however, 
there are no similarities in their interactions with the ssDNA (Figure III.5A, 
Figure III.8, and Figure III.9). H70 of A3A forms a π-hydrogen bond with dC0, 
while H65 of rA3G-NTD forms a hydrogen bond with C3’-carbonyl group of the 
ribose of dT0. W98 and S99 of A3A use their backbone carbonyl group to 
hydrogen bond with amino group of the target cytidine (dC0), while W94 of rA3G-
NTD is stacking with the pyrimidine of dT0. Y130 of A3A forms a π–π interaction 
with dC0 and a hydrogen bond with the phosphate between dC0 and dT-1, while 
Y125 of rA3G-NTD forms a hydrogen bond with C3’-carbonyl group of the ribose 
of dT1. Many of these interactions preclude the interactions observed in A3A–
ssDNA (Figure III.2 and Figure III.5). Amino acids with more extensive 
interactions with substrate ssDNA are not conserved in sequence or structure 
including: H29, which is D, T31, which is V, and the critical N57, which is G 
(Figure III.1). In addition, interactions at -1 and +1 positions are not observed in  
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Figure III.8. View of the atomic interactions between rA3G-NTD and ssDNA 
(5K83).  
rA3G-NTD (gray ribbon) bound to ssDNA (orange sticks: dT0 base, the backbone 
of dT1 and the sugar of dT0), magenta and red spheres are water and Zn 
respectively. 
 
 
 
 
 
Supplementary Fig. 5. Stereo-view of the atomic interactions between rA3G-NTD and ssDNA 
(5K83). rA3G-NTD (gr y ibbon) bound to ssDNA (orange sticks: dT0 base, the backbone of dT1 
and the sugar of dT0), magenta and red spheres are water and Zn respectively.  
 
 
 
 
Supplementary Fig. 6. (a) 2Fo-Fc and Fo-Fc maps of the bound DNA. A3A and DNA structure 
are represented as cartoon and stick model, respectively. The 2Fo-Fc map is indicated with a 
cyan-colored mesh (1.0σ), the Fc-Fo map is depicted blue (3.0σ) and red (-3.0σ). (b) The 
simulated-annealing composite omit map of the bound DNA. The 2mFo-DFc map (pink) is 
contoured at 1.0σ. 
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Figure III.9. Structure and substrate-binding similarity between A3A and 
RNA deaminase TadA.  
A. A3A structure (green ribbon) bound to substrate DNA (orange sticks, as in 
Fig. 1b). Three DNA nucleotides (dT-1, dC0 and dT1) are displayed. A zinc ion at 
the active center is coordinated by H70 (helix α2), C101 and C106 (helix α3).  
B. TadA structure (60) (PDB code 2B3J) (grey ribbon) bound to substrate RNA 
(orange sticks). Three RNA nucleotides (rU-1, Neb0 (nebularine) and rC1) are 
displayed. Zinc-coordinating residues H53 (helix α2), C83 and C86 (helix α3) are 
shown in stick representation (carbons, white; nitrogens, blue; oxygen, red; 
sulfurs, yellow).  
 
Methods
Preparation of protein and DNA. The preparation method of A3A(E72A/C171A)
protein was described previously26 as follows: the protein was expressed in E. coli
strain BL21 DE3 Star (Stratagene) cells with pCold-GST-A3A(E72A/C171A)
vector. Expression was induced with 1 mM isopropyl b-D-1-thiogalactopyranoside
at 16 !C for 22 h in lysogeny broth medium containing 100 mg ml! l ampicillin.
Cells were pelleted, resuspended in purification buffer (50 mM Tris-HCl (pH 8.0),
300 mM NaCl and 1 mM dithiothreitol) and lysed through sonication. Cellular
debris was separated by centrifugation (45,000g, 30 min, 4 !C). The protein was
purified as a GST-fused protein with glutathione-immobilized resin (Clontech).
After digesting with HRV 3C protease, the protein was further purified with a
size-exclusion column (GE Healthcare) equilibrated with a buffer (10 mM Tris-HCl
(pH 8.0), 200 mM NaCl and 1 mM dithiothreitol). The fraction containing the
monomeric form was collected and concentrated for crystallization. The purity and
integrity of A3A(E72A/C171A) was confirmed by SDS–polyacrylamide gel
electrophoresis. E72A inactivates the enzyme, while C171A (distal the active site)
enhances solubility of the expressed protein.
The DNA oligo, d(TTTTTTTTCTTTTTT), was synthesized (Integrated DNA
Technologies), and mixed with the purified A3A(E72A/C171A) protein at a molar
ratio of 2:1.
Crystallization and data collection. Crystals of the A3A(E72A/C171A)–DNA
complex were grown by hanging-drop vapour-diffusion method over a reservoir of
100 mM MOPS (pH 6.5), 50 mM MgCl2, 50 mM CaCl2, 23% polyethylene glycol
3,350 and 15% 2-methyl-2,4-pentanediol. Drops were formed by mixing 1 ml of
A3A(E72A/C171A)–DNA solution (B20 mg ml! l of protein concentration) and
1 ml of reservoir solution, with equilibration over the reservoir at 20 !C. Micro-
seeding was performed using a cat whisker and larger crystals suitable for X-ray
diffraction were obtained. Crystals were flash-frozen directly in the cryogenic
stream. Diffraction data were collected using an in-house X-ray source MicroMax-
007 HF (Rigaku) with a copper anode at a wavelength of 1.54178 Å and a Saturn
944 HG (Rigaku) detector. The space group of the crystals was I222 with unit cell
dimensions of a¼ 56.6 Å, b¼ 72.7 Å, c¼ 115.0 Å (Table 1). The collected inten-
sities were indexed, integrated, corrected for absorption and scaled using HKL2000
(ref. 62).
Structure determination. The protein structure was solved by molecular repla-
cement phasing using a previously determined apo A3A(E72A/C171A) crystal
structure (PDB code 4XXO)26 with the program Phaser63. Model building of the
protein and bound DNA, and refinements were manually performed using the
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Figure 4 | Structure and substrate-binding similarity between A3A and RNA deaminase TadA. (a) A3A structure (green ribbon) bound to substrate
DNA (orange sticks, as in Fig. 1b). Three DNA nucleotides (dT! 1, dC0 and dT1) are displayed. A zinc ion at the active centre is coordinated by H70 (helix
a2), C101 and C106 (helix a3). (b) TadA structure60 (PDB code 2B3J) (grey ribbon) bound to substrate RNA (orange sticks). Three RNA nucleotides (rU! 1,
Neb0 (nebularine) and rC1) are displayed. Zinc-coordinating residues H53 (helix a2), C83 and C86 (helix a3) are shown in stick representation (carbons,
white; nitrogens, blue; oxygen, red; sulfurs, yellow). (c) rA3G-NTD structure (grey ribbon) bound to ssDNA (orange sticks), only dT0 has the base while the
backbone of dT1 and the sugar of dT0 is mapped. Surface representation of the nucleotide-binding site of (d) A3A, (e) TadA (f) A3G-NTD. Close-up view of
the active site of (g) A3A, (h) TadA and (i) A3G-NTD. The catalytic glutamic acid side chain was modelled in instead of alanine at position 72 in the A3A
crystal structure.
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Figure III.9. Structure and substrate-binding similarity between A3A and 
RNA deaminase TadA. (Continued) 
C. rA3G-NTD structure (grey ribbon) bound to ssDNA (orange sticks), only dT0 
has the base while the backbone of dT1 and the sugar of dT0 is mapped.  
Surface representation of the nucleotide-binding site of D. A3A, E. TadA F. 
A3G-NTD. Close-up view of the active site of G. A3A, H. TadA and I. A3G-
NTD. The catalytic glutamic acid side chain was modelled in instead of alanine 
at position 72 in the A3A crystal structure. 
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the rA3G-NTD–ssDNA complex structure as only a single dT0 is ordered in the 
electron density. Critically, the target cytidine (dC0) in the A3A is located ready for 
deamination, while non- substrate dT0 in the rA3G-NTD is not located close to 
the catalytic Zn2+. This binding mode corresponds to a much lower affinity of the 
pseudo-catalytic rA3G-NTD to ssDNA (~1.6 µM) (42) confirming non-specific 
binding, compared to ~60 nM (26) we observed for substrate ssDNA binding to 
A3A. While the rA3G-NTD-dT structure may represent mechanisms by which 
non-substrate ssDNA binds A3 domains, the A3A–ssDNA structure we present 
here elucidates the mechanism by which ssDNAs are recognized as substrates 
by catalytically active A3s. 
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III.c.7. Molecular recognition in polynucleotide deaminases.  
Our crystal structure of the A3A–ssDNA complex and the crystal structure 
of Staphylococcus aureus tRNA adenosine deaminase (TadA) in complex with 
RNA (2B3J) (60) are structures of single- stranded polynucleotide deaminases 
bound to their substrates. Although their substrates are different, as TadA 
deaminates adenosine at the anti-codon stem-loop of tRNAArg2 and A3A 
deaminates cytosines in ssDNA, their active sites are similar in that both have a 
HAEx~30Cx2-4C zinc-binding motif. We observe the most striking similarity in the 
phosphate-sugar backbone traces of RNA (TadA) and ssDNA (A3A) (Figure 
III.9): 5’–3’ directionality is the same, and the polynucleotide is sharply bent with 
the target nucleotide deep in the active site pocket. Five nucleotides located in 
the anti-codon stem-loop of tRNAArg2 have adopted C2’-endo ribose conformation 
that is typical for DNA, explaining how the RNA forms a similar backbone 
conformation to the ssDNA bound to A3A (Figure III.9A,D,G). This remarkable 
similarity of the phosphate-sugar backbone, despite different substrates, tRNA 
for TadA and ssDNA for A3A, implies that the HAEx~30Cx2-4C type zinc-dependent 
deaminases have an evolutionary conserved substrate-binding topology as well 
as catalytic mechanism. 
This crystal structure of an ssDNA substrate–enzyme complex reveals 
how substrate recognition occurs by single-stranded polynucleotide-modifying 
enzymes, for APOBEC family members and other ssDNA deaminases. This is in 
contrast with the pseudo-catalytic domain A3G-NTD (42), which is not a 
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substrate complex and has a single base ordered in the structure that is only 
partially buried in the binding pocket, displaying a very dissimilar binding mode 
(Figure  III.9C,F,I). The striking similarity of A3A–ssDNA (Figure III.9A,D,G) with 
the structure of TadA–tRNA complex (Figure III.9B,E,H) implies structural and 
mechanistic conservation among single-stranded nucleotide-modifying enzymes 
that have evolved to acquire distinct specificities. These specificities may be 
leveraged for specific gene editing. APOBEC1 and other cytidine deaminases 
were recently combined with CRISPR/Cas9 technology in direct ‘base editing’ to 
correct point mutations, without the need for a donor template or double-stranded 
DNA breaks (61). By leveraging the directionality, specificity and binding 
architecture of ssDNA revealed by our A3A–ssDNA complex, base-editing 
technologies will become even more targeted and specific to expand the scope 
and effectiveness of genome editing. 
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III.d. Methods 
III.d.1. Preparation of protein and DNA.  
The preparation method of A3A(E72A/C171A) protein was described previously 
(26) as follows: the protein was expressed in E. coli strain BL21 DE3 Star 
(Stratagene) cells with pCold-GST-A3A(E72A/C171A) vector. Expression was 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside at 16 °C for 22 h in 
lysogeny broth medium containing 100 µg ml-1 ampicillin. Cells were pelleted, 
resuspended in purification buffer (50 mM Tris-HCl (pH 8.0), 300 mM NaCl and 1 
mM dithiothreitol) and lysed through sonication. Cellular debris was separated by 
centrifugation (45,000g, 30 min, 4 °C). The protein was purified as a GST-fused 
protein with glutathione-immobilized resin (Clontech). After digesting with HRV 
3C protease, the protein was further purified with a size-exclusion column (GE 
Healthcare) equilibrated with a buffer (10 mM Tris-HCl (pH 8.0), 200 mM NaCl 
and 1 mM dithiothreitol). The fraction containing the monomeric form was 
collected and concentrated for crystallization. The purity and integrity of 
A3A(E72A/C171A) was confirmed by SDS–polyacrylamide gel electrophoresis. 
E72A inactivates the enzyme, while C171A (distal the active site) enhances 
solubility of the expressed protein. 
The DNA oligo, d(TTTTTTTTCTTTTTT), was synthesized (Integrated DNA 
Technologies), and mixed with the purified A3A(E72A/C171A) protein at a molar 
ratio of 2:1. 
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III.d.2. Crystallization and data collection.  
Crystals of the A3A(E72A/C171A)–DNA complex were grown by hanging-
drop vapour-diffusion method over a reservoir of 100 mM MOPS (pH 6.5), 50 mM 
MgCl2, 50 mM CaCl2, 23% polyethylene glycol 3,350 and 15% 2-methyl-2,4-
pentanediol. Drops were formed by mixing 1 µl of A3A(E72A/C171A)–DNA 
solution (~20 mg ml-1 of protein concentration) and 1 µl of reservoir solution, with 
equilibration over the reservoir at 20 °C. Micro- seeding was performed using a 
cat whisker and larger crystals suitable for X-ray diffraction were obtained. 
Crystals were flash-frozen directly in the cryogenic stream. Diffraction data were 
collected using an in-house X-ray source MicroMax- 007 HF (Rigaku) with a 
copper anode at a wavelength of 1.54178 Å and a Saturn 944 HG (Rigaku) 
detector. The space group of the crystals was I222 with unit cell dimensions of a 
a = 56.6 Å, b = 72.7 Å, c = 115.0 Å (Table III.1). The collected intensities were 
indexed, integrated, corrected for absorption and scaled using HKL2000 (62). 
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III.d.3. Structure determination.  
The protein structure was solved by molecular replacement phasing using a 
previously determined apo A3A(E72A/C171A) crystal structure (PDB code 
4XXO) (26) with the program Phaser (63). Model building of the protein and 
bound DNA, and refinements were manually performed using the programs Coot 
(64) and Phenix (65,66), respectively. A simulated annealing omit map was 
calculated to confirm the ssDNA positioning (Figure III.10). The first nine 
residues and the side chains of residues R10, H11, H16, K30, N42, V46, K47, 
Q50, Q58, K60, L62, L63, F66, Y67, D177, E181 and N196 of A3A(E72A/C171A) 
were not modelled in due to lack of electron density. Residues N42–T44 and 
L62– G65 were somewhat disordered; the occupancy values were set to 0.5 for 
residues N42–T44, L62 and G65, and to 0.75 for residues L63 and C64 due to 
poor electron density. A density proximal to a zinc ion at the active center was 
assigned to chloride considering the statistics of zinc ligand (67), resulting in a 
good fit without phase-error signals (Figure III.11). The identification of the active 
site zinc is further supported by the highest peak, 9.5σ, in an anomalous 
difference Fourier map at this position. A smaller peak at 5.6σ in this map is 
present at the assigned chloride position. The final model was refined to 
R(work)/R(free) values of 0.177/ 0.225 at 2.20 Å resolution (Table III.1). The quality 
of the final model was assessed by Molprobity68, which indicated that 96.2% of 
the residues were in the favored dihedral angle configuration and there were no 
Ramachandran outliers. 
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Figure III.10. Simulated annealing omit map confirms ssDNA positioning 
A. 2Fo-Fc and Fo-Fc maps of the bound DNA. A3A and DNA structure are 
represented as cartoon and stick model, respectively. The 2Fo-Fc map is 
indicated with a cyan-colored mesh (1.0σ), the Fc-Fo map is depicted blue 
(3.0σ) and red (-3.0σ).  
B. The simulated-annealing composite omit map of the bound DNA. The 
2mFo-DFc map (pink) is contoured at 1.0σ. 
 
 
 
 
Supplementary Fig. 5. Stereo-view of the atomic interactions between rA3G-NTD and ssDNA 
(5K83). rA3G-NTD (gray ribbon) bound to ssDNA (orange sticks: dT0 base, the backbone of dT1 
and the sugar of dT0), magenta and red spheres are water and Zn respectively.  
 
 
 
 
Supplementary Fig. 6. (a) 2Fo-Fc and Fo-Fc maps of the bound DNA. A3A and DNA structure 
are represented as cartoon and stick model, respectively. The 2Fo-Fc map is indicated with a 
cyan-colored mesh (1.0σ), the Fc-Fo ap is depicted blue (3.0σ) and red (-3.0σ). (b) The 
simulated-a nealing composite omit map of the bound DNA. The 2mFo-DFc map (pink) is 
contoured at 1.0σ. 
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Figure III.11. Modeling in the electron density. 
Modeling in the electron density next to the active site zinc (Zn) with a  
A. chloride ion (Cl) versus  
B. water molecule (W). The 2Fo-Fc map is indicated with a cyan- colored 
mesh (1.0σ), the Fc-Fo map is depicted by meshes colored in blue (3.0σ) and 
red (-3.0σ). 
 
 
Supplementary Fig. 7 Modeling in the ele tron density next to the active site zinc (Zn) with a 
(a) chloride ion (Cl) versus (b) water molecule (W).  The 2Fo-Fc map is indicated with a cyan-
colored mesh (1.0σ), the Fc-Fo map is depicted by meshes colored in blue (3.0σ) and red (-
3.0σ).  
!
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III.d.4. Structure analysis.  
Figures of structure models were generated by Pymol (69), which was 
also used to model in the catalytic E72 side chain in Figs 3 and 4. The 
electrostatic distribution of A3A(E72A/C171A) was calculated and visualized 
using PDB2PQR server (70) and Pymol with the APBS plugin, where the 
cysteine was modelled as thiolate anion (S-) and solutes were excluded. Solvent-
accessible and buried surface area was calculated with PISA (71). Local root 
mean square deviation between apo and DNA-bound forms of 
A3A(E72A/C171A) was calculated using Molmol (72). The distance difference 
matrices between the apo- and DNA-bound forms of A3A(E72A/C171A) were 
calculated and visualized using a custom-made script in MacOS Xcode 
(https://developer.apple.com/xcode/).   
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Chapter IV  
 
Substrate Sequence Selectivity of APOBEC3A 
Implicates Intra-DNA Interactions 
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IV.a. Abstract 
The APOBEC3 (A3) family of human cytidine deaminases is renowned for 
providing a first line of defense against many exogenous and endogenous 
retroviruses. However, the ability of these proteins to deaminate deoxycytidines 
in ssDNA makes A3s a double-edged sword. When overexpressed, A3s can 
mutate endogenous genomic DNA resulting in a variety of cancers. Although the 
sequence context for mutating DNA varies among A3s, the mechanism for 
substrate sequence specificity is not well understood. To characterize substrate 
specificity of A3A, a systematic approach was used to quantify the affinity for 
substrate as a function of sequence context, length, secondary structure, and 
solution pH. We identified the A3A ssDNA binding motif as (T/C)TC(A/G), which 
correlated with enzymatic activity. We also validated that A3A binds RNA in a 
sequence specific manner. A3A bound tighter to substrate binding motif within a 
hairpin loop compared to linear oligonucleotide, suggesting A3A affinity is 
modulated by substrate structure. Based on these findings and previously 
published A3A–ssDNA co-crystal structures, we propose a new model with intra-
DNA interactions for the molecular mechanism underlying A3A sequence 
preference. Overall, the sequence and structural preferences identified for A3A 
leads to a new paradigm for identifying A3A’s involvement in mutation of 
endogenous or exogenous DNA. 
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IV.b. Introduction 
The APOBEC3 (short for “apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like”) family of human cytidine deaminases provides a first line of 
defense against many exogenous and endogenous retroviruses such as HIV-1 
and the retro-element LINE-1 (1-6). APOBEC3 (A3) proteins restrict replication of 
retroviruses by inducing hypermutations in the viral genome (7). A3s deaminate 
deoxycytidines in ssDNA into uridines during reverse transcription. This results in 
G to A hypermutations, as adenosines are transcribed across from uridines 
during second strand DNA synthesis. While all A3 enzymes deaminate 
deoxycytidines in ssDNA, they have differential substrate specificities that are 
context dependent, resulting in altered frequencies of mutation for the 
deoxycytidines. Some A3s deaminate the second deoxycytidine in a sequence 
containing CC while others deaminate deoxycytidine in a TC context (8-10). 
However, not every cognate dinucleotide motif (CC or TC) in the ssDNA of the 
HIV genome is deaminated (11). Nevertheless, hypermutation in a viral genome 
results in defective proteins and proviruses, thus decreasing the probability of 
further viral replication (12). 
Beyond restricting viral replication, the ability of A3s to deaminate 
deoxycytidines in ssDNA have made A3s a double-edged sword. When 
overexpressed, A3s can mutate the host genome resulting in a variety of 
cancers. The identities and patterns of the mutations observed in cancer 
genomes can define the source of these mutations. Recently, the search for the 
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deaminase(s) responsible for kataegic mutations found in breast cancer was 
narrowed down to APOBEC3B, through the comparison of all known APOBEC 
mutational signatures and eliminating APOBEC3G and other deaminases from 
potential mutational contributors (9, 13). Soon after, APOBEC3B was found to be 
correlated with a variety of other cancers such as ovarian, cervical, bladder lung, 
head and neck; signature sequence analysis was also a contributing factor that 
led to these conclusions (14, 15). Most recently APOBEC3H, which has a 
different sequence preference than APOBEC3B, has been identified to also play 
a role in breast and lung cancer (16). Thus, defining A3 sequence specificity can 
be helpful in identifying A3’s role in viral restriction and in cancer.  
 A3 signature sequences proposed for deaminating deoxycytidines range 
between di-nucleotide to quad-nucleotide motifs (8-11, 16-21). Although A3s are 
known to have varied sequence preference, quantitative and systematic studies 
of sequence specificity are incomplete. Recently, crystal structures of 
APOBEC3A (A3A) and APOBEC3B-CTD (an active site A3A chimera) with 
ssDNA have been solved (20, 22). However, despite these breakthrough 
structures, the molecular mechanism underlying substrate sequence specificity 
flanking the TC dinucleotide sequence remains unclear.  
 A3A is a single-domain enzyme with the highest catalytic activity among 
human APOBEC3 proteins (23) and a known restriction factor for the 
retroelement LINE-1 and HPV (24, 25). A3A can also contribute to 
carcinogenesis with increased expression or defective regulation (26). A3A is the 
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only A3 where both the intact apo and substrate bound structures have been 
determined (19, 20, 22, 27, 28). Initial substrate specificity studies have shown a 
preference for DNA over RNA, suggested by NMR chemical shift perturbation 
(19). Since A3A is the best biochemically characterized A3 human cytidine 
deaminase and thus a critical benchmark within the family, we chose A3A to 
elucidate the extended characteristics of ssDNA specificity.  
 To determine the substrate specificity of A3A, we systematically quantified 
the affinity of A3A for nucleic acid substrates as a function of substrate 
sequence, length, secondary structure, and solution pH. We identified the A3A 
preferred ssDNA binding motif, (T/C)TC(A/G) and found this sequence correlated 
with enzymatic activity.  Also, we determined that A3A can bind RNA in a 
sequence specific manner. Surprisingly, A3A’s signature sequence was 
necessary but not sufficient to account for A3A’s high affinity for ssDNA. 
Significantly, A3A bound more tightly to the motif in longer oligonucleotides, and 
in the context of a hairpin loop. Using recently published structures of A3As 
complexed with ssDNA from our lab and others, we propose a structural model 
for the molecular mechanism for this enhanced affinity where inter-DNA 
interactions contribute to A3A recognition of the cognate sequence. This model 
provides insights into how the nucleotides flanking the canonical TC sequence 
may contribute to substrate sequence preference of A3A.  
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IV.c. Results 
IV.c.1. A3A binding to ssDNA is context dependent.  
To interrogate the substrate sequence preference of A3A, we systematically 
quantified the changes in binding affinity of catalytically inactive A3A bearing the 
mutation E72A to a library of labeled ssDNA sequences using a fluorescence 
anisotropy-based DNA binding assay (28). First, to ensure that the affinity for 
substrate was due entirely to the sequence of interest and not due to nonspecific 
binding or undesired secondary structure effects, an appropriate control 
background sequence was identified. The dissociation constants (Kd’s) for homo-
12-mer ssDNA sequences, Poly A, Poly T, Poly C, were determined (Figure 
IV.1A). Poly G was not tested due its propensity to form secondary structure 
elements. Poly T (750 ± 44 nM), which had previously been used in background 
sequences (28), bound to A3A with 2-fold higher affinity than Poly C (1,600 ± 117 
nM). Thus without a greater context for A3A to target, Poly C was only weakly 
bound. A3A had the lowest affinity for Poly A with a Kd of >11,00 nM (Table IV.1). 
For all subsequent assays, Poly A was used as the background, as there is no 
detectible binding affinity of A3A to Poly A.  
The specificity of A3A for substrate versus product was measured by 
binding to Poly A with a single C versus Poly A with a single U (Figure IV.1B). 
Surprisingly, the presence of a single deoxycytidine in a Poly A background was 
not sufficient for binding with appreciable affinity. The affinity of A3A for the Poly 
A-C (5A-1C-6A) (>5,000 nM) is similar to the affinity for Poly A-U (5A-1U-6A)  
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Figure IV.1. A3A specificity to ssDNA background and substrate.  
Fluorescence anisotropy of TAMRA-labeled ssDNA sequences binding to 
A3A(E72A).  
A. Binding of A3A to poly nucleotide (12 mers): Poly A (blue), Poly T (red) and 
Poly C (green),  
B. Binding to Poly A (blue), 5A-C-6A (red), 5A-U-6A (green),  
C. Binding to Poly T (blue), 5T-C-6T (red), 5T-U-6T (green). 
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Table IV.1. A3A affinity for DNA sequences used in this analysis 
 
 
 
 
Table 1 A3A affinity for DNA sequences used in this analysis
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(>6,500 nM) and even the background Poly A. This is in contrast to A3A’s 
specificity for binding a single C over U in a Poly T background, which is more 
than ten-fold (35 ± 2 nM and 500 ± 23 nM respectively) (Figure IV.1C), as we 
previously measured (28). This strong context dependence differentiating 
substrate C versus product U within the background of Poly A versus Poly T 
indicates that A3A heavily relies on the identity of the surrounding nucleotide 
sequence to recognize and bind substrate deoxycytidine.  
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IV.c.2. A3A affinity for ssDNA is pH dependent. 
A systematic measurement of A3A affinity in a broad range of pH values was 
performed to verify and quantify the pH dependence of A3A to substrate ssDNA 
(21, 26), and set a reference pH for subsequent experiments. The Kd of A3A for 
TTC in a Poly A background was determined at pH ranging from 4.0 to 9.0 in 0.5 
pH increments (Figure IV.2 and Table IV.2). A3A had the highest affinity for Poly 
A-TTC at pH 5.5 with a Kd of 68 ± 3 nM. The isotherms for A3A binding ssDNA at 
pHs below 6.0 show some secondary binding event that may be due to non-
specific binding or aggregation (Figure IV.2A). A steady decrease was also 
observed for the affinity of A3A for ssDNA when pH was increased above 6 
(Figure IV.2B), in agreement with decreased deamination activity at higher pH 
(26). A3A affinity also overall correlated with reported deamination activity 
determined using a different assay at pH 7.5 (30). Interestingly, A3A had no 
appreciable affinity for Poly A-TTC above pH 8.0. Since A3A is stable at these 
higher pH values, the lower affinity for ssDNA with increased pH is likely not due 
to aggregation but due to the protonation of His 29, as previously described (26) 
and reported to be responsible for coordinating ssDNA (31). Therefore, all of the  
subsequent binding experiments were performed at pH 6.0 to avoid any potential 
for secondary binding events or aggregation of the protein. 
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Figure IV.2. A3A affinity to ssDNA at different pHs.  
Fluorescence anisotropy of TAMRA-labeled ssDNA 4A-TTC-6A binding to 
A3A(E72A).  
A. Binding of A3A to ssDNA at pH 6.0 (blue), 6.5 (red), 7.0 (green), 7.5 
(orange), 8.0 (purple), 8.5 (black), 9.0 (brown).  
B. Binding of A3A to ssDNA at pH 4.0 (blue), 4.5 (red), 5.0 (green), 5.5 
(orange), and 6.0 (purple). 
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Table IV.2. A3A affinity for ssDNA Poly A -TTC in a range of pHs 
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IV.c.3. Substrate recognition is dependent on thymidine directly 
upstream of target deoxycytidine, with preference for 
pyrimidines over purines.  
 To study the effect of the nucleotide identity at position -1 relative to target 
deoxycytidine (NC) on A3A affinity for substrate (Figure IV.3A), the Kd values of 
A3A for (4A)-TC-(6A), AC, CC, GC in a Poly A background were determined. A 
preference for TC (143 ± 4 nM), followed by CC (250 ± 14 nM) was identified. 
Interestingly, AC and GC had similarly very weak binding affinities for A3A 
(>5,000 and >6,500 nM respectively), validating a preference for pyrimidines (T 
or C) over purines (A or G) at -1 position with T as the strongest binder.  
The effects of the sequence identity around the cognate dinucleotide 
deamination motif (TC) on affinity of A3A for ssDNA was determined by first 
testing the change in affinity for all nucleotide substitutions at -2 position (3A)-
NTC-(6A). A3A has a preference for pyrimidine over purine at -2 position (Figure 
IV.3B) with TTC and CTC having similar affinities (90 ± 1 nM and 85 ± 1 nM 
respectively) compared to that of purines ATC and GTC (145 ± 2 nM and 150 ± 3 
nM respectively). While not as strong as for -1 position, there is a preference for 
the smaller pyrimidines at position -2. Next, the effect of +1 position on affinity of 
A3A to TC was determined (Figure IV.3C). A3A did not demonstrate a strong 
preference for any particular nucleotide, although disfavoring T, at the +1 position 
(145 ± 2 nM for background versus 209 ± 5 nM).  
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Figure IV.3. A3A specificity for nucleotides flanking substrate cytidine. 
Fluorescence anisotropy of TAMRA-labeled ssDNA sequences to A3A(E72A).  
A. Binding of A3A to ssDNA with changes at -1 position of substrate C and TU 
(purple) in a poly A background (12 mers): 4A-AC-6A (blue), 4A-TC-6A (red), 4A-
CC-6A (green), and 4A-GC-6A (orange).  
B. Binding of A3A to ssDNA with changes at -2 position in a TC context in a Poly 
A background (12 mers): 4A-ATC-6A (blue), 4A-TTC-6A (red), 4A-CTC-6A 
(green), and 4A-GTC-6A (orange).  
C. Binding of A3A to ssDNA with changes at +1 position in a TC context in a Poly 
A background (12 mers): 4A-TCA-6A (blue), 4A-TCT-6A (red), 4A-TCC-6A 
(green), and 4A-TCG-6A (orange).  
D.Three substrate sequences, TTCA (green), ATCG (red) and ATCA (blue), in 
closed circles with the corresponding 3 product sequences TTUA, ATUG and 
ATUA in open circles.   
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Figure IV.4. A3A specificity for poly A xTCx.  
Binding affinity of A3A(E72A) to TAMRA-labeled ssDNA sequences in a Poly A 
background. Gray boxes bin sequences by -2 nucleotide identity. Colors 
represent +1 nucleotide identity: A (blue), T (red), C (green), G (orange). 
Consensus sequence derived from these Kd values is shown above the graph. 
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Finally, to identify if there was any interdependency between nucleotide 
identity at -2 and +1 positions, the affinity of A3A for (3A)-NTCN-(5A) was 
determined (Figure IV.4, Table IV.1). A3A displayed preference for pyrimidines 
at -2 position regardless of the nucleotide at +1. A3A also disfavored T at +1 
position regardless of the nucleotide identity at -2. Most interestingly, A3A 
preferred a pyrimidine at -2 when there was a purine at +1 position. However, the 
reverse was not true; purine at -2 position with pyrimidine at +1 position did not 
result in comparable affinities. In fact, the worst binders (ATCT and GTCT) were 
those that contained purines at -2 with pyrimidines at +1 position. Thus, we have 
broadly have three classes of substrate binders high affinity (80-130 nM), 
medium affinity (150-165nM), and weak affinity (210-220 nM) and have identified 
(T/C)TC(A/G) as the preferred sequence for ssDNA recognition by A3A. 
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IV.c.4. A3A preference for binding to substrate over product in 
context dependent. 
A3A’s affinity for substrate C was compared to product U in the context of 
variations of the signature A3A substrate sequence (T/C)TC(A/G). The affinity of 
three substrate sequences, TTCA, ATCG and ATCA, were compared to the 
corresponding product sequences (Figure IV.3D). For all three sequences, a 
substantial loss of binding affinity was observed for the corresponding TTUA, 
ATUG and ATUA, with the most substantial loss with ATUA. Thus, the decrease 
in affinity for product over substrate was context dependent. 
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IV.c.5. Positive correlation between sequence preference of 
binding and enzymatic activity. 
Although enzymatic activity and binding affinity are not expected to be 
directly correlated, the trends for specificity would likely be similar. Thus A3A’s 
deamination activity was determined in the context of variations of the signature 
sequence (T/C)TC(A/G) using a 1H NMR based A3 deaminase activity assay. 
High (TTCA and TTCG), medium (ATCA, ATCG, GTCA, GTCG, TTCT) and low 
(ATCT and GTCT) affinity sequences were tested (Table IV.3) to determine the 
correlation between binding and activity. Overall, activity by NMR has the same 
trend as affinity from the binding assay (Figure IV.5). This indicates that in 
general those substrates sequences with varying binding affinity (high, medium 
and weak) are also processed in a similar order.  
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Table IV.3. A3A enzyme activity for DNA sequences 
 
 
 
 
 
Tabl  2 A3A enzyme activity for DNA sequences
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Figure IV.5.  Binding affinity versus enzyme activity. 
The enzyme activity of active A3A measured by NMR based deamination assay 
versus the free energy of binding calculated (∆G =-RTln (Kd) from the binding 
affinity for nine 12-mers.  These nine represent, 2 high binding (green), 5 
medium binding (orange) and 2 weak binding (red) sequences. 
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IV.c.6. Structural basis for A3A specificity for binding to preferred 
recognition sequence. 
To determine the structural basis for the A3A consensus sequence 
(T/C)TC(A/G), crystal structures of A3A bound to ssDNA recently determined by 
our group and others (PDB ID: 5KEG and 5SWW) were analyzed (20, 22). The 
target deoxycytidine is well coordinated and buried within the active site of A3A 
(Figure IV.6A) in these structures. The thymidine at position -1 has extensive 
contacts with loop 7 (Y130, D131 and Y132), and van der Waals contacts with 
loop 5 (W98) (Figure IV.6B). The Watson-Crick edge of the thymidine base 
faces the loop 7 residues, and makes three hydrogen bonds: one with the 
backbone nitrogen of Y132 and the other two, one is water mediated, are with 
the D131 sidechain. The D131 side chain further forms a salt bridge to the R189, 
which stabilizes the overall hydrogen-bonding configuration of loop 7 to the 
thymine base. This coordination appears critical, as residue 189 is conserved as 
a basic residue (Arg/Lys) in catalytically active A3 domains. This coordination 
also explains why -1 must be the thymidine base.  If the -1 position is modeled as 
a cytidine the N3 atom lacks the proton to hydrogen bond with D131 (Figure 
IV.6C) and wouldn’t be as well coordinated thus would be less preferential. 
Residues Y130 and D131, in loop 7, physically would preclude a larger purine 
base from fitting in this position (as modelled Figure IV.6D). Thus the T 
specificity at the -1 position is consistent with the crystal structures.  
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Figure IV.6. A3A recognition of substrate cytidine and pyrimidines at -1.  
Crystal structure of A3A(E72A/C171A) shown in surface view (gray) bound to 
Poly T-1C ssDNA sequence represented as sticks (PDB ID: 5KEG).  
A. Substrate cytidine (orange sticks) is buried in active site of A3A. Residues 
interacting with cytidine are shown in green sticks.  
B. -1 nucleotide thymidine (orange sticks) surrounded by Y130, D131 and Y132 
of loop 7 (light blue sticks), W98 of loop 5 (pink sticks), and R189 (green sticks). 
C. Cytidine modeled into -1 position (orange sticks). N3 atom lacks proton to 
hydrogen bond with D131 indicate with a red X.  
D. Adenosine modeled into -1 position (orange sticks) shows severe van der 
Waal clashes if occupying the same site as the pyrimidines. Other nucleotides 
are shown as orange sticks. Hydrogen bond and a salt bridges shown in dashes 
black lines. Water shown as red spheres. Nitrogen and oxygen of residues and 
nucleic acids are in blue and red respectively.  
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Although A3A prefers (T/C)TC(A/G), neither of the co-crystal structures 
has the optimal nucleotide identity at the -2 and +1 positions (20, 22). Specificity 
for purine at the -2 position was not evident in the available A3A–ssDNA 
structures, presumably as neither structure contains an optimal ssDNA 
sequence. For instance, even though the 5KEG structure contains a preferred 
pyrimidine in the -2 position, the thymidine is disordered in this complex. 
However, in both structures (20, 22), the base at +1 (pyrimidine T in 5KEG and a 
purine G in 5SWW) stacks with the critical histidine 29 (Figure IV.7A & B) (20, 
22). This type of histidine π-π stacking can occur with either a purine or a 
pyrimidine. However, protonated histidine prefers to stack with a purine base 
over pyrimidine, with thymidine stacking being the least preferred (32) at pH 6. 
Thus the base stacking potential with protonated histidine 29 provides strong 
rationale for the specificity for purines and the disfavoring of thymidine at the +1 
position relative to substrate deoxycytidine observed in our biochemical assays 
(Figure IV.4). 
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Figure IV.7. ssDNA is bent within the complex with A3A.  
Crystal structure of A3A shown in surface and cartoon representation (gray) 
bound to ssDNA displayed as orange sticks;  
A. +1 thymidine (light blue) is interacting with His 29 (light green sticks) through 
aromatic stacking (PDB ID: 5KEG).  
B. +1 guanine (light blue) also interacting with His 29 through aromatic stacking 
(light green sticks) (PDB ID: 5SWW).  
C. A3A(E72A/C171A) with TTTTTTTTCTTTTTT (PDB ID: 5KEG)  
D. A3A(E72A) with AAAAAAATCGGGAAA (PDB ID: 5SWW). Other nucleotides 
are shown as orange sticks, while water (red), zinc (blue), and chloride (gray) in 
the active site are shown as spheres. Nitrogen and oxygen of residues and 
nucleic acids are in blue and red respectively.  
E. A schematic of hydrogen bonding between pyrimidine (pink) at -2 and purine (light 
blue) at +1 position via bending of the DNA by A3A upon binding.  
F. Model of inter-DNA base interactions through binding of A3A to ssDNA. A3A(E72A)–
ssDNA complex (PDB ID: 5SWW) was used to model A3A signature sequence CTCG 
bound at the active site. A3A is shown as gray surface and cartoon, His29 as light green 
sticks, original ssDNA as orange sticks with +1G in light blue. Adenosine at -1 position 
was switched to cytosine (pink) with hydrogen bonds to +1G displayed as yellow dashes. 
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IV.c.7. A3A bends ssDNA to potentially allow for intra-DNA 
interaction between -2 and +1 nucleotides.  
A common feature between the two A3A–ssDNA complex structures is 
that the ssDNA forms a “U” shape in the active site (Figure IV.7C & D) (20, 22). 
This U shape of the bound polynucleotide may be conserved among 
deaminases, including adenosine deaminases (20, 33). In both A3A-ssDNA 
structures, the U shape of the ssDNA orients the -2 and +1 bases in close 
proximity to each other. Thus, we hypothesized that the observed sequence 
preference (Figure IV.4) for the -2 position is a result of intra-DNA interactions 
rather than specific interactions with the protein.  
To determine the potential for intra-DNA interactions when A3A is bound 
to a (T/C)TC(A/G) signature sequence, molecular models were developed based 
on the crystal structures of A3A bound to ssDNA (PDB ID: 5KEG and 5SWW) 
(20, 22). These models orient the bases of the -2 and +1 nucleotides so that they 
form hydrogen bonds, with the larger purine at +1 position stacking on His 29 and 
the smaller -2 pyrimidine coordinating the +1 base (Figure IV.7E and 7F). The 
reversal of the nucleotides at +1 and -2 positions would not result in a fit nearly 
as well, which could explain the lower affinity of purine-TC-pyrimidine. Thus the 
structural model explains the preference for (T/C)TC(A/G) and suggests 
stabilizing the inter-DNA interactions may further increase the affinity. 
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IV.c.8. Length of ssDNA affects affinity of A3A for substrate 
sequence. 
 
If the bending of the ssDNA is important for substrate recognition, 
dependence of binding affinity on substrate length may be expected. To 
determine if the DNA beyond the four-nucleotide signature sequence contributed 
to the binding, the length of the ssDNA that contained the recognition sequence 
was varied in Poly A-TTC (AAA TTCA AAA AAA). A competition assay with 
different length oligonucleotides was performed to test the effect of ssDNA length 
on affinity for substrate (Figure IV.8). Length was varied from 1 nucleotide 
flanking each end of TTCA (TTCAA and ATTCA) to 3 nucleotides flanking each 
end, increasing by one nucleotide addition on either end. Surprisingly, a single 
nucleotide flanking TTCA signature sequence was not enough to permit binding 
(Figure IV.8A), and even three nucleotides on either side still did not bring A3A 
binding to original binding affinity as Poly A-TTC (AAA TTCA AAA AAA) (Figure 
IV.8B). Thus, binding affinity is impacted beyond the recognition motif to prefer 
longer sequences, although the additional nucleotides not expected to have any 
direct contacts with A3A, consistent with the model that intra-DNA interactions 
modulate A3A affinity. 
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Figure IV.9. A3A affinity to ssDNA of varied lengths.  
Fluorescence anisotropy of TAMRA-labeled ssDNA 3A-TTCA-6A to A3A(E72A) 
competing with unlabeled ssDNA of different lengths.  
A. Binding of A3A to labeled ssDNA preincubated with unlabeled 3A-TTCA-6A 
(red), 1A-TTCA (blue), and TTCA-1A (green).  
B. Binding of A3A to labeled ssDNA preincubated with unlabeled 3A-TTCA-6A 
(red), 2A-TTCA-3A (blue), 3A-TTCA-2A (green), 2A-TTCA-2A (blue), 1A-TTCA-
2A (purple), 2A-TTCA-1A (black), and 1A-TTCA-1A (gray). 
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IV.c.9. A3A prefers binding to target sequence in the loop of 
structured hairpins. 
Another implication of this model would be that pre-bent DNA could be a 
better substrate for A3A binding, as A3A would not have to pay the entropic cost 
of bending the DNA. This bending of DNA could be achieved either by the inter-
DNA interactions modeled in Figure IV.7F, or when within a loop of a hairpin. To 
determine the significance of the bent U shape DNA structure in the mechanism 
of A3 binding, we tested A3A affinity to a target deoxycytidine in the loop region 
of a DNA hairpin. The hairpin sequence was based on a previously identified 
potential RNA substrate for A3A, from succinate dehydrogenase complex iron 
sulfur subunit B (SDHB)(34). The affinity for TTC in the loop region of hairpin 
DNA was higher than that in linear DNA (26 nM vs 90–127 nM respectively). As 
expected, A3A had a higher affinity for the DNA hairpin with loop region 
containing TTC compared to one with AAA (26 nM vs ~676 nM respectively) 
(Figure IV.9A). Interestingly, the Kd value for the hairpin (26 nM) is comparable 
to that for a single C in a polyT background (35 nM) (28). This may imply that the 
polyT DNA adopts a hairpin structure in solution, as has been reported (35). 
A3A affinity to a target cytidine in the loop region of an RNA hairpin was 
also tested. The exact SDHB hairpin RNA sequence including UC in the loop of 
this hairpin versus a modified SDHB hairpin RNA replacing the AUC with AAA 
was compared. A3A had specific affinity for the hairpin RNA containing UC 
compared to AA (37 nM vs 202 nM respectively) (Figure IV.9B). In contrast to 
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what has been previously proposed (19), we found that A3A has high affinity and 
specificity for RNA. Furthermore, A3A has a higher affinity for AUC in the loop 
region of a hairpin compared to UUC in a linear sequence (Figure IV.10). The 
potential UUC substrate sequence in linear RNA has no measurable affinity, 
comparable to linear RNA without a potential substrate sequence. Overall, A3A 
has higher affinity for target sequence in the context of a pre-ordered loop region 
rather than linear DNA, and specific affinity for RNA hairpins with a substrate site.  
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Figure IV.10. A3A specificity for substrate in loop region of stem-loop 
nucleic acids.  
Fluorescence anisotropy of TAMRA-labeled hairpin DNA and RNA to 
A3A(E72A).  
A. Binding of A3A to a DNA version of the hairpin SDHB RNA containing TTC 
(dark blue) and AAA (light blue) in the loop region.  
B. Binding of A3A to hairpin SDHB RNA (dark orange) and the same RNA 
sequence replacing the UC with AA in the loop region of the hairpin (light 
orange). 
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Figure IV.11. A3A affinity to ssRNA 
Fluorescence anisotropy of TAMRA-labeled ssRNA sequences to A3A(E72A).  
Binding of A3A to ssRNA with PolyA UUCA (blue) and ssRNA Poly A (red). 
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IV.d. Discussion 
A3A is a single-domain enzyme with the highest catalytic activity among 
the human APOBEC3 proteins (23), a known restriction factor (24, 25), and also 
likely contributes to carcinogenesis (26). In this study we quantified the ssDNA 
specificity of A3A, and identified the consensus signature sequence as 
(T/C)TC(A/G). The dinucleotide sequence preference for A3A, TC, which was 
previously found through activity assays (10, 20, 21) was confirmed and 
expanded to a preference for pyrimidine-TC-purine. Surprisingly context matters, 
in that the background nucleotide sequence impacts binding affinity, with 
essentially no binding observed for Poly A 1C (Figure IV.1B), while Poly T 1C 
binds with 35 ± 2 nM affinity (28). Furthermore, the length of the ssDNA in which 
(T/C)TC(A/G) is imbedded within also modulates affinity (Figure IV.8). Structural 
analysis of the two A3A-ssDNA complexes containing two distinct, but 
suboptimal ssDNA sequences have led us to develop a model with intra-DNA 
interactions for the molecular mechanism for A3A’s specificity to ssDNA. In 
contrast to previous results (27), which implicate the -2 position as defining 
specificity, the base at this position observed in both A3A–ssDNA co-crystal 
structures do not make any specific interactions with the protein. Rather, the 
hydrogen bonding edge of the -2 base is in close proximity to corresponding 
edge of +1 base, suggesting possible intra-DNA interactions as being 
determinants of preference. Our molecular modeling confirmed such interactions 
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could stabilize the U-shaped DNA conformation within the A3A active site, 
explaining the -2 position specificity. 
We found that A3A binds to RNA in a highly specific and structural 
context-dependent manner. Previous reports (19) suggested that A3A bound 
only weakly and did not deaminate RNA. However, the potential substrate 
sequence was designed to lack secondary structure, which in light of our results 
on hairpin versus linear RNAs, may have inadvertently precluded RNA 
deamination. Recently, A3G and A3A were implicated in deaminating RNA in 
proposed RNA hairpins in whole cell lysates but the specificity was not quantified 
(34, 36). Intriguingly, our data show that A3A binds RNA hairpins with similar 
affinity as for DNA hairpins, which suggests that RNA-editing activity of A3A 
might be more prevalent than previously anticipated. Future experiments will 
identify if A3A’s catalytic efficiency is similar for DNA and RNA hairpins. 
The comprehensive identification of A3A signature sequences and 
preference for loop structures will enable a more accurate evaluation of A3 
activity based on sequence analysis. Previous studies used only a single 
identified A3 signature sequence to implicate A3’s role in viral restriction or 
cancer progression. In contrast, our study suggests a more accurate method for 
determining evidence of A3 activity would be to use a set of sequences. In the 
case of A3A, we have identified four almost equivalent substrate signature 
sequences, TTCA, TTCG, CTCA, and CTCG, which should be used for 
identifying A3A’s involvement in mutagenesis. We also found a positive 
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correlation between A3A’s sequence preference of binding and enzymatic 
activity. Correlation not only legitimizes the use of a DNA binding assay with 
inactive enzyme as a reliable method for studying specificity of A3s, it also shows 
that affinity for substrate is a driving factor for catalysis. Thus, factors that could 
enhance or perturb binding, such as pH or nucleic acid structure, would result in 
modulation of deamination activity. 
In addition to using the full A3A signature sequences, the probability of 
mutagenesis should not be solely based on nucleotide sequence, but should also 
be weighted by the propensity of the target sequence to be within a structured 
loop. Secondary structure prediction software could be used to identify the 
consensus sequence in loop regions of structured DNA or RNA. A3A signature 
sequences, (T/C)TC(A/G), that we identified, not only accounts for the 
discrepancies in the A3A target sequences reported in the literature such as 
TTCA versus CTCG (21) (20), but also leads us to advocate a new paradigm for 
identifying A3A’s involvement in mutation of endogenous or exogenous DNA. 
Designing inhibitors or activators for A3s has been extremely challenging. 
Our results implicate a need to incorporate the structural context of the target 
deoxycytidine in the therapeutic design. Larger “U” shaped macrocycles may 
serve as more appropriate starting scaffolds in designing cancer therapies 
targeting A3s, which would mimic the “U” shape of the bound ssDNA. 
Macrocycles have recently been shown to have good drug-like properties and 
may be a strategy to target these critical enzymes(37).  
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IV.e. Methods 
IV.e.1. Cloning of APOBEC3A E72A overexpression construct.  
The pColdII His-6-SUMO-A3A(E72A) was constructed by first cloning the SUMO 
gene from pOPINS His-6-SUMO into pColdII His-6 vector (Takara Biosciences) 
using NdeI and KpnI restriction sites. Human APOBEC3A coding sequence from 
pColdIII GST-A3A(E72A, C171A) was then cloned into the pColdII His-6-SUMO 
vector with KpnI and HindIII. The C171A mutation in the A3A construct was 
reverted to wild type residue by site directed mutagenesis resulting in the pColdII 
His-6-SUMO-APOBEC3A(E72A) catalytically inactive over-expression construct 
used for all experiments in this study. 
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IV.e.2. Expression and purification of APOBEC3A E72A.  
Escherichia coli BL21 DE3 Star (Stratagene) cells were transformed with the 
pColdII His-6-SUMO-APOBEC3A(E72A) vector described above. The E72A 
mutation was chosen to render the protein inactive. Expression occurred at 16 °C 
for 22 hours in lysogeny broth medium containing 0.5 mM IPTG and 100 µg/mL 
ampicillin. Cells were pelleted, re-suspended in purification buffer (50 mM Tris-
HCl [pH 7.4], 300 mM NaCl, 1 mM DTT) and lysed with a cell disruptor. Cellular 
debris was separated by centrifugation (45,000 g, 30 min, 4C). The fusion protein 
was separated using HisPur Ni-NTA resin (Thermo Scientific). The His6-SUMO 
tag was removed by means of a Ulp1 protease digest overnight at 4 °C. 
Untagged A3A(E72A) was separated from tag and Ulp1 protease using HisPur 
Ni-NTA resin. Size-exclusion chromatography using a HiLoad 16/60 Superdex 75 
column (GE Healthcare) was used as a final purification step. Purified 
recombinant A3A was determined to be free of nucleic acid prior to binding 
experiments by checking OD 260/280 ratios, which was at 0.54 
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IV.e.3. Oligo source and preparation.  
Labeled and unlabeled oligonucleotides used in this assay were obtained 
through Integrated DNA Technologies (IDT). Labeled oligonucleotides used in 
the fluorescence anisotropy based binding assay contain a 50-TAMRA 
flourophore at their 5’ end and were re-suspended in ultra-pure water at a 
concentration of 20 µM. Unlabeled oligonucleotides used for the competition 
assays were resuspended in ultra-pure water to a concentration of 4 mM.  
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IV.e.4. Fluorescence anisotropy based DNA binding assay.  
Fluorescence anisotropy based DNA binding assay was performed as 
described (28) with minor alterations. A fixed concentration of 10 nM 50-TAMRA-
labeled oligonucleotides was added to A3A-E72A in 50 mM MES buffer (pH 6.0), 
100 mM NaCl, 0.5 mM TCEP in a total reaction volume of 150 mL per well in 
nonbinding 96-well plates (Greiner). For the fluorescence anisotropy based DNA 
binding assay with APOBEC3B-CTD E255A was performed in 50 mM Tris buffer 
(pH 7.4), 100 mM NaCl, 0.5 mM TCEP. The concentration of APOBEC3 was 
varied in triplicate wells. Plates were incubated for overnight at room 
temperature.  
For the pH dependence experiments the buffer reagent used for testing 
was pH 4.0–5.0 sodium acetate, pH 5.5-6.5 MES, pH 7.0-8.0 HEPES, pH 8.5-9.0 
TRIS. Assay was performed as described above. For the competition assays, a 
fixed concentration of 300 nM A3A(E72A) was used and unlabeled 
oligonucleotide of varied concentration was added from 0–6.1uM. A3A(E72A) 
was pre-incubated with unlabeled oligonucleotide for an hour in assay buffer, 
then labeled DNA was added and incubated overnight at room temperature.  
For all experiments, fluorescence anisotropy was measured using an 
EnVision plate reader (PerkinElmer), exciting at 531 nm and detecting polarized 
emission at 579 nm wavelength. For analyzing data and determining Kd values, 
Prism (GraphPad) was used for least-square fitting of the measured fluorescence 
anisotropy values (Y) at different protein concentrations (X) with a single-site 
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binding curve with Hill slope, a nonspecific linear term, and a constant 
background using the equation Y=(Bmax * X^h)/ (Kd^h + X^h) +NS*X + 
Background, where Kd is the equilibrium dissociation constant, h is the Hill 
coefficient, and Bmax is the extrapolated maximum anisotropy at complete 
binding.  
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IV.e.5. 1H NMR based A3 deaminase activity assay. 
Deaminase activity was determined for A3A protein by assaying active enzyme 
against linear DNA substrates and measuring the product formation using 1H 
NMR. Active A3A protein (50 nM) was assayed against linear DNA substrates 
(200 µM) in buffer with 50 mM MES pH 6.0, 100 mM NaCl, 0.5 mM TCEP, and 
5% D2O. Experiments were performed on 9-mer substrates containing the target 
sequences AA(A/G/T)TC(A/G/T)AAA and at 40°C to prevent the DNA from 
oligomerizing due to high concentration. Experiments were performed using a 
Bruker Avance III NMR spectrometer operating at a 1H Larmor frequency of 600 
MHz and equipped with a cryogenic probe. Product concentration was estimated 
from peak integrals with Topspin 3.5 software (Bruker Biospin Corporation, 
Billerica, MA) using an external standard. Activity was determined from the initial 
rate of product formation via first-order exponential fitting of the progress curve. 
Rate errors were estimated by Monte Carlo simulation using 100 synthetic data 
sets and taking the residuals of the initial fit to the experimental data as the 
concentration error. 
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IV.e.6. Molecular Modeling. 
 The crystal structures of A3A bound to ssDNA (PDB ID: 5KEG and 5SWW) were 
used for molecular modeling (20, 22). The DNA sequence was first mutated 
using Coot (29). The complex structure was then prepared and minimized by 
ProteinPrep Wizard in Maestro (Schrödinger) at pH6.0 with other settings as 
default. 
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V.a. Abstract 
Mutations in profilin 1 (PFN1) are associated with amyotrophic lateral 
sclerosis (ALS); however, the pathological mechanism of PFN1 in this fatal 
disease is unknown. We demonstrate that ALS-linked mutations severely 
destabilize the native conformation of PFN1 in vitro and cause accelerated 
turnover of the PFN1 protein in cells. This mutation- induced destabilization can 
account for the high propensity of ALS- linked variants to aggregate and also 
provides rationale for their reported loss-of-function phenotypes in cell-based 
assays. The source of this destabilization is illuminated by the X-ray crystal 
structures of several PFN1 proteins, revealing an expanded cavity near the 
protein core of the destabilized M114T variant. In contrast, the E117G mutation 
only modestly perturbs the structure and stability of PFN1, an observation that 
reconciles the occurrence of this mutation in the control population. These 
findings suggest that a destabilized form of PFN1 underlies PFN1-mediated ALS 
pathogenesis. 
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V.b. Introduction 
Mutations in the profilin 1 gene (PFN1) were recently associated with both 
familial and sporadic forms of amyotrophic lateral sclerosis (ALS) (1, 2), an 
incurable and fatal neurodegenerative disease that primarily targets motor 
neurons (3). The etiology of sporadic ALS is poorly understood, whereas familial 
ALS is caused by inheritable genetic defects in defined genes such as PFN1 (3). 
PFN1 is a 15-kDa protein that is best known for its role in actin dynamics in the 
context of endocytosis, membrane trafficking, cell motility, and neuronal growth 
and differentiation (4). In addition to binding monomeric or G-actin, PFN1 also 
binds to a host of different proteins through their poly-L-proline motifs and to 
lipids such as phosphatidylinositol 4,5-bisphosphate (4, 5). However, little is 
known about the mechanism(s) associated with PFN1-mediated ALS 
pathogenesis. The observation that most ALS-linked PFN1 variants are highly 
prone to aggregation in mammalian cultured cells suggests that disease-causing 
mutations induce an altered, or misfolded, conformation within PFN1 (2). Protein 
misfolding is a hallmark feature of most neurodegenerative diseases, including 
ALS (3), and can contribute to disease through both gain-of-toxic-function and 
loss-of-normal-function mechanisms (6). Although mutations in PFN1 cause ALS 
through a dominant inheritance mode (2), there is some evidence supporting a 
loss-of-function mechanism for mutant PFN1. For example, ALS-linked mutations 
were shown to abrogate the binding of PFN1 to actin (2) and to impair the 
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incorporation of PFN1 into cytoplasmic stress granules during arsenite-induced 
stress (7) in cultured cells. Moreover, ectopic expression of these variants in 
murine motor neurons led to a reduction in both axon outgrowth and growth cone 
size, consistent with a loss of function through a dominant-negative mechanism 
(2). 
Although ALS-linked mutations were shown to induce PFN1 aggregation, 
the effect of these mutations on protein stability and structure has not been 
studied. Because the impact of disease-causing mutations on protein stability 
varies from protein to protein (8–10), these parameters must be determined 
empirically. Here, we demonstrate that certain familial ALS-linked mutations 
severely destabilize PFN1 in vitro and cause faster turnover of the protein in 
neuronal cells. To gain insight into the source of this mutation-induced instability, 
the 3D crystal structures for three PFN1 proteins, including the WT protein, were 
solved by X-ray crystallography. We discovered that the M114T mutation created 
a cleft that extended into the interior of PFN1. Further, we predict that the most 
severely destabilizing C71G mutation also creates a cavity near the core of the 
PFN1 protein, proximal to the cleft formed by M114T. Experimental mutations 
that create enlarged pockets or cavities are known to exert a destabilizing effect 
on the protein’s native conformation (11), and there are several examples of 
mutation-induced cavity formation occurring in nature and disease (12, 13). 
Interestingly, the variant predicted to be the least pathogenic according to recent 
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genetics studies, E117G, was relatively stable and closely resembled the WT 
protein in every assessment performed herein (2, 14). These data implicate a 
destabilized form of PFN1 in ALS pathogenesis and call for therapeutic strategies 
that can stabilize mutant PFN1. 
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V.c. Results 
V.c.1. ALS-Linked Mutations Destabilize PFN1 in Vitro.  
To investigate the effect of ALS-linked mutations on the stability of PFN1, 
PFN1 proteins were expressed and purified from Escherichia coli and subjected 
to chemical and thermal denaturation analyses. A novel purification protocol that 
includes sequential cation-exchange and gel filtration chromatography steps was 
developed here and applied to all PFN1 variants (V.d.Methods). PFN1 C71G 
was found to be highly prone to aggregation in E. coli, consistent with 
observations that this variant exhibited particularly low solubility in mammalian 
cells (2), and therefore was isolated from inclusion bodies (V.d.Methods). The 
biochemical properties of PFN1 C71G purified from inclusion bodies are 
indistinguishable from PFN1 C71G purified from the soluble lysate of E. coli as 
determined by several assays (Figure V.1), providing confidence that PFN1 
proteins purified by these two methods can be directly compared. 
To examine the stability of PFN1 proteins, fluorescence from tryptophans 
(W4 and W32) in PFN1 WT and ALS-linked variants was measured as a function 
of increasing urea concentration (Figure V.2A). To ensure reversibility, the 
reciprocal analysis was also performed, where denatured PFN1 proteins in urea 
were refolded upon dilution with buffer (Figure IV.3 A–E). Only one transition 
was observed between the folded or native (N) and unfolded (U) states for all 
PFN1 proteins, indicative of a two-state unfolding mechanism. This two-state 
unfolding model was further substantiated with an unfolding study of two PFN1  
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Figure V.1. A comparison of PFN1 C71G purified from the soluble lysate 
of Escherichia coli vs. from inclusion bodies.  
A. Equilibrium unfolding and B. thermal denaturation curves (described in 
Figure V.2) for PFN1 C71G purified from the soluble lysate and inclusion 
bodies. The apparent melting temperature of PFN1 C71G purified from 
inclusion bodies (34.62 ± 0.05 °C) is the same as that purified from soluble 
lysate (34.60 ± 0.03 °C).  
C. PFN1 C71G has similar affinities to poly-L-proline as determined by the 
binding assay described in Figure V.14 irrespective of whether this variant 
was purified from the soluble lysate or inclusion bodies. 
Fig. S1. A comparison of PFN1 C71G purified from the soluble lysate of Escherichia coli vs. from inclusion bodies. (A) Equilibrium unfolding and (B) thermal
denaturation curves (described in Fig. 1) for PFN1 C71G purified from the soluble lysate and inclusion bodies. The apparent melting temperature of PFN1 C71G
purified from inclusion bodies (34.62 ± 0.05 °C) is the same as that purified from soluble lysate (34.60 ± 0.03 °C). (C) PFN1 C71G has similar affinities to poly-L-
proline as determined by the binding assay described in Fig. 6 irrespective of whether this variant was purified from the soluble lysate or inclusion bodies.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 3 of 10
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Figure V.2. ALS-linked mutations destabilize PFN1.  
Chemical and thermal denaturation studies reveal that ALS-linked variants 
C71G, M114T, and G118V, but not E117G, are severely destabilized relative 
to PFN1 WT.  
A. Equilibrium unfolding curves for PFN1 WT and ALS-linked variants 
generated by measuring the intrinsic tryptophan fluorescence of the indicated 
protein equilibrated in increasing concentrations of urea. Data were processed 
to obtain the center of mass (COM) of the emission spectrum and then fit to a 
two- state model for protein folding. The resulting fits are displayed as solid 
lines. The corresponding thermodynamic parameters obtained from the fitted 
data are shown in Table 1.  
B. Thermal denaturation profiles of PFN1 proteins measured by SYPRO 
Orange fluorescence as a function of increasing temperature were used to 
determine the apparent Tm, which is the temperature corresponding to 0.50 
fluorescence signal as denoted by the intersection of the dashed lines for each 
curve. 
 here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to aggregation in
E. coli, consistent with observations that this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials and Methods). The
biochemical properties of PFN1 C71G purified from inclusion
bodies are indistinguishable from PFN1 C71G purified from the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 proteins purified by these two
methods can be directly compared.
To examine the stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked variants
was measured as a function of increasing urea concentration (Fig.
1A). To ensure reversibility, the reciprocal analysis was also per-
formed, where denatured PFN1 proteins in urea were refolded
upon dilution with buffer (Fig. S2 A–E). Only one transition was
observed between the folded or native (N) and unfolded (U) states
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determined by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
and Table 1). Differential scanning fluorimetry (DSF) with SYPRO
Orange, a fluorescent indicator of hydrophobic regions exposed
upon protein unfolding, was used next to determine the apparent
melting temperature, Tm, for all PFN1 proteins used in this study
(15). Consistent with the chemical denaturation results, all ALS-
linked variants except E117G exhibited a Tm that was at least 10 °C
lower than WT (Fig. 1B and Table 1). Based on the denaturation
studies, C71G emerges as the most destabilizing mutation in the
context of PFN1, whereas the E117G mutation has a relatively
modest impact on PFN1 stability.
ALS-Linked PFN1 Exhibits Faster Turnover in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
faster relative to their WT counterparts, generally because
destabilized proteins are misfolded and targeted for degradation
by the cellular quality control machinery (16). To determine
whether the results of our in vitro denaturation studies extend to
a cellular environment, V5-tagged PFN1 variants were tran-
siently transfected into human neuronal SKNAS cells, and PFN1
turnover was assessed by tracking V5-PFN1 protein expression
over a 12.5-h time course in the presence of cycloheximide. At
the start of the experiment (t = 0 of the cycloheximide time
course), all V5-tagged PFN1 variants were expressed at similar
levels except that V5-PFN1 C71G, M114T, and G118V parti-
tioned into the insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
occurred significantly faster than that of PFN1 WT. As early as
2.5 h, the majority of PFN1 C71G and M114T within the soluble
fraction had already degraded (Fig. 2 A and C). This decrease in
soluble PFN1 content was not simply due to further PFN1 ag-
gregation, which could confound our analysis, as evidenced by
the concomitant clearance of PFN1 from the insoluble fraction
at the early time points of cycloheximide exposure (Fig. 2B). The
faster turnover of PFN1 C71G and M114T in cells closely cor-
relates with their reduced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fraction (Fig. S3), likely be-
cause clearance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to a similar degree as M114T in vitro, the turnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing effect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or that this variant
is not properly handled by the quality control machinery in the cell.
In fact, we detected a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies reveal that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed to obtain
the center of mass (COM) of the emission spectrum and then fit to a two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data are shown in Table 1. (B) Thermal denaturation profiles of PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temperature were used to determine the apparent Tm, which is the tem-
perature c responding to 0.50 flu res ence signal as denoted by the in-
ters ction of the d shed lines for each curve.
Table 1. Summary of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein alone + 4 mM proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
Boopathy et al. PNAS | June 30, 2015 | vol. 112 | no. 26 | 7985
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 Fig. S2. All PFN1 variants unfold by a two-state process. (A–E) PFN1 variants denatured in urea were refolded by diluting the urea. The final concentration of
PFN1 in each sample was 10 μM and tryptophan fluorescence was used to monitor folding. The equilibrium transition regions overlay closely for the unfolding
and refolding curves, indicating that the unfolding reaction is reversible. Filled and open circles represent unfolding and refolding, respectively. (F) The two-
state unfolding of PFN1 observed by intrinsic fluorescence (data from Fig. 1A; Fluor) was verified by CD measurements for PFN1 WT and M114T. The con-
centration of protein used was 2 μM and 10 μM for tryptophan fluorescence and CD measurements, respectively. The y axis on the left is the mean residue
ellipticity at 220 nm (MRE220) obtained from CD experiments, whereas the y axis on the right reflects the change in the COM (as shown in Fig. 1). The
thermodynamic parameters obtained by fitting the CD data agree well with those obtained from the fluorescence data (Table 1) and are as follows: for WT
ΔG° = 7.16 ± 0.11 kcal·mol−1, m = 2.36 ± 0.04 kcal·mol−1·M−1, Cm = 3.03 ± 0.07 M; for M114T ΔG° = 4.35 ± 0.10 kcal·mol−1, m = 2.95 ± 0.06 kcal·mol−1·M−1, Cm =
1.47 ± 0.05 M.
Fig. S3. The turnover of insoluble PFN1 in SKNAS cells. The experiment was carried out as described in Fig. 2, and a representative Western blot analysis of the
insoluble fraction is shown in Fig. 2B. The data above reflect the densitometry results from an average of n = 2 (M114T) or n = 3 (C71G and G118V) independent
experiments and error bars represent SEM. Each sample was normalized to the PFN1 C71G band corresponding to “time 0.” The turnover of C71G within the
insoluble fraction was slower relative to C71G within the soluble fraction (compare this graph to that in Fig. 2C). There was relatively less M114T and G118V in
the insoluble fraction compared with C71G, and the small fraction of insoluble G118V persisted throughout the experimental time course.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 4 of 10
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Figure V.3. All PFN1 variants unfold by a two-state process.  
A–E. PFN1 variants denatured in urea were refolded by diluting the urea. The 
final concentration of PFN1 in each sample was 10 μM and tryptophan 
fluorescence was used to monitor folding. The equilibrium transition regions 
overlay closely for the unfolding and refolding curves, indicating that the 
unfolding reaction is reversible. Filled and open circles represent unfolding and 
refolding, respectively.  
F. The two- state unfolding of PFN1 observed by intrinsic fluorescence (data 
from Figure V.2A; Fluor) was verified by CD measurements for PFN1 WT and 
M114T. The concentration of protein used was 2 μM and 10 μM for tryptophan 
fluorescence and CD measurements, respectively. The y axis on the left is the 
mean residue ellipticity at 220 nm (MRE220) obtained from CD experiments, 
whereas the y axis on the right reflects the change in the COM (as shown in 
Figure IV.2). The thermodynamic parameters obtained by fitting the CD data 
agree well with those obtained from the fluorescence data (Table V.1) and are 
as follows: for WT ΔG° = 7.16 ± 0.11 kcal·mol−1, m = 2.36 ± 0.04 
kcal·mol−1·M−1, Cm = 3.03 ± 0.07 M; for M114T ΔG° = 4.35 ± 0.10 
kcal·mol−1, m = 2.95 ± 0.06 kcal·mol−1·M−1, Cm = 1.47 ± 0.05 M. 
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proteins (WT and M114T) using CD spectroscopy (Figure  V.3F). The following 
thermo- dynamic parameters were determined by fitting the fluorescence data to 
a two-state folding model: apparent ΔG°, the free energy of folding; m, the 
denaturant dependence of ΔG°; and Cm, the mid-point of the unfolding transition 
(Table 1). Both ΔG° and Cm were reduced for ALS-linked variants relative to 
PFN1 WT, particularly for the PFN1 variants C71G, M114T, and G118V, 
indicating these variants are severely destabilized compared with PFN1 WT 
(Figure V.2A and Table V.1). Differential scanning fluorimetry (DSF) with 
SYPRO Orange, a fluorescent indicator of hydrophobic regions exposed upon 
protein unfolding, was used next to determine the apparent melting temperature, 
Tm, for all PFN1 proteins used in this study (15). Consistent with the chemical 
denaturation results, all ALS- linked variants except E117G exhibited a Tm that 
was at least 10 °C lower than WT (Figure V.2B and Table V.1). Based on the 
denaturation studies, C71G emerges as the most destabilizing mutation in the 
context of PFN1, whereas the E117G mutation has a relatively modest impact on 
PFN1 stability. 
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Table V.1.Summary of experimental stability and binding measurements 
for PFN1 variants 
 
 
 
 
 
 
 
 
here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to aggregation in
E. coli, consistent with observations that this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials and Methods). The
biochemical properties of PFN1 C71G purified from inclusion
bodies are indistinguishable from PFN1 C71G purified from the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 proteins purified by these two
methods can be directly compared.
To examine the stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked variants
was measured as a function of increasing urea concentration (Fig.
1A). To ensure reversibility, the reciprocal analysis was also per-
formed, where denatured PFN1 proteins in urea were refolded
upon dilution with buffer (Fig. S2 A–E). Only one transition was
observed between the folded or native (N) and unfolded (U) states
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determined by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
and Table 1). Differential scanning fluorimetry (DSF) with SYPRO
Orange, a fluorescent indicator of hydrophobic regions exposed
upon protein unfolding, was used next to determine the apparent
melting temperature, Tm, for all PFN1 proteins used in this study
(15). Consistent with the chemical denaturation results, all ALS-
linked variants except E117G exhibited a Tm that was at least 10 °C
lower than WT (Fig. 1B and Table 1). Based on the denaturation
studies, C71G emerges as the most destabilizing mutation in the
context of PFN1, whereas the E117G mutation has a relatively
modest impact on PFN1 stability.
ALS-Linked PFN1 Exhibits Faster Turnover in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
faster relative to their WT counterparts, generally because
destabilized proteins are misfolded and targeted for degradation
by the cellular quality control machinery (16). To determine
whether the results of our in vitro denaturation studies extend to
a cellular environment, V5-tagged PFN1 variants were tran-
siently transfected into human neuronal SKNAS cells, and PFN1
turnover was assessed by tracking V5-PFN1 protein expression
over a 12.5-h time course in the presence of cycloheximide. At
the start of the experiment (t = 0 of the cycloheximide time
course), all V5-tagged PFN1 variants were expressed at similar
levels except that V5-PFN1 C71G, M114T, and G118V parti-
tioned into the insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
occurred significantly faster than that of PFN1 WT. As early as
2.5 h, the majority of PFN1 C71G and M114T within the soluble
fraction had already degraded (Fig. 2 A and C). This decrease in
soluble PFN1 content was not simply due to further PFN1 ag-
gregation, which could confound our analysis, as evidenced by
the concomitant clearance of PFN1 from the insoluble fraction
at the early time points of cycloheximide exposure (Fig. 2B). The
faster turnover of PFN1 C71G and M114T in cells closely cor-
relates with their reduced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fraction (Fig. S3), likely be-
cause clearance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to a similar degree as M114T in vitro, the turnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing effect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or that this variant
is not properly handled by the quality control machinery in the cell.
In fact, we detected a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies reveal that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed to obtain
the center of mass (COM) of the emission spectrum and then fit to a two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data are shown in Table 1. (B) Thermal denaturation profiles of PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temperature were used to determine the apparent Tm, which is the tem-
perature corresponding to 0.50 fluorescence signal as denoted by the in-
tersection of the dashed lines for each curve.
Table 1. Summary of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein alone + 4 mM proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
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here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to aggregation in
E. coli, co sistent with observations th t this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials a d Methods). The
biochemical properties of PFN1 C71G purified from inclusion
b dies are indistinguishable from PFN1 C71G purified fr m the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 proteins purified by these two
methods ca be directly compared.
To examine th stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked variants
was measured as a function of i creasing urea concentration (Fig.
1A). To ens re reversibility, the reciprocal analysis was also per-
formed, where de atured PFN1 prot ins in urea were refolded
upon dilution with buffer (Fig. S2 A–E). Only one transition was
o s rved b twe n the folded or native (N) and unfolde (U) states
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determined by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
and Table 1). Differenti l scanni g fluorimetry (DSF) with SYPRO
Orange, flu escent indicator of hydrophobic region exposed
upon protein unfolding, was used next to det rmine the apparent
melting temperature, Tm, for all PFN1 p oteins used in this study
(15). Consistent with the chemic l denaturation results, all ALS-
linked variant except E117G exhibited a Tm tha was at least 10 °C
lower than WT (Fig. 1B and Table 1). Based on he dena uration
studies, C71G emerges as the most destabilizing mutation in the
context of PFN1, whereas the E117G mutati n has a relatively
modest impact on PFN1 stability.
ALS-Linked PFN1 Exhibits Faster Tur over in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
faster relative to their WT counterparts, generally because
d stabi ized prot ins are misfolded and targeted for egradation
by the cellular quality control machinery (16). To determine
whether the results of our in vitro denaturation studies extend to
a cellular environm nt, V5-ta ged PFN1 variants w re tran-
siently transfected into human neuronal SKNAS cells, and PFN1
turnover as assessed by tracking V5-PFN1 protein expression
over a 12.5-h im course in the presence of cycloheximide. At
he st t of the experiment (t = 0 of the cycloheximide time
cou se), all V5-tagged PFN1 variants were expressed at similar
level excep that V5-PFN1 C71G, M114T, and G118V parti-
tioned into th insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
ccurred significantly faster than tha f P N1 WT. As early as
2.5 h, the majority of PFN1 C71G and M114T within the soluble
fraction had already degraded (Fig. 2 A and C). This decrease in
soluble PFN1 cont nt was not simply due to further PFN1 ag-
gregation, which could confound our analysis, as evidenced by
the concomi ant clearance of PFN1 from the insoluble fraction
at t e early time points of cycloheximide exposure (Fig. 2B). The
f ster turnover of PFN1 C71G nd M11 T in cells closely cor-
relates with their reduced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fraction (Fig. S3), likely be-
cause clearance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to a similar degree as M114T in vitro, the turnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing effect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or that this variant
is not properly handled by the quality control machinery in the cell.
In fact, we detected a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies reveal that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed o obtain
the center f mass (COM) of the emission spectrum and then fit to a two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data are shown in Table 1. (B) Thermal denaturation profiles of PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temperature were used to determine the apparent Tm, which is the tem-
perature corresponding to 0.50 fluorescence signal as denoted by the in-
te sectio of the dashed lines for each curv .
Table 1. Summ ry of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein alone + 4 mM proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
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here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to aggregation in
E. coli, consistent with observations that this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials and Methods). The
biochemical properties of PFN1 C71G purified from inclusion
bodies are indistinguishable from PFN1 C71G purified from the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 proteins purified by these two
methods can be directly compared.
To examine the stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked varia ts
was measured as a function of increasing urea concentration (Fig.
1A). To ensure reversibility, the reciprocal analysis was also p r-
formed, where denatured PFN1 proteins in urea were ref lde
upon dilution with buffer (Fig. S2 A–E). Only one transition was
observed between the folded or native (N) and unfolded (U) st tes
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determined by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
and Table 1). Differential scanning fluorimetry (DSF) with SYPRO
Orange, a fluorescent indicator of hydrophobic regions exposed
upon protein unfolding, was used next to determine the apparent
melting temperature, Tm, for all PFN1 proteins used in this study
(15). Consistent with the chemical denaturation results, all ALS-
linked variants except E117G exhibited a Tm that was at least 10 °C
lower than WT (Fig. 1B and Tabl 1). Based on t d naturation
studies, C71G emerges as th most destabilizing mutation in the
context of PFN1, whereas the E117G mutation has a relatively
modest impact on PFN1 stability.
ALS-Linked PFN1 Exhibits Faster Turnover in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
aster relative to their WT co nterparts, gener lly because
destabil zed proteins are misfolded and t rgeted for degradation
by the c llular quality control mach ry (16). To d termine
hether the results of our in vitro de aturation studies extend to
a cellular environment, V5-tagged PFN1 variants were tran-
siently transfected into human neuronal SKNAS cells, and PFN1
turnover was assessed by tracking V5-PFN1 protein expression
over a 12.5-h time course in the presence of cycloheximide. At
the start of the experiment (t = 0 of the cycloheximide time
course), all V5-tagged PFN1 variants were expressed at similar
levels except that V5-PFN1 C71G, M114T, and G118V parti-
tioned into the insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
occurr d significantly faster than that of PFN1 WT. As early as
2.5 h, e majority of PFN1 C71G and M114T within the soluble
fraction ad alr ady degraded (Fig. 2 A and C). This d crease in
soluble PFN1 content was not simply d e to fu ther PFN1 ag-
gregation, which could confound ou analysis, as evidenced by
the concomitant clearance of PFN1 from the insoluble fraction
at the early time points of cycloheximide exposure (Fig. 2B). The
faster turnover of PFN1 C71G and M114T in cells closely cor-
relates with their reduced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fraction (Fig. S3), likely be-
cause clearance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to a similar degree as M114T in vitro, the turnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing effect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or at this variant
is not properly handl d by the quality control machinery in the cell.
In fact, we detecte a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies reveal that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed to obtain
the center of mass (COM) of the emission spectrum and then fit to two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data are shown in Table 1. (B) Thermal denaturation profiles of PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temperature were used to determine the apparent Tm, which is the tem-
perature corresponding to 0.50 fluorescence signal as denoted by the in-
tersection of the dashed lines for each curve.
Table 1. Summary of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein lone + 4 M proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.0 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
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here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to ggr gation in
E. coli, consistent with observations that this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials and Methods). The
bi chemical properti s of PFN1 C71G purified from inclusio
bodies are indistinguishable from PFN1 C71G purified from the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 protein p rifi d by these two
m thods can be directly compared.
To examine the stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked variants
was measured as a func ion f incr asing urea concentration (F g.
1A). To ensure reversibility, the reciprocal analysis was also per-
formed, where denatured PFN1 proteins in urea were refolded
up n dilution with buffer (Fig. S2 A–E). Only one transiti n was
observed between the folded or native (N) and unfolded (U) states
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determi ed by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
nd Table 1). Differential scanning fluorimetry (DSF) with SYPRO
Orange, a fluorescent indicator of hydrophobic regions exposed
upon protein unfolding, was used next to determine the apparent
melting temperature, Tm, for all PFN1 proteins used in this stu y
(15). Consistent with the chemical denaturation results, all ALS-
linked variants except E117G exhibited a Tm that was at least 10 °C
lower than WT (Fig. 1B and Table 1). Based on the denaturation
studies, C71G emerges as the most destabilizing mutation in the
co text of PFN1, whereas the E117G mutation has a relatively
modest impact on PFN1 stability.
ALS-Link d PFN1 Exhibits Faste Turnover in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
faster relative to their WT counterparts, gen rally because
destabilized proteins are misfolded and targeted for degradation
by th cellular quality control machinery (16). To determine
whether the results of our in vitro denaturation studies extend to
a cellular environment, V5-tagged PFN1 variants were tran-
siently transfect d into human neuronal SKNAS cells, and PFN1
turnover was assessed by tracking V5-PFN1 protein expression
over a 12.5-h time course in the pres nce of cycloheximide. At
the start of th experi ent (t = 0 of the cycloheximide time
course), all V5-tagged PFN1 variants were expressed at similar
levels except that V5-PFN1 C71G, M114T, and G118V parti-
tio ed into the insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
occurred significantly faster than that of PFN1 WT. As early as
2.5 h, the majority of PFN1 C71G and M114T within the soluble
fraction h d already degraded (Fig. 2 A and C). This decrease in
soluble PFN1 content was not simply due to further PFN1 ag-
gregation, which could confound our analysis, as evidenced by
the concomitant cleara ce of PFN1 from the insoluble fraction
at the early time points of cycloheximide exposure (Fig. 2B). The
faster turnover of PFN1 C71G and M114T in cells closely cor-
relates with their re uced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fr ction (Fig. S3), lik ly be-
cause cl arance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to similar degr e as M114T in vitro, the t rnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing ffect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or that this variant
is not properly handled by the quality control machinery in the cell.
In fact, we detected a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies rev al that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed to obtain
the center of mass (COM) of the emission spectrum and then fit to a two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data re shown in Table 1. (B) Thermal enaturation profiles f PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temp rature were used to determine the apparent Tm, which is the tem-
perature corresponding to 0.50 fluorescence signal as denoted by the in-
tersection of the dashed lines for each curve.
Table 1. Summary of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein alone + 4 mM proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
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V.c.2. ALS-Linked PFN1 Exhibits Faster Turnover in a Neuronal Cell Line.  
The turnover rate for proteins with destabilizing mutations is often faster 
relative to their WT counterparts, generally because destabilized proteins are 
misfolded and targeted for degradation by the cellular quality control machinery 
(16). To determine whether the results of our in vitro denaturation studies extend 
to a cellular environment, V5-tagged PFN1 variants were transiently transfected 
into human neuronal SKNAS cells, and PFN1 turnover was assessed by tracking 
V5-PFN1 protein expression over a 12.5-h time course in the presence of 
cycloheximide. At the start of the experiment (t = 0 of the cycloheximide time 
course), all V5-tagged PFN1 variants were expressed at similar levels except 
that V5-PFN1 C71G, M114T, and G118V partitioned into the insoluble fraction 
(Figure V.4A and B) as reported previously (2). The turnover of both PFN1 
C71G and M114T occurred significantly faster than that of PFN1 WT. As early as 
2.5 h, the majority of PFN1 C71G and M114T within the soluble fraction had 
already degraded (Figure V.4A and C). This decrease in soluble PFN1 content 
was not simply due to further PFN1 aggregation, which could confound our 
analysis, as evidenced by the concomitant clearance of PFN1 from the insoluble 
fraction at the early time points of cycloheximide exposure (Figure V.4B). The 
faster turnover of PFN1 C71G and M114T in cells closely correlates with their 
reduced stabilities in vitro, confirming the destabilizing effect of the C71G and 
M114T mutations. We note that the turnover of PFN1 C71G was faster in the 
soluble fraction compared with the insoluble fraction (Figure V.5), likely because  
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the secondary structural elements of PFN1 as determined by CD
spectroscopy (Fig. S4), and the fact that similar m values were de-
termined for all PFN1 variants by the urea denaturation analysis
suggested these proteins adopt similar tertiary structures as well
(Table 1) (18). To probe further for potential structural differences
between PFN1 WT and ALS-linked variants, these proteins were
subjected to native gel electrophoresis, a biochemical technique
capable of detecting conformational differences between misfolded
variants and their WT counterparts (19). PFN1 WT and E117G
migrated predominately as single, distinct bands with similar mo-
bility, whereas multiple bands of slower mobility were observed for
PFN1 variants C71G, M114T, and G118V (Fig. S5A). The slower
mobility bands likely reflect the larger hydrodynamic volume due to
partial unfolding of these variants. In addition, PFN1 C71G,
M114T, and G118V produced relatively large-molecular-weight
species that were retained in the stacking gel and unable to elec-
trophorese through the separating native gel but were resolublized
under conditions used for the denaturing gel (Fig. S5A). Analytical
size-exclusion chromatography revealed that all PFN1 proteins
eluted as expected for soluble, monomeric PFN1 (Fig. S5 B–G).
However, despite equal loading of PFN1 proteins onto the ana-
lytical size-exclusion column, the peak area corresponding to
soluble monomer PFN1 is reduced for ALS-linked variants, par-
ticularly for the most aggregation-prone variant, C71G. These
data are consistent with a loss of soluble monomer PFN1 in the
form of insoluble species that cannot pass through the analytical
size-exclusion column filter.
A Source of Mutation-Induced Destabilization Revealed by X-Ray
Crystallography of PFN1. Crystal structures of PFN1 proteins
were determined to identify regions within mutant PFN1 that are
conformationally distinct from PFN1 WT at atomic resolution.
PFN1 WT, E117G, and M114T produced crystals that diffracted
at relatively high resolution (∼2.2 Å; Table S1). The 3D structure
of human PFN1 WT agrees well with previously determined
structures (20–22). PFN1 WT and E117G crystallized in the
same space group, C121, whereas M114T crystallized in the P6
space group, with two molecules (designated as chains A and B)
in the asymmetric unit (Table S1).
Residues 22–36, 46–52, 101–105, 112–120, and 125–128 within
PFN1 were used for Cα superimposition of the four molecules
(PFN1 WT, M114T chains A and B, and E117G). In agreement
with the biochemical analyses described above (Table 1 and Fig.
S4), the secondary and tertiary structures of all three PFN1
proteins, including chains A and B of M114T, are highly similar
(Fig. 3). Although the space groups for PFN1 WT and M114T
crystals were different, we calculated the double difference plots
between these and the other PFN1 structures to get a sense for
structural perturbations potentially induced by the ALS-linked
mutations. Double difference plots were constructed by calcu-
lating the distances between all of the Cα atoms in PFN1 WT
and an ALS-linked variant separately, and then plotting the
difference of the difference between PFN1 structures as de-
scribed previously (23). Virtually no structural deviations were
observed between PFN1 WT and E117G, whereas moderate
differences were detected between WT and M114T (Fig. S6).
Next we sought to determine whether these moderate struc-
tural changes between PFN1 WT and M114T mapped to regions
involved in PFN1 function, namely to residues that make contact
with actin (24–31) or poly-L-proline (21, 22, 24, 32, 33). The
ternary complex comprised of PFN1 WT, actin, and the poly-L-
proline peptide derived from vasodilator-stimulated phospho-
protein (VASP) (21) (PDB ID code 2PAV) is shown in Fig. 4.
Residues with the highest (0.3 Å or greater) average of absolute
double difference (Avg-Abs-DD) values between PFN1 WT and
M114T chain B (Fig. S6C) were mapped onto PFN1 WT (Fig.
S7). PFN1 M114T chain B was used for this and all subsequent
structural comparisons because chain B had lower B factors
compared with chain A (Fig. S8). Indeed, several PFN1 residues
that reportedly make contacts with actin (V119, H120, G122,
and K126) and poly-L-proline (W4, Y7, H134, and S138) also
have relatively high Avg-Abs-DD values (Fig. S7).
To assess whether these mutation-induced structural changes
are sufficient to alter the normal binding interactions of PFN1,
Fig. 2. ALS-linked PFN1 variants exhibit faster turnover in a neuronal cell
line. SKNAS cells transiently transfected with V5-PFN1 constructs were treated
with cycloheximide (CHX) for up to 12.5 h, during which time lysates were
collected and probed by Western analysis with a V5-specific antibody to assess
the rate of PFN1 turnover in cells. (A and B) A representative Western blot
analysis of soluble and insoluble fractions from cell lysates demonstrates a de-
crease in V5-PFN1 protein with time. GAPDH serves a loading control for the
soluble fraction. (C) Densitometry analysis ofA reveals that the turnover of PFN1
C71G and M114T is significantly faster than that of PFN1 WT. Statistical signif-
icance was determined using a two-way ANOVA followed by a Tukey’s post hoc
analysis (*P < 0.05, **P < 0.01, #P < 0.0001). Error bars represent SEM. WT and
E117G, n = 3; G118V, M114T and C71G, n = 4 independent experiments.
Fig. 3. Superimposition of the crystal structures for PFN1 WT, E117G, and
M114T. (A and B) The secondary and tertiary structures for PFN1 WT (green),
E117G (mustard), M114T chain A (pink), and B (red) are highly superimpos-
able. For each structure, sticks and spheres denote the side chains and van
der Waals radii, respectively, for residues at position 114 and 117. Residue
117 is located within a solvent-exposed flexible loop that has no discernible
secondary structure, whereas Met114 is located within a β-sheet toward the
interior of the protein. (B) A zoomed cartoon representation showing resi-
dues within 4 Å of residue 114. The side chains of these residues are in-
dicated as sticks with nitrogen, oxygen, and sulfur atoms indicated in blue,
red, and yellow, respectively. The van der Waals radii of the atoms com-
prising residue 114 are reduced upon mutation of methionine (green and
mustard structures) to threonine (red and pink structures).
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Figure V.4. ALS-linked PFN1 variants exhibit faster turnover in a 
neuronal cell line.  
SKNAS cells transiently transfected with V5-PFN1 constructs were treated 
with cycloheximide (CHX) for up to 12.5 h, during which time lysates were 
collected and probed by Western analysis with a V5-specific antibody to 
assess the rate of PFN1 turnover in cells.  
A and B. A representative Western blot analysis of soluble and insoluble 
fractions from cell lysates demonstrates a de- crease in V5-PFN1 protein with 
time. GAPDH serves a loading control for the soluble fraction.  
C. Densitometry analysis of A reveals that the turnover of PFN1 C71G and 
M114T is significantly faster than that of PFN1 WT. Statistical significance was 
determined using a two-way ANOVA followed by a Tukey’s post hoc analysis 
(*P < 0.05, **P < 0.01, #P < 0.0001). Error bars represent SEM. WT and 
E117G, n = 3; G118V, M114T and C71G, n = 4 independent experiments. 
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Figure V.5. The turnover of insoluble PFN1 in SKNAS cells.  
The experiment was carried out as described in Figure V.4, and a representative 
Western blot analysis of the insoluble fraction is shown in Figure V.4B. The data 
above reflect the densitometry results from an average of n = 2 (M114T) or n = 3 
(C71G and G118V) independent experiments and error bars represent SEM. Each 
sample was normalized to the PFN1 C71G band corresponding to “time 0.” The 
turnover of C71G within the insoluble fraction was slower relative to C71G within the 
soluble fraction (compare this graph to that in Figure V.4C). There was relatively less 
M114T and G118V in the insoluble fraction compared with C71G, and the small 
fraction of insoluble G118V persisted throughout the experimental time course. 
Fig. S2. All PFN1 variants unfold by a two-state process. (A–E) PFN1 variants denatured in urea were refolded by diluting the urea. The final concentration of
PFN1 in each sample was 10 μM and tryptophan fluorescence was used to monitor folding. The equilibrium transition regions overlay closely for the unfolding
and refolding curves, indicating that the unfolding reaction is reversible. Filled and open circles represent unfolding and refolding, respectively. (F) The two-
state unfolding of PFN1 observed by intrinsic fluorescence (data from Fig. 1A; Fluor) was verified by CD measurements for PFN1 WT and M114T. The con-
centration of protein used was 2 μM and 10 μM for tryptophan fluorescence and CD measurements, respectively. The y axis on the left is the mean residue
ellipticity at 220 nm (MRE220) obtained from CD experiments, whereas the y axis on the right reflects the change in the COM (as shown in Fig. 1). The
thermodynamic parameters obtained by fitting the CD data agree well with those obtained from the fluorescence data (Table 1) and are as follows: for WT
ΔG° = 7.16 ± 0.11 kcal·mol−1, m = 2.36 ± 0.04 kcal·mol−1·M−1, Cm = 3.03 ± 0.07 M; for M114T ΔG° = 4.35 ± 0.10 kcal·mol−1, m = 2.95 ± 0.06 kcal·mol−1·M−1, Cm =
1.47 ± 0.05 M.
Fig. S3. The turnover of insoluble PFN1 in SKNAS cells. The experiment was carried out as described in Fig. 2, and a representative Western blot analysis of the
insoluble fraction is shown in Fig. 2B. The data above reflect the densitometry results from an average of n = 2 (M114T) or n = 3 (C71G and G118V) independent
experiments and error bars represent SEM. Each sample was normalized to the PFN1 C71G band corresponding to “time 0.” The turnover of C71G within the
insoluble fraction was slower relative to C71G within the soluble fraction (compare this graph to that in Fig. 2C). There was relatively less M114T and G118V in
the insoluble fraction compared with C71G, and the small fraction of insoluble G118V persisted throughout the experimental time course.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 4 of 10
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clearance of insoluble cellular aggregates by the quality control machinery is less 
efficient compared with the turnover of smaller, soluble species (17). Although 
PFN1 G118V was destabilized to a similar degree as M114T in vitro, the turnover 
of this variant within the soluble fraction seemed slower in cells (Fig. V.4C), 
which may reflect a stabilizing effect of other proteins and/or factors that interact 
with PFN1 in the cellular milieu (4), or that this variant is not properly handled by 
the quality control machinery in the cell. In fact, we detected a low level of 
insoluble PFN1 G118V that persisted throughout the 12.5-h time course (Figure 
V.4B and Figure V.5). 
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V.c3. ALS-Linked Mutations Induce a Misfolded Conformation 
Within PFN1. 
We reasoned that ALS-linked variants must undergo some degree of 
structural or conformational change to account for their destabilization. However, 
ALS-causing mutations did not perturb the secondary structural elements of 
PFN1 as determined by CD spectroscopy (Figure V.6), and the fact that similar 
m values were determined for all PFN1 variants by the urea denaturation 
analysis suggested these proteins adopt similar tertiary structures as well (Table 
V.1) (18). To probe further for potential structural differences between PFN1 WT 
and ALS-linked variants, these proteins were subjected to native gel 
electrophoresis, a biochemical technique capable of detecting conformational 
differences between misfolded variants and their WT counterparts (19). PFN1 
WT and E117G migrated predominately as single, distinct bands with similar 
mobility, whereas multiple bands of slower mobility were observed for PFN1 
variants C71G, M114T, and G118V (Figure V.7A). The slower mobility bands 
likely reflect the larger hydrodynamic volume due to partial unfolding of these 
variants. In addition, PFN1 C71G, M114T, and G118V produced relatively large-
molecular-weight species that were retained in the stacking gel and unable to 
electrophorese through the separating native gel but were resolublized under 
conditions used for the denaturing gel (Figure V.7A). Analytical size-exclusion 
chromatography revealed that all PFN1 proteins eluted as expected for soluble, 
monomeric PFN1 (Figure V.7B–G). However, despite equal loading of PFN1  
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Figure V.6. ALS-linked PFN1 variants retain the same secondary 
structure as PFN1 WT.  
A–D. Far UV CD spectra for the indicated PFN1 variant (10 μM) overlaid with 
CD spectrum for PFN1 WT (10 μM). 
Fig. S4. ALS-linked PFN1 variants retain the same secondary structure as PFN1 WT. (A–D) Far UV CD spectra for the indicated PFN1 variant (10 μM) overlaid
with CD spectrum for PFN1 WT (10 μM).
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 5 of 10
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Fig. S5. Analysis of PFN1 proteins by native page and analytical size-exclusion chromatography. (A) PFN1 proteins (10 μg) were subjected to native (Top) or denaturing (Bottom) gel electrophoresis and detected
with Coomassie Brilliant Blue stain. The mobility of native PFN1 WT is indicated. PFN1 E117G migrates with a slightly faster mobility than PFN1 WT owing to the addition of a negatively charged amino acid.
Misfolded ALS-linked PFN1 variants migrate with slower mobility and form aggregated species that are retained in the stacking gel. This gel is representative of n = 2 experiments using proteins from different
purification preparations. (B–F) The indicated PFN1 protein (40 μg) was subjected to analytical size-exclusion chromatography using a Superdex 75 column. A single peak corresponding to the expected elution
volume (∼15 mL) for monomeric PFN1 was detected for all PFN1 proteins. The experiments were carried out in duplicate for each variant, indicated by solid (n = 1 experiment) and dashed (n = 2 experiment) lines.
The average relative peak area ± the SD is indicated to the right of each curve. Despite equal sample loading, the peak area of PFN1 C71G and M114T is lower than that of WT (within error), consistent with a
reduced level of soluble protein for these ALS-linked variants. (G) An overlay of B–F for the n = 1 experiment demonstrates a similar elution profile for all PFN1 proteins.
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Fig. S5. Analysis of PFN1 proteins by native page and analytical size-exclusion chromatography. (A) PFN1 proteins (10 μg) were subjected to native (Top) or denaturing (Bottom) gel electrophoresis and detected
with Coomassie Brilliant Blue stain. The mobility of native PFN1 WT is indicated. PFN1 E117G migrates with a slightly faster mobility than PFN1 WT owing to the addition of a negatively charged amino acid.
Misfolded ALS-linked PFN1 variants migrate with slower mobility and form aggregated species that are retained in the stacking gel. This gel is representative of n = 2 experiments using proteins from different
purification preparations. (B–F) The indicated PFN1 protein (40 μg) was subjected to analytical size-exclusion chromatography using a Superdex 75 column. A single peak corresponding to the expected elution
volume (∼15 mL) for monomeric PFN1 was detected for all PFN1 proteins. The experiments were carried out in duplicate for each variant, indicated by solid (n = 1 experiment) and dashed (n = 2 experiment) lines.
The average relative peak area ± the SD is indicated to the right of each curve. Despite equal sample loading, the peak area of PFN1 C71G and M114T is lower than that of WT (within error), consistent with a
reduced level of soluble protein for these ALS-linked variants. (G) An overlay of B–F for the n = 1 experiment demonstrates a similar elution profile for all PFN1 proteins.
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Figure V.7. Analysis of PFN1 proteins by native page and analytical size-
exclusion chromatography.  
A. PFN1 proteins (10 μg) were subjected to native (Top) or denaturing 
(Bottom) gel electrophoresis and detected with Coomassie Brilliant Blue stain. 
The mobility of native PFN1 WT is indicated. PFN1 E117G migrates with a 
slightly faster mobility than PFN1 WT owing to the addition of a negatively 
charged amino acid. Misfolded ALS-linked PFN1 variants migrate with slower 
mobility and form aggregated species that are retained in the stacking gel. 
This gel is representative of n = 2 experiments using proteins from different 
purification preparations.  
B–F. The indicated PFN1 protein (40 μg) was subjected to analytical size-
exclusion chromatography using a Superdex 75 column. A single peak 
corresponding to the expected elution volume (∼15 mL) for monomeric PFN1 
was detected for all PFN1 proteins. The experiments were carried out in 
duplicate for each variant, indicated by solid (n = 1 experiment) and dashed (n 
= 2 experiment) lines. The average relative peak area ± the SD is indicated to 
the right of each curve. Despite equal sample loading, the peak area of PFN1 
C71G and M114T is lower than that of WT (within error), consistent with a 
reduced level of soluble protein for these ALS-linked variants.  
G. An overlay of B–F for the n = 1 experiment demonstrates a similar elution 
profile for all PFN1 proteins. 
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proteins onto the analytical size-exclusion column, the peak area corresponding 
to soluble monomer PFN1 is reduced for ALS-linked variants, particularly for the 
most aggregation-prone variant, C71G. These data are consistent with a loss of 
soluble monomer PFN1 in the form of insoluble species that cannot pass through 
the analytical size-exclusion column filter. 
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V.c.4. A Source of Mutation-Induced Destabilization Revealed by 
X-Ray Crystallography of PFN1.  
Crystal structures of PFN1 proteins were determined to identify regions 
within mutant PFN1 that are conformationally distinct from PFN1 WT at atomic 
resolution. PFN1 WT, E117G, and M114T produced crystals that diffracted at 
relatively high resolution (∼2.2 Å; Table V.2). The 3D structure of human PFN1 
WT agrees well with previously determined structures (20–22). PFN1 WT and 
E117G crystallized in the same space group, C121, whereas M114T crystallized 
in the P6 space group, with two molecules (designated as chains A and B) in the 
asymmetric unit (Table V.2). 
Residues 22–36, 46–52, 101–105, 112–120, and 125–128 within PFN1 were 
used for Cα superimposition of the four molecules (PFN1 WT, M114T chains A 
and B, and E117G). In agreement with the biochemical analyses described 
above (Table V.1 and Figure V.6), the secondary and tertiary structures of all 
three PFN1 proteins, including chains A and B of M114T, are highly similar 
(Figure V.8). Although the space groups for PFN1 WT and M114T crystals were 
different, we calculated the double difference plots between these and the other 
PFN1 structures to get a sense for structural perturbations potentially induced by 
the ALS-linked mutations. Double difference plots were constructed by 
calculating the distances between all of the Cα atoms in PFN1 WT and an ALS-
linked variant separately, and then plotting the difference of the difference 
between PFN1 structures as described previously (23). Virtually no structural  
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Table V.2. Crystallographic and refinement statistics of human PFN1 
structures 
 
  
Table 1. Crystallographic and refinement statistics of human Profilin-1 structures 
  WT  E117G M114T 
Resolution  (Å) 2.16    2.17 2.23 
Space group C121 C121 P6 
a (Å) 74.26 73.65 81.69 
b (Å) 31.84 31.71 81.69 
c (Å) 61.02 60.54 65.35 
α	 90° 90° 90° 
β	 122.66° 122.03° 90° 
γ 90° 90° 120° 
Z 1 1 2 
Rmerge (%) linear 0.075 0.036 (2.25-2.17: 0.095) 0.147  
I/sigma 13.3(2.63 at 2.16) 12.2 (2.25-2.17: 26.1) 12.4 
Completeness (%) 99.28 99.49 (2.25-2.17: 100) 99.58 
Total no. of reflections 20,783 16,453  76,801 
No. of unique reflections 6,416 6,422 (2.25-2.17: 644) 12,156 
Rfactor (%) 0.2159 (2.72-2.16: 0.2592) 0.1965 (2.73-2.17: 0.1926) 0.1952 (2.45-2.23: 0.2375) 
Rfree (%) 0.2469 (2.72-2.16: 0.2837) 0.2139 (2.33-2.17: 0.2528) 0.2383 (2.45-2.23: 0.2871) 
RMSD in: Bond lengths (Å) 0.002 0.003 0.003 
RMS Angle (°) 0.62 0.67 0.61 
Temperature (°C) -80 -80 -80 
Residues Missing:    
Chain A 1, 2, 57-62, 92-96 1, 2, 59-62, 81,82, 93-95, 140 1, 93-97 
Chain B --- --- 1, 13, 91-97 
PDB ID 4XIL 4X1M 4X25 
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Figure V.8. Superimposition of the crystal structures for PFN1 WT, 
E117G, and M114T.  
A and B. The secondary and tertiary structures for PFN1 WT (green), E117G 
(mustard), M114T chain A (pink), and B (red) are highly superimposable. For 
each structure, sticks and spheres denote the side chains and van der Waals 
radii, respectively, for residues at position 114 and 117. Residue 117 is 
located within a solvent-exposed flexible loop that has no discernible 
secondary structure, whereas Met114 is located within a β-sheet toward the 
interior of the protein.  
B. A zoomed cartoon representation showing residues within 4 Å of residue 
114. The side chains of these residues are indicated as sticks with nitrogen, 
oxygen, and sulfur atoms indicated in blue, red, and yellow, respectively. The 
van der Waals radii of the atoms comprising residue 114 are reduced upon 
mutation of methionine (green and mustard structures) to threonine (red and 
pink structures). 
the secondary structural elements of PFN1 as determined by CD
spectroscopy (Fig. S4), and the fact that similar m values were de-
termined for all PFN1 variants by the urea denaturation analysis
suggested these proteins adopt similar tertiary structures as well
(Table 1) (18). To probe further for potential structural differences
between PFN1 WT and ALS-linked variants, these proteins were
subjected to native gel electrophoresis, a biochemical technique
capable of detecting conformational differences between misfolded
variants and their WT counterparts (19). PFN1 WT and E117G
migrated predominately as single, distinct bands with similar mo-
bility, whereas multiple bands of slower mobility were observed for
PFN1 variants C71G, M114T, and G118V (Fig. S5A). The slower
mobility bands likely reflect the larger hydrodynamic volume due to
partial unfolding of these variants. In addition, PFN1 C71G,
M114T, and G118V produced relatively large-molecular-weight
species that were retained in the stacking gel and unable to elec-
trophorese through the separating native gel but were resolublized
under conditions used for the denaturing gel (Fig. S5A). Analytical
size-exclusion chromatography revealed that all PFN1 proteins
eluted as expected for soluble, monomeric PFN1 (Fig. S5 B–G).
However, despite equal loading of PFN1 proteins onto the ana-
lytical size-exclusion column, the peak area corresponding to
soluble monomer PFN1 is reduced for ALS-linked variants, par-
ticularly for the most aggregation-prone variant, C71G. These
data are consistent with a loss of soluble monomer PFN1 in the
form of insoluble species that cannot pass through the analytical
size-exclusion column filter.
A Source of Mutation-Induced Destabilization Revealed by X-Ray
Crystallography of PFN1. Crystal structures of PFN1 proteins
were determined to identify regions within mutant PFN1 that are
conformationally distinct from PFN1 WT at atomic resolution.
PFN1 WT, E117G, and M114T produced crystals that diffracted
at relatively high resolution (∼2.2 Å; Table S1). The 3D structure
of human PFN1 WT agrees well with previously determined
structures (20–22). PFN1 WT and E117G crystallized in the
same space group, C121, whereas M114T crystallized in the P6
space group, with two molecules (designated as chains A and B)
in the asymmetric unit (Table S1).
Residues 22–36, 46–52, 101–105, 112–120, and 125–128 within
PFN1 were used for Cα superimposition of the four molecules
(PFN1 WT, M114T chains A and B, and E117G). In agreement
with the biochemical analyses described above (Table 1 and Fig.
S4), the secondary and tertiary structures of all three PFN1
proteins, including chains A and B of M114T, are highly similar
(Fig. 3). Although the space groups for PFN1 WT and M114T
crystals were different, we calculated the double difference plots
between these and the other PFN1 structures to get a sense for
structural perturbations potentially induced by the ALS-linked
mutations. Double difference plots were constructed by calcu-
lating the distances between all of the Cα atoms in PFN1 WT
and an ALS-linked variant separately, and then plotting the
difference of the difference between PFN1 structures as de-
scribed previously (23). Virtually no structural deviations were
observed between PFN1 WT and E117G, whereas moderate
differences were detected between WT and M114T (Fig. S6).
Next we sought to determine whether these moderate struc-
tural changes between PFN1 WT and M114T mapped to regions
involved in PFN1 function, namely to residues that make contact
with actin (24–31) or poly-L-proline (21, 22, 24, 32, 33). The
ternary complex comprised of PFN1 WT, actin, and the poly-L-
proline peptide derived from vasodilator-stimulated phospho-
protein (VASP) (21) (PDB ID code 2PAV) is shown in Fig. 4.
Residues with the highest (0.3 Å or greater) average of absolute
double difference (Avg-Abs-DD) values between PFN1 WT and
M114T chain B (Fig. S6C) were mapped onto PFN1 WT (Fig.
S7). PFN1 M114T chain B was used for this and all subsequent
structural comparisons because chain B had lower B factors
compared with chain A (Fig. S8). Indeed, several PFN1 residues
that reportedly make contacts with actin (V119, H120, G122,
and K126) and poly-L-proline (W4, Y7, H134, and S138) also
have relatively high Avg-Abs-DD values (Fig. S7).
To assess whether these mutation-induced structural changes
are sufficient to alter the normal binding interactions of PFN1,
Fig. 2. ALS-linked PFN1 variants exhibit faster turnover in a neuronal cell
line. SKNAS cells transiently transfected with V5-PFN1 constructs were treated
with cycloheximide (CHX) for up to 12.5 h, during which time lysates were
collected and probed by Western analysis with a V5-specific antibody to assess
the rate of PFN1 turnover in cells. (A and B) A representative Western blot
analysis of soluble and insoluble fractions from cell lysates demonstrates a de-
crease in V5-PFN1 protein with time. GAPDH serves a loading control for the
soluble fraction. (C) Densitometry analysis ofA reveals that the turnover of PFN1
C71G and M114T is significantly faster than that of PFN1 WT. Statistical signif-
icance was determined using a two-way ANOVA followed by a Tukey’s post hoc
analysis (*P < 0.05, **P < 0.01, #P < 0.0001). Error bars represent SEM. WT and
E117G, n = 3; G118V, M114T and C71G, n = 4 independent experiments.
Fig. 3. Superimposition of the crystal structures for PFN1 WT, E117G, and
M114T. (A and B) The secondary and tertiary structures for PFN1 WT (green),
E117G (mustard), M114T chain A (pink), and B (red) are highly superimpos-
able. For each structure, sticks and spheres denote the side chains and van
der Waals radii, respectively, for residu s at position 114 and 117. Residue
117 is located within a olv nt-exposed flexible loop that has no di cernible
se ondary structure, whereas Met114 is located within a β-sheet toward the
interior of the protein. (B) A zoomed cartoon representation showing resi-
dues within 4 Å of residue 114. The side chains of these residues are in-
dicated as sticks with nitrogen, oxygen, and sulfur atoms indicated in blue,
red, and yellow, respectively. The van der Waals radii of the atoms com-
prising residue 114 are reduced upon mutation of methionine (green and
ustard structures) to threonine (red and pink structures).
7986 | www.pnas.org/cgi/doi/10.1073/pnas.1424108112 Boopathy et al.
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deviations were observed between PFN1 WT and E117G, whereas moderate 
differences were detected between WT and M114T (Figure V.9). 
Next we sought to determine whether these moderate structural changes 
between PFN1 WT and M114T mapped to regions involved in PFN1 function, 
namely to residues that make contact with actin (24–31) or poly-L-proline (21, 22, 
24, 32, 33). The ternary complex comprised of PFN1 WT, actin, and the poly-L- 
proline peptide derived from vasodilator-stimulated phospho-protein (VASP) (21) 
(PDB ID code 2PAV) is shown in Figure V.10. Residues with the highest (0.3 Å 
or greater) average of absolute double difference (Avg-Abs-DD) values between 
PFN1 WT and M114T chain B (Figure V.9C) were mapped onto PFN1 WT 
(Figure V.11). PFN1 M114T chain B was used for this and all subsequent 
structural comparisons because chain B had lower B factors compared with 
chain A (Figure V.12). Indeed, several PFN1 residues that reportedly make 
contacts with actin (V119, H120, G122, and K126) and poly-L-proline (W4, Y7, 
H134, and S138) also have relatively high Avg-Abs-DD values (Figure V.11). 
To assess whether these mutation-induced structural changes are 
sufficient to alter the normal binding interactions of PFN1, we first monitored 
changes in the intrinsic tryptophan fluorescence of PFN1 as a function of poly-L-
proline peptide concentration (Figure V.13A). Our results revealed that the effect 
of ALS-linked mutations on the PFN1-poly-L-proline interaction was modest, 
because the apparent dissociation constants (Kd) were within twofold for all 
PFN1 proteins in this study (Table V.1). In fact, excess concentrations of poly-L- 
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Fig. S6. Structural changes induced by the M114T mutation revealed in double difference plots. Double different plots (Left) of WT vs. E117G (A), WT vs. M114T chain A (B), WT vs. M114T chain B (C), and M114T chains A vs. B
(D). The Avg-Abs-DD values are plotted as a function of residue number for each structural comparison (Middle); these plots provide an indication for residues that undergo a structural change between the proteins that are
being compared. Residues with Avg-Abs-DD values of 0.3 Å or greater are plotted onto the structure (Right) of PFN1 WT (A–C) and PFN1 M114T chain A (D) in green. Residues not used in this analysis are colored black.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 7 of 10
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Figure V.9. Structural changes induced by the M114T mutation revealed 
in double difference plots.  
Double different plots (Left) of WT vs. E117G (A), WT vs. M114T chain A (B), 
WT vs. M114T chain B (C), and M114T chains A vs. B (D). The Avg-Abs-DD 
values are plotted as a function of residue number for each structural 
comparison (Middle); these plots provide an indication for residues that 
undergo a structural change between the proteins that are being compared. 
Residues with Avg-Abs-DD values of 0.3 Å or greater are plotted onto the 
structure (Right) of PFN1 WT (A–C) and PFN1 M114T chain A (D) in green. 
Residues not used in this analysis are colored black. 
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Figure V.10. Structure of actin–PFN1–VASP peptide ternary complex with 
the actin and poly-L-proline binding residues mapped on PFN1.  
The X-ray structure of the PFN1 WT (gray)–actin (blue)–poly-L-proline peptide 
(gold) complex (PDB ID code 2PAV) is shown. Residues reportedly involved in 
actin binding (V61, K70, S72, V73, I74, R75, E83, R89, K91, P97, T98, N100, 
V119, H120, G122, N125, K126, Y129, and E130) and poly-L-proline binding 
(W4, Y7, N10, A13, S28, S30, W32, H134, S138, and Y140) are highlighted in 
blue and gold, respectively. The sites of ALS-linked mutations investigated in 
this study are highlighted and labeled in black with side chains displayed as 
black sticks. Residues involved in actin or poly-L-proline binding that also 
exhibit Avg- Abs-DD values of 0.3 Å or greater between PFN1 WT and M114T 
chain B (W4, K126, and S138) are labeled in black (the remaining residues 
that fulfill this criteria are shown in Figure V.11). 
 
we first monitored changes in the intrinsic tryptophan fluorescence
of PFN1 as a function of poly-L-proline peptide concentration (Fig.
5A). Our results revealed that the effect of ALS-linked mutations
on the PFN1-poly-L-proline interaction was modest, because the
apparent dissociation constants (Kd) were within twofold for all
PFN1 proteins in this study (Table 1). In fact, excess concentrations
of poly-L-proline effectively stabilized all PFN1 proteins as de-
termined by DSF, with the largest increase in Tm observed upon
poly-L-proline peptide binding to C71G (Fig. 5B and Table 1). Next,
we measured the binding capacity of our PFN1 proteins for G-actin
by comparing their concentration-dependent abilities to suppress
spontaneous polymerization of pyrenyliodoacetamide‐labeled actin
monomers (34). This assay is based on the fact that PFN1 binds
G-actin and inhibits actin nucleation in the absence of formins (34).
As expected, increasing concentrations of recombinant PFN1 WT
reduced the rate of actin polymerization, whereas the H120E var-
iant that exhibits impaired binding to actin failed to suppress actin
polymerization to the same extent (Fig. 6). Of the four ALS-linked
variants, only G118V was defective in suppressing actin polymeri-
zation, which was most apparent at the highest concentration of
PFN1 used in this assay, although this effect did not reach statistical
significance (Fig. 6). These data argue against a general mechanism
for PFN1-mediated ALS pathogenesis that involves impaired direct
binding between PFN1 and either poly-L-proline or actin.
Importantly, the X-ray crystal structures reveal a possible
mechanism by which ALS-linked mutations destabilize PFN1.
Residues Thr90, Met114, and Gln18 contribute to the formation
of a surface exposed pocket that was detected using SiteMap
(Fig. 7). Mutation of methionine to threonine at position 114
increased the size of this pocket, thereby forming a cleft, because
the residues nearby failed to rearrange and compensate for the
loss of van der Waals contacts (Fig. 7B). This cleft is expected to
exert a destabilizing effect on the native conformation of PFN1
owing to this loss of van der Waals contacts and the reduced
hydrophobicity of the threonine side chain relative to that of
methionine (11). Moreover, hydrophobic residues that are oth-
erwise buried in the PFN1 WT structure were exposed by the
cleft in the PFN1 M114T structure (Fig. 7 and Fig. S9). To in-
vestigate the potential impact of the C71G mutation on PFN1
structure, the cysteine side chain of residue 71 was removed to
mimic a glycine amino acid in the PFN1 WT structure using
PyMOL. Interestingly, this mutation is predicted to form a void
in the core of the protein that partially overlaps with the cleft
observed in the PFN1 M114T crystal structure (Fig. 7B). Anal-
ysis using PyMOL and SiteMap suggest that, unlike the solvent-
accessible WT and the M114T pocket, the proposed C71G void
is buried within the core of the protein. Solvent-inaccessible
voids have a more destabilizing effect than solvent-exposed
cavities (11, 35), providing an explanation for why the C71G
mutation is more destabilizing than M114T (Fig. 1).
Discussion
Here we show that ALS-linked mutations severely destabilize (Fig.
1) and alter the native protein conformation (Fig. 3) of PFN1.
Changes in protein stability owing to disease-causing mutations,
whether these mutations stabilize or destabilize the protein, are
thought to play a pivotal role in various disease mechanisms (13).
In the context of ALS, disease-linked mutations destabilize Cu,
Zn-superoxide dismutase (SOD1) (9), but instead hyperstabilize
TAR DNA-binding protein 43 (TDP-43) (8, 10, 36). These find-
ings underscore the importance of defining the toxic properties of
disease-linked proteins, thereby directing the rational design of
therapeutic strategies against those offending proteins (3).
Our X-ray crystal structures of PFN1 proteins illuminate a
probable source of mutation-induced destabilization. An enlarged
surface pocket, or void, forms as a result of the M114T mutation
(Fig. 7). The destabilizing effect of similar voids has been dem-
onstrated using a systematic site-directed mutagenesis approach
with lysozyme and is thought to arise from a loss of hydrophobic
interactions (11, 35). Examples of mutation-induced cavity for-
mation and destabilization have also been observed in nature (13).
Interestingly, modeling the removal of the cysteine side chain at
position 71 creates an internal cavity that is predicted to partially
overlap the cleft formed by M114T, raising the intriguing possi-
bility that both mutations destabilize PFN1 through a common
mechanism that involves the loss of hydrophobic and van der
Waals contacts within the same region of PFN1 (Fig. 7). Because
ig. 4. Structu e of actin–PFN1–VASP peptide ternary complex with the
actin and poly-L-proline binding residues mapp d on PFN1. The X-ray structure
of the PFN1 WT (gray)–actin (blue)–poly-L-proline peptide (gold) complex
(PDB ID code 2PAV) is shown. Residues reportedly involved in actin binding
(V61, K70, S72, V73, I74, R75, E83, R89, K91, P97, T98, N100, V119, H120,
G122, N125, K126, Y129, and E130) and poly-L-proline binding (W4, Y7, N10,
A13, S28, S30, W32, H134, S138, and Y140) are highlighted in blue and gold,
respectively. The sites of ALS-linked mutations investigated in this study are
highlighted and labeled in black with side chains displayed as black sticks.
Residues involved in ctin r poly-L-proline binding that also exhibit Avg-
Abs-DD values of 0.3 Å or greater tween PFN1 WT and M114T chain B
(W4, K126, and S138) are labeled in black (the remaining residues that fulfill
this criteria are shown in Fig. S7).
Fig. 5. ALS-linked PFN1 variants retain the ability to bind poly-L-proline.
(A) Binding of PFN1 to the poly-L-proline peptide was monitored by measuring
the intrinsic tryptophan fluorescence of the indicated PFN1 protein as a
function of increasing peptide concentration. The data points were fit using
a one-site total binding model in GraphPad Prism and the apparent disso-
ciation constants (Kd) obtained from the fit are shown in Table 1. Note that
the concentration of the peptide is reported in terms of [proline] because
the peptide stock is supplied as a mixture of poly-L-proline species (Materials
and Methods). (B) DSF was performed as described in Fig. 1B in the presence
(dashed lines) and absence (solid lines) of 4 mM proline. The presence of
proline increases the Tm for all PFN1 proteins used in this study (Table 1), as
illustrated here for WT, C71G, and M114T.
Boopathy et al. PNAS | June 30, 2015 | vol. 112 | no. 26 | 7987
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Figure V.11. Actin and poly-L-proline binding residues exhibit relatively 
high double difference values.  
Residues that have Avg-Abs-DD values of 0.3 Å or greater that are also 
engaged in actin binding (V119, H120, G122, and K126) or poly-Pro binding 
(W4, Y7, H134, and S138) are mapped onto the structure of PFN1 WT in 
magenta. All other residues with Avg-Abs-DD values of 0.3 Å or greater are 
highlighted in green. Residues with Avg-Abs-DD values between chain A and 
chain B of M114T 0.3 Å or greater (Figure V.9D) were excluded from this 
analysis. Residues not used in this analysis are colored black. 
Fig. S7. Actin and poly-L-proline binding residues exhibit relatively high double difference values. Residues that have Avg-Abs-DD values of 0.3 Å or greater
that are also engaged in actin binding (V119, H120, G122, and K126) or poly-Pro binding (W4, Y7, H134, and S138) are mapped onto the structure of PFN1 WT
in magenta. All other residues with Avg-Abs-DD values of 0.3 Å or greater are highlighted in green. Residues with Avg-Abs-DD values between chain A and
chain B of M114T 0.3 Å or greater (Fig. S6D) were excluded from this analysis. Residues not used in this analysis are colored black.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 8 of 10
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Figure V.12. The calculated α-carbon B factors for all PFN1 structures. 
Cartoon representations of WT (A), E117G (B), and M114T chains A (C) and 
B (D). Residues are colored according to the α-carbon B factors using the 
scale shown at the bottom. The average α-carbon B factor for WT, E117G, 
and M114T chains A and B structures are 30.52, 22.94, 29.47, and 27.33, 
respectively. Because the average B factor is higher for M114T chain A, 
M114T chain B was used for structural analyses unless otherwise noted. 
Fig. S8. The calculated α-carbon B factors for all PFN1 structures. Cartoon representations of WT (A), E117G (B), and M114T chains A (C) and B (D). Residues are
colored according to the α-carbon B factors using the scale shown at the bottom. The average α-carbon B factor for WT, E117G, and M114T chains A and B
structures are 30.52, 22.94, 29.47, and 27.33, respectively. Because the average B factor is higher for M114T chain A, M114T chain B was used for structural
analyses unless otherwise noted.
Fig. S9. Electrostatic surface potential (ESP) of PFN1 WT and PFN1 M114T. A comparison of the ESP for PFN1 WT (A) and M114T (B) around the surface pocket
(for WT) and cleft (for M114T) shown in Fig. 7. Comparison of the ESP was calculated using Maestro (Schrödinger, LLC). The Red_White_Blue color scheme was
used to depict the ESP of both surfaces, where red denotes negative, blue denotes positive, and white denotes neutral ESP. The minimum and maximum values
are −0.12 and 0.12, respectively. The cleft (boxed region in B) formed by M114T exposes a deeper pocket comprised of hydrophobic residues that would
otherwise be buried beneath the surface-exposed pocket (boxed region in A) in PFN1 WT.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 9 of 10
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Figure V.13. ALS-linked PFN1 variants retain the ability to bind poly-L-
proline.  
A. Binding of PFN1 to the poly-L-proline peptide was monitored by measuring 
the intrinsic tryptophan fluorescence of the indicated PFN1 protein as a 
function of increasing peptide concentration. The data points were fit using a 
one-site total binding model in GraphPad Prism and the apparent dissociation 
constants (Kd) obtained from the fit are shown in Table 1. Note that the 
concentration of the peptide is reported in terms of [proline] because the 
peptide stock is supplied as a mixture of poly-L-proline species (Materials and 
Methods).  
B. DSF was performed as described in Figure V.2B in the presence (dashed 
lines) and absence (solid lines) of 4 mM proline. The presence of proline 
increases the Tm for all PFN1 proteins used in this study (Table 1), as 
illustrated here for WT, C71G, and M114T. 
we first monitored changes in the intrinsic tryptophan fluorescence
of PFN1 as a function of poly-L-proline peptide concentration (Fig.
5A). Our results revealed that the effect of ALS-linked mutations
on the PFN1-poly-L-proline interaction was modest, because the
apparent dissociation constants (Kd) were within twofold for all
PFN1 proteins in this study (Table 1). In fact, excess concentrations
of poly-L-proline effectively stabilized all PFN1 proteins as de-
termined by DSF, with the largest increase in Tm observed upon
poly-L-proline peptide binding to C71G (Fig. 5B and Table 1). Next,
we measured the binding capacity of our PFN1 proteins for G-actin
by comparing their concentration-dependent abilities to suppress
spontaneous polymerization of pyrenyliodoacetamide‐labeled actin
monomers (34). This assay is based on the fact that PFN1 binds
G-actin and inhibits actin nucleation in the absence of formins (34).
As expected, increasing concentrations of recombinant PFN1 WT
reduced the rate of actin polymerization, whereas the H120E var-
iant that exhibits impaired binding to actin failed to suppress actin
polymerization to the same extent (Fig. 6). Of the four ALS-linked
variants, only G118V was defective in suppressing actin polymeri-
zation, which was most apparent at the highest concentration of
PFN1 used in this assay, although this effect did not reach statistical
significance (Fig. 6). These data argue against a general mechanism
for PFN1-mediated ALS pathogenesis that involves impaired direct
binding between PFN1 and either poly-L-proline or actin.
Importantly, the X-ray crystal structures reveal a possible
mechanism by which ALS-linked mutations destabilize PFN1.
Residues Thr90, Met114, and Gln18 contribute to the formation
of a surface exposed pocket that was detected using SiteMap
(Fig. 7). Mutation of methionine to threonine at position 114
increased the size of this pocket, thereby forming a cleft, because
the residues nearby failed to rearrange and compensate for the
loss of van der Waals contacts (Fig. 7B). This cleft is expected to
exert a destabilizing effect on the native conformation of PFN1
owing to this loss of van der Waals contacts and the reduced
hydrophobicity of the threonine side chain relative to that of
methionine (11). Moreover, hydrophobic residues that are oth-
erwise buried in the PFN1 WT structure were exposed by the
cleft in the PFN1 M114T structure (Fig. 7 and Fig. S9). To in-
vestigate the potential impact of the C71G mutation on PFN1
structure, the cysteine side chain of residue 71 was removed to
mimic a glycine amino acid in the PFN1 WT structure using
PyMOL. Interestingly, this mutation is predicted to form a void
in the core of the protein that partially overlaps with the cleft
observed in the PFN1 M114T crystal structure (Fig. 7B). Anal-
ysis using PyMOL and SiteMap suggest that, unlike the solvent-
accessible WT and the M114T pocket, the proposed C71G void
is buried within the core of the protein. Solvent-inaccessible
voids have a more destabilizing effect than solvent-exposed
cavities (11, 35), providing an explanation for why the C71G
mutation is more destabilizing than M114T (Fig. 1).
Discussion
Here we show that ALS-linked mutations severely destabilize (Fig.
1) and alter the native protein conformation (Fig. 3) of PFN1.
Changes in protein stability owing to disease-causing mutations,
whether these mutations stabilize or destabilize the protein, are
thought to play a pivotal role in various disease mechanisms (13).
In the context of ALS, disease-linked mutations destabilize Cu,
Zn-superoxide dismutase (SOD1) (9), but instead hyperstabilize
TAR DNA-binding protein 43 (TDP-43) (8, 10, 36). These find-
ings underscore the importance of defining the toxic properties of
disease-linked proteins, thereby directing the rational design of
therapeutic strategies against those offending proteins (3).
Our X-ray crystal structures of PFN1 proteins illuminate a
probable source of mutation-induced destabilization. An enlarged
surface pocket, or void, forms as a result of the M114T mutation
(Fig. 7). The destabilizing effect of similar voids has been dem-
onstrated using a systematic site-directed mutagenesis approach
with lysozyme and is thought to arise from a loss of hydrophobic
interactions (11, 35). Examples of mutation-induced cavity for-
mation and destabilization have also been observed in nature (13).
Interestingly, modeling the removal of the cysteine side chain at
position 71 creates an internal cavity that is predicted to partially
overlap the cleft formed by M114T, raising the intriguing possi-
bility that both mutations destabilize PFN1 through a common
mechanism that involves the loss of hydrophobic and van der
Waals contacts within the same region of PFN1 (Fig. 7). Because
Fig. 4. Structure of actin–PFN1–VASP peptide ternary complex with the
actin and poly-L-proline binding residues mapped on PFN1. The X-ray structure
of the PFN1 WT (gray)–actin (blue)–poly-L-proline peptide (gold) complex
(PDB ID code 2PAV) is shown. Residues reportedly involved in actin binding
(V61, K70, S72, V73, I74, R75, E83, R89, K91, P97, T98, N100, V119, H120,
G122, N125, K126, Y129, and E130) and poly-L-proline binding (W4, Y7, N10,
A13, S28, S30, W32, H134, S138, and Y140) are highlighted in blue and gold,
respectively. The sites of ALS-linked mutations investigated in this study are
highlighted and labeled in black with side chains displayed as black sticks.
Residues involved in actin or poly-L-proline binding that also exhibit Avg-
Abs-DD values of 0.3 Å or greater between PFN1 WT and M114T chain B
(W4, K126, and S138) are labeled in black (the remaining residues that fulfill
this criteria are shown in Fig. S7).
Fig. 5. ALS-linked PFN1 variants retain the ability to bind poly-L-proline.
(A) Binding of PFN1 to the poly-L-proline peptide was monitored by measuring
the intrinsic tryptophan fluorescence of the indicated PFN1 protein as a
function of increasing peptide concentration. The data points were fit using
a one-site total binding model in GraphPad Prism and the apparent disso-
ciation constants (Kd) obtained from the fit are shown in Table 1. Note that
the concentration of the peptide is reported in terms of [proline] because
the peptide stock is supplied as a mixture of poly-L-proline species (Materials
and Meth ds). (B) DSF w s performed as described in Fig. 1B in the presence
(das e lines) and absence (solid lines) of 4 mM proline. The presence of
proline increases the Tm for all PFN1 proteins used in t is study (Table 1), as
illustrate here for WT, C71G, and M114T.
Boopathy et al. PNAS | June 30, 2015 | vol. 112 | no. 26 | 7987
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proline effectively stabilized all PFN1 proteins as determined by DSF, with 
the largest increase in Tm observed upon poly-L-proline peptide binding to C71G 
(Figure V.13B and Table V.1). Next, we measured the binding capacity of our 
PFN1 proteins for G-actin by comparing their concentration-dependent abilities to 
suppress spontaneous polymerization of pyrenyliodoacetamide-labeled actin 
monomers (34). This assay is based on the fact that PFN1 binds G-actin and 
inhibits actin nucleation in the absence of formins (34). As expected, increasing 
concentrations of recombinant PFN1 WT reduced the rate of actin 
polymerization, whereas the H120E variant that exhibits impaired binding to actin 
failed to suppress actin polymerization to the same extent (Figure V.14). Of the 
four ALS-linked variants, only G118V was defective in suppressing actin 
polymerization, which was most apparent at the highest concentration of PFN1 
used in this assay, although this effect did not reach statistical significance 
(Figure V.14). These data argue against a general mechanism for PFN1-
mediated ALS pathogenesis that involves impaired direct binding between PFN1 
and either poly-L-proline or actin. 
Importantly, the X-ray crystal structures reveal a possible mechanism by 
which ALS-linked mutations destabilize PFN1. Residues Thr90, Met114, and 
Gln18 contribute to the formation of a surface exposed pocket that was detected 
using SiteMap (Figure V.15). Mutation of methionine to threonine at position 114 
increased the size of this pocket, thereby forming a cleft, because the residues 
nearby failed to rearrange and compensate for the loss of van der Waals  
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Figure V.14. The binding of PFN1 proteins to G-actin.  
Polymerization of monomeric rabbit muscle actin (3 μM, 5% pyrene-labeled) 
was monitored in the presence of increasing concentrations of WT or ALS-
linked PFN1 variants and used to derive relative rates of polymerization (n = 
3). The variant H120E, which is impaired in binding to actin, fails to suppress 
spontaneous actin polymerization as effectively as WT PFN1. Although G118V 
is relatively weak in suppressing actin polymerization, the data did not reach 
statistical significance. Statistical significance was determined using a two-way 
ANOVA followed by a Tukey’s post hoc analysis. **P ≤ 0.01 for WT vs. H120E 
at 7 μM concentration. No other significant comparisons with WT were 
obtained. Other significant comparisons included C71G vs. H120E and E117G 
vs. H120E (P ≤ 0.05) at 7 μM concentration. Error bars represent SD. 
G118V is located within a solvent-exposed flexible loop, it is dif-
ficult to predict whether this mutation propagates structural
changes to the same region affected by M114T. We note that the
phi and psi angles for Gly118 are in a region of the Ramachandran
plot that are generally disallowed for a valine residue, and therefore
we speculate that the G118V mutation also induces a conforma-
tional change within PFN1 that allows valine to adapt dihedral
angles that are energetically more favorable.
Our study also provides insight into the relative pathogenicity
of ALS-linked PFN1 variants. The pathogenicity of the E117G
variant was called into question after it had been detected in the
control population (2, 14, 37, 38). Moreover, this variant exhibited
mild phenotypes compared with other ALS-linked PFN1 variants in
cell-based functional experiments (2, 7). Here, the E117G mutation
had only a modest effect on the stability and structure of PFN1
(Table 1 and Fig. S6), supporting the view that E117G is a risk
factor for disease rather than overtly pathogenic (1, 14). Further,
the E117G mutation was detected in sporadic ALS and fronto-
temporal lobar degeneration cases (14, 37–40), consistent with the
idea that environmental factors and/or genetic modifiers contribute
to PFN1 E117G toxicity. In fact, proteasome inhibition triggered
the aggregation of PFN1 E117G (2), suggesting that cellular stress
may exacerbate PFN1 misfolding and dysfunction in vivo.
Although the mechanism of PFN1 in ALS has yet to be fully
elucidated, the destabilized mutant-PFN1 species identified here
can serve as an upstream trigger for either loss-of-function or gain-
of-toxic-function mechanisms. Several investigations from cell-based
experiments support a loss-of-function mechanism for ALS-linked
PFN1 variants with respect to actin binding (2), actin dynamics (2),
and stress granule assembly (7). For example, PFN1 variants immu-
noprecipitated less actin from mammalian cells compared with PFN1
WT (2). Our in vitro results suggest this is unlikely due to a general
defect in the inherent ability of mutant PFN1 to directly bind actin
(Fig. 6) but may be the consequence of mutant PFN1 being se-
questered away from actin and/or engaged in other aberrant in-
teractions within the cell. Moreover, ALS-linked mutations do not
simply abrogate the direct-binding interaction between PFN1 and
the poly-L-proline motif (Fig. 5A) that is present in many biological
PFN1 ligands. These data, however, do not rule out the possibility
that mutation-induced misfolding and destabilization culminate in
defective actin homeostasis in vivo. PFN1 plays a complex role in
actin homeostasis, requiring coordinated interactions between PFN1
and many other cellular factors that ultimately dictate the fate of
different actin networks within the cell (41).
The misfolding of PFN1 variants may also induce gain of toxic
functions and interactions, the latter via aberrant protein–pro-
tein interactions through exposed hydrophobic patches, such as
those detected for PFN1 M114T (Fig. S9). Further, the aggregation
of PFN1 variants can potentially sequester other vital proteins, in-
cluding those with poly-L-proline binding motifs (4), culminating in
compromised actin and/or cellular homeostasis (6).
Although the downstream effect of ALS-linked PFN1 on actin
dynamics and other cellular processes have not been elucidated,
our data identify misfolded and destabilized PFN1 as a potential
upstream trigger of the adverse events that culminate in ALS,
opening new avenues for therapeutic advancement in ALS.
One potential direction is the development of pharmacological
chaperones (16). For example, small molecules that fill the void
formed by the M114T mutation are expected to stabilize the
protein (35). Our data with poly-L-proline (Fig. 5B) suggest that
small-molecules binding to other regions of PFN1 could also
stabilize the protein. We posit that stabilizing mutant PFN1 will
restore the normal structure and function of the protein, thereby
preventing the pathogenic cascade leading to ALS.
Materials and Methods
A pET vector containing human PFN1 flanked by NdeI and EcoRI restriction
sites was kindly provided by Bruce Goode, Brandeis University, Waltham,MA.
The mutant PFN1 DNA (2) was amplified using primers 5′- GGACCA-
TATGGCCGGGTGGAAC -3′ and 5′- GCCTGAATTCTCAGTACTGGGAACGC -3′
and ligated into the pET vector using NdeI and EcoRI restriction sites. BL21
(DE3) pLysS cells (200132; Agilent Technologies) transformed with PFN1
constructs were cultured in LB containing 100 μg·mL–1 ampicillin and
34 μg·mL–1 chloramphenicol at 37 °C until an OD600 of 0.7, at which point PFN1
expression was induced by addition of 1 mM isopropyl β-D-thiogalactopy-
ranoside (0487; Amresco) for either 3 h at 37 °C (for WT and E117G) or 24 h at
18 °C (for C71G, M114T, and G118V). Cells were harvested by centrifugation
and stored until purification. Refer to Supporting Information for complete
details on methods.
Fig. 7. The M114T mutation causes a surface-exposed pocket to expand
into the core of the PFN1 protein. (A) Residues are depicted as described in
Fig. 3. The van der Waals radii of residues 90, 114, and 18 are in contact in
the PFN1 WT structure (Top). These contacts are reduced by the M114T
mutation (Bottom) owing to the smaller size of threonine, leading to an
enlargement of the surface-exposed pocket. (B) PFN1 WT is shown with a
transparent surface and the secondary structure is shown in cartoon repre-
sentation. The surface pocket volume for PFN1 WT (green) and the cleft volume
for PFN1 M114T chain B (red) are depicted as opaque surfaces and were gen-
erated using SiteMap. The predicted cavity (blue) for PFN1 C71G (generated
using PyMOL) overlays with the M114T void, and unlike the WT and M114T
volumes, is not surface-exposed. The insets (Right) show the aforementioned
voids for WT (Top), M114T chain B (Middle), and C71G (Bottom).
Fig. 6. The binding of PFN1 proteins to G-actin. Polymerization of mono-
meric rabbit muscle actin (3 μM, 5% pyrene-labeled) was monitored in the
presence of increasing concentrations of WT or ALS-linked PFN1 variants and
used to derive relative rates of polymerization (n = 3). The variant H120E,
which is impaired in binding to actin, fails to suppress spontaneous actin po-
lymerization as effectively as WT PFN1. Although G118V is relatively weak in
suppressing actin polymerization, the data did not reach statistical signifi-
cance. Statistical significance was determined using a two-way ANOVA fol-
lowed by a Tukey’s post hoc analysis. **P ≤ 0.01 for WT vs. H120E at 7 μM
concentration. No other significant comparisons with WT were obtained.
Other significant comparisons included C71G vs. H120E and E117G vs. H120E
(P ≤ 0.05) at 7 μM concentration. Error bars represent SD.
7988 | www.pnas.org/cgi/doi/10.1073/pnas.1424108112 Boopathy et al.
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Figure V.15. The M114T mutation causes a surface-exposed pocket to 
expand into the core of the PFN1 protein.  
A. Residues are depicted as described in Figure V.8. The van der Waals radii 
of residues 90, 114, and 18 are in contact in the PFN1 WT structure (Top). 
These contacts are reduced by the M114T mutation (Bottom) owing to the 
smaller size of threonine, leading to an enlargement of the surface-exposed 
pocket.  
B. PFN1 WT is shown with a transparent surface and the secondary structure 
is shown in cartoon representation. The surface pocket volume for PFN1 WT 
(green) and the cleft volume for PFN1 M114T chain B (red) are depicted as 
opaque surfaces and were generated using SiteMap. The predicted cavity 
(blue) for PFN1 C71G (generated using PyMOL) overlays with the M114T 
void, and unlike the WT and M114T volumes, is not surface-exposed. The 
insets (Right) show the aforementioned voids for WT (Top), M114T chain B 
(Middle), and C71G (Bottom). 
G118V is located within a solvent-exposed flexible loop, it is dif-
ficult to predict whether this mutation propagates structural
changes to the same region affected by M114T. We note that the
phi and psi angles for Gly118 are in a region of the Ramachandran
plot that are generally disallowed for a valine residue, and therefore
we speculate that the G118V mutation also induces a conforma-
tional change within PFN1 that allows valine to adapt dihedral
angles that are energetically more favorable.
Our study also provides insight into the relative pathogenicity
of ALS-linked PFN1 variants. The pathogenicity of the E117G
variant was called into question after it had been detected in the
control population (2, 14, 37, 38). Moreover, this variant exhibited
mild phenotypes compared with other ALS-linked PFN1 variants in
cell-based functional experiments (2, 7). Here, the E117G mutation
had only a modest effect on the stability and structure of PFN1
(Table 1 and Fig. S6), supporting the view that E117G is a risk
factor for disease rather than overtly pathogenic (1, 14). Further,
the E117G mutation was detected in sporadic ALS and fronto-
temporal lobar degeneration cases (14, 37–40), consistent with the
idea that environmental factors and/or genetic modifiers contribute
to PFN1 E117G toxicity. In fact, proteasome inhibition triggered
the aggregation of PFN1 E117G (2), suggesting that cellular stress
may exacerbate PFN1 misfolding and dysfunction in vivo.
Although the mechanism of PFN1 in ALS has yet to be fully
elucidated, the destabilized mutant-PFN1 species identified here
can serve as an upstream trigger for either loss-of-function or gain-
of-toxic-function mechanisms. Several investigations from cell-based
experiments support a loss-of-function mechanism for ALS-linked
PFN1 variants with respect to actin binding (2), actin dynamics (2),
and stress granule assembly (7). For example, PFN1 variants immu-
noprecipitated less actin from mammalian cells compared with PFN1
WT (2). Our in vitro results suggest this is unlikely due to a general
defect in the inherent ability of mutant PFN1 to directly bind actin
(Fig. 6) but may be the consequence of mutant PFN1 being se-
questered away from actin and/or engaged in other aberrant in-
teractions within the cell. Moreover, ALS-linked mutations do not
simply abrogate the direct-binding interaction between PFN1 and
the poly-L-proline motif (Fig. 5A) that is present in many biological
PFN1 ligands. These data, however, do not rule out the possibility
that mutation-induced misfolding and destabilization culminate in
defective actin homeostasis in vivo. PFN1 plays a complex role in
actin homeostasis, requiring coordinated interactions between PFN1
and many other cellular factors that ultimately dictate the fate of
different actin networks within the cell (41).
The misfolding of PFN1 variants may also induce gain of toxic
functions and interactions, the latter via aberrant protein–pro-
tein interactions through exposed hydrophobic patches, such as
those detected for PFN1 M114T (Fig. S9). Further, the aggregation
of PFN1 variants can potentially sequester other vital proteins, in-
cluding those with poly-L-proline binding motifs (4), culminating in
compromised actin and/or cellular homeostasis (6).
Although the downstream effect of ALS-linked PFN1 on actin
dynamics and other cellular processes have not been elucidated,
our data identify misfolded and destabilized PFN1 as a potential
upstream trigger of the adverse events that culminate in ALS,
opening new avenues for therapeutic advancement in ALS.
One potential direction is the development of pharmacological
chaperones (16). For example, small molecules that fill the void
formed by the M114T mutation are expected to stabilize the
protein (35). Our data with poly-L-proline (Fig. 5B) suggest that
small-molecules binding to other regions of PFN1 could also
stabilize the protein. We posit that stabilizing mutant PFN1 will
restore the normal structure and function of the protein, thereby
preventing the pathogenic cascade leading to ALS.
Materials and Methods
A pET vector containing human PFN1 flanked by NdeI and EcoRI restriction
sites was kindly provided by Bruce Goode, Brandeis University, Waltham,MA.
The mutant PFN1 DNA (2) was amplified using primers 5′- GGACCA-
TATGGCCGGGTGGAAC -3′ and 5′- GCCTGAATTCTCAGTACTGGGAACGC -3′
and ligated into the pET vector using NdeI and EcoRI restriction sites. BL21
(DE3) pLysS cells (200132; Agilent Technologies) transformed with PFN1
constructs were cultured in LB containing 100 μg·mL–1 ampicillin and
34 μg·mL–1 chloramphenicol at 37 °C until an OD600 of 0.7, at which point PFN1
expression was induced by addition of 1 mM isopropyl β-D-thiogalactopy-
ranoside (0487; Amresco) for either 3 h at 37 °C (for WT and E117G) or 24 h at
18 °C (for C71G, M114T, and G118V). Cells were harvested by centrifugation
and stored until purification. Refer to Supporting Information for complete
details on methods.
Fig. 7. The M114T mutation causes a surface-exposed pocket to expand
into the core of the PFN1 protein. (A) Residues are depicted as described in
Fig. 3. The van der Waals radii of residues 90, 114, and 18 are in contact in
the PFN1 WT structure (Top). These o tacts are reduced by the M114T
mutation (Bottom) owing to smaller size f thre nine, leading to an
enlargement of the surface-exposed pocket. (B) PFN1 WT is shown with a
transparent surface and the secondary structure is shown in cartoon repre-
sentation. The surface pocket volume for PFN1 WT (green) and the cleft volume
for PFN1 M114T chain B (red) are depicted as opaque surfaces and were gen-
erated using SiteMap. The predicted cavity (blue) for PFN1 C71G (generated
using PyMOL) overlays with the M114T void, and unlike the WT and M114T
volumes, is not surface-exposed. The insets (Right) show the aforementioned
voids for WT (Top), M114T chain B (Middle), and C71G (Bottom).
Fig. 6. The binding of PFN1 proteins to G-actin. Polymerization of mono-
meric rabbit muscle actin (3 μM, 5% pyrene-labeled) was monitored in the
presence of increasing concentrations of WT or ALS-linked PFN1 variants and
used to derive relative rates of polymerization (n = 3). The variant H120E,
which is impaired in binding to actin, fails to suppress spontaneous actin po-
lymerization as effectively as WT PFN1. Although G118V is relatively weak in
suppressing actin polymerization, the data did not reach statistical signifi-
cance. Statistical significance was determined using a two-way ANOVA fol-
lowed by a Tukey’s post hoc analysis. **P ≤ 0.01 for WT vs. H120E at 7 μM
concentration. No other significant comparisons with WT were obtained.
Other significant comparisons included C71G vs. H120E and E117G vs. H120E
(P ≤ 0.05) at 7 μM concentration. Error bars represent SD.
7988 | www.pnas.org/cgi/doi/10.1073/pnas.1424108112 Boopathy et al.
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contacts (Figure V.15B). This cleft is expected to exert a destabilizing effect on 
the native conformation of PFN1 owing to this loss of van der Waals contacts and 
the reduced hydrophobicity of the threonine side chain relative to that of 
methionine (11). Moreover, hydrophobic residues that are otherwise buried in the 
PFN1 WT structure were exposed by the cleft in the PFN1 M114T structure 
(Figure V.15 and Figure V.16). To investigate the potential impact of the C71G 
mutation on PFN1 structure, the cysteine side chain of residue 71 was removed 
to mimic a glycine amino acid in the PFN1 WT structure using PyMOL. 
Interestingly, this mutation is predicted to form a void in the core of the protein 
that partially overlaps with the cleft observed in the PFN1 M114T crystal structure 
(Figure V.15B). Analysis using PyMOL and SiteMap suggest that, unlike the 
solvent-accessible WT and the M114T pocket, the proposed C71G void is buried 
within the core of the protein. Solvent-inaccessible voids have a more 
destabilizing effect than solvent-exposed cavities (11, 35), providing an 
explanation for why the C71G mutation is more destabilizing than M114T (Figure 
V.2). 
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Figure V.16. Electrostatic surface potential (ESP) of PFN1 WT and PFN1 
M114T.  
A comparison of the ESP for PFN1 WT (A) and M114T (B) around the surface 
pocket (for WT) and cleft (for M114T) shown in Figure V.15. Comparison of 
the ESP was calculated using Maestro (Schrödinger, LLC). The 
Red_White_Blue color scheme was used to depict the ESP of both surfaces, 
where red denotes negative, blue denotes positive, and white denotes neutral 
ESP. The minimum and maximum values are −0.12 and 0.12, respectively. 
The cleft (boxed region in B) formed by M114T exposes a deeper pocket 
comprised of hydrophobic residues that would otherwise be buried beneath 
the surface-exposed pocket (boxed region in A) in PFN1 WT. 
Fig. S8. The calculated α-carbon B factors for all PFN1 structures. Cartoon representations of WT (A), E117G (B), and M114T chains A (C) and B (D). Residues are
colored according to the α-carbon B factors using the scale shown at the bottom. The average α-carbon B factor for WT, E117G, and M114T chains A and B
structures are 30.52, 22.94, 29.47, and 27.33, respectively. Because the average B factor is higher for M114T chain A, M114T chain B was used for structural
analyses unless otherwise noted.
Fig. S9. Electrostatic surface potential (ESP) of PFN1 WT and PFN1 M114T. A comparison of the ESP for PFN1 WT (A) and M114T (B) around the surface pocket
(for WT) and cleft (for M114T) shown in Fig. 7. Comparison of the ESP was calculated using Maestro (Schrödinger, LLC). The Red_White_Blue color scheme was
used to depict the ESP of both surfaces, where red denotes negative, blue denotes positive, and white denotes neutral ESP. The minimum and maximum values
are −0.12 and 0.12, respectively. The cleft (boxed region in B) formed by M114T exposes a deeper pocket comprised of hydrophobic residues that would
otherwise be buried beneath the surface-exposed pocket (boxed region in A) in PFN1 WT.
Boopathy et al. www.pnas.org/cgi/content/short/1424108112 9 of 10
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V.d. Discussion 
Here we show that ALS-linked mutations severely destabilize (Figure V.2) and 
alter the native protein conformation (Figure V.8) of PFN1. Changes in protein 
stability owing to disease-causing mutations, whether these mutations stabilize or 
destabilize the protein, are thought to play a pivotal role in various disease 
mechanisms (13). In the context of ALS, disease-linked mutations destabilize Cu, 
Zn-superoxide dismutase (SOD1) (9), but instead hyperstabilize TAR DNA-
binding protein 43 (TDP-43) (8, 10, 36). These findings underscore the 
importance of defining the toxic properties of disease-linked proteins, thereby 
directing the rational design of therapeutic strategies against those offending 
proteins (3). 
Our X-ray crystal structures of PFN1 proteins illuminate a probable source 
of mutation-induced destabilization. An enlarged surface pocket, or void, forms 
as a result of the M114T mutation (Figure V.15). The destabilizing effect of 
similar voids has been demonstrated using a systematic site-directed 
mutagenesis approach with lysozyme and is thought to arise from a loss of 
hydrophobic interactions (11, 35). Examples of mutation-induced cavity formation 
and destabilization have also been observed in nature (13). Interestingly, 
modeling the removal of the cysteine side chain at position 71 creates an internal 
cavity that is predicted to partially overlap the cleft formed by M114T, raising the 
intriguing possibility that both mutations destabilize PFN1 through a common 
mechanism that involves the loss of hydrophobic and van der Waals contacts 
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within the same region of PFN1 (Figure V.15.). Because G118V is located within 
a solvent-exposed flexible loop, it is difficult to predict whether this mutation 
propagates structural changes to the same region affected by M114T. We note 
that the phi and psi angles for Gly118 are in a region of the Ramachandran plot 
that are generally disallowed for a valine residue, and therefore we speculate that 
the G118V mutation also induces a conformational change within PFN1 that 
allows valine to adapt dihedral angles that are energetically more favorable. 
Our study also provides insight into the relative pathogenicity of ALS-linked PFN1 
variants. The pathogenicity of the E117G variant was called into question after it 
had been detected in the control population (2, 14, 37, 38). Moreover, this variant 
exhibited mild phenotypes compared with other ALS-linked PFN1 variants in cell-
based functional experiments (2, 7). Here, the E117G mutation had only a 
modest effect on the stability and structure of PFN1 (Table V.1 and Figure V.9), 
supporting the view that E117G is a risk factor for disease rather than overtly 
pathogenic (1, 14). Further, the E117G mutation was detected in sporadic ALS 
and fronto-temporal lobar degeneration cases (14, 37–40), consistent with the 
idea that environmental factors and/or genetic modifiers contribute to PFN1 
E117G toxicity. In fact, proteasome inhibition triggered the aggregation of PFN1 
E117G (2), suggesting that cellular stress may exacerbate PFN1 misfolding and 
dysfunction in vivo. 
Although the mechanism of PFN1 in ALS has yet to be fully elucidated, 
the destabilized mutant-PFN1 species identified here can serve as an upstream 
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trigger for either loss-of-function or gain-of-toxic-function mechanisms. Several 
investigations from cell-based experiments support a loss-of-function mechanism 
for ALS-linked PFN1 variants with respect to actin binding (2), actin dynamics (2), 
and stress granule assembly (7). For example, PFN1 variants 
immunoprecipitated less actin from mammalian cells compared with PFN1 WT 
(2). Our in vitro results suggest this is unlikely due to a general defect in the 
inherent ability of mutant PFN1 to directly bind actin (Figure V.14) but may be 
the consequence of mutant PFN1 being sequestered away from actin and/or 
engaged in other aberrant interactions within the cell. Moreover, ALS-linked 
mutations do not simply abrogate the direct-binding interaction between PFN1 
and the poly-L-proline motif (Figure V.13A) that is present in many biological 
PFN1 ligands. These data, however, do not rule out the possibility that mutation-
induced misfolding and destabilization culminate in defective actin homeostasis 
in vivo. PFN1 plays a complex role in actin homeostasis, requiring coordinated 
interactions between PFN1 and many other cellular factors that ultimately dictate 
the fate of different actin networks within the cell (41). 
The misfolding of PFN1 variants may also induce gain of toxic functions 
and interactions, the latter via aberrant protein–protein interactions through 
exposed hydrophobic patches, such as those detected for PFN1 M114T (Figure 
V.16). Further, the aggregation of PFN1 variants can potentially sequester other 
vital proteins, including those with poly-L-proline binding motifs (4), culminating in 
compromised actin and/or cellular homeostasis (6). 
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Although the downstream effect of ALS-linked PFN1 on actin dynamics 
and other cellular processes have not been elucidated, our data identify 
misfolded and destabilized PFN1 as a potential upstream trigger of the adverse 
events that culminate in ALS, opening new avenues for therapeutic advancement 
in ALS. One potential direction is the development of pharmacological 
chaperones (16). For example, small molecules that fill the void formed by the 
M114T mutation are expected to stabilize the protein (35). Our data with poly-L-
proline (Figure V.13B) suggest that small-molecules binding to other regions of 
PFN1 could also stabilize the protein. We posit that stabilizing mutant PFN1 will 
restore the normal structure and function of the protein, thereby preventing the 
pathogenic cascade leading to ALS. 
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V.e. Methods 
V.e.1. Cloning and over expression of PFN1. 
A pET vector containing human PFN1 flanked by NdeI and EcoRI 
restriction sites was kindly provided by Bruce Goode, Brandeis University, 
Waltham, MA. The mutant PFN1 DNA (2) was amplified using primers 5′- 
GGACCATATGGCCGGGTGGAAC -3′ and 5′- 
GCCTGAATTCTCAGTACTGGGAACGC -3′ and ligated into the pET vector 
using NdeI and EcoRI restriction sites. BL21 (DE3) pLysS cells (200132; Agilent 
Technologies) transformed with PFN1 constructs were cultured in LB containing 
100 μg·mL–1 ampicillin and 34 μg·mL–1 chloramphenicol at 37 °C until an OD600 
of 0.7, at which point PFN1 expression was induced by addition of 1 mM 
isopropyl β-D-thiogalactopyranoside (0487; Amresco) for either 3 h at 37 °C (for 
WT and E117G) or 24 h at 18 °C (for C71G, M114T, and G118V). Cells were 
harvested by centrifugation and stored until purification.  
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V.e.2. Purification of Recombinant PFN1.  
Cells containing recombinant PFN1 were lysed by sonication in 10 mM 
citrate and 10 mM NaCl, pH 5.0 (buffer A) containing protease inhibitor 
(11873580001; Roche). The lysate was cleared by centrifugation and applied to 
a Nuvia cPrime hydrophobic cation exchange column (35-mL column volume) 
(156-3402; Bio-Rad) preequilibrated with buffer A using an ÄKTAPurifier FPLC 
system (GE Healthcare). Bound impurities were eluted with 200 mL linear 
gradient of 10 mM citrate and 1 M NaCl, pH 5.0 (buffer B). PFN1-containing 
fractions eluted at 100% buffer B at ∼300 mL from the start of the gradient. 
SDS/PAGE was used to identify PFN1-containing fractions, which were pooled 
and dialyzed into buffer A with 6,000–8,000 molecular weight cut-off dialysis 
tubing (8015-40; Membrane Filtration Products, Inc.) before being applied to an 
anion (Q-resin) exchange column (17-0510-01; GE Healthcare). PFN1 eluted in 
the flow-through and was concentrated to 1–2 mL using stirred ultrafiltration cells 
(5123 and 5121; Millipore) and then applied to a Sephacryl S-100 HR (17-1194-
01; GE Healthcare) size-exclusion column preequilibrated with PBS. PFN1 
proteins eluted at ∼200 mL and were >95% pure as assessed by SDS/PAGE 
analysis with Coomassie Brilliant Blue stain. The identity and purity of the PFN1 
proteins were verified by intact mass analysis at the Proteomics and Mass 
Spectrometry Facility (University of Massachusetts Medical School). The 
concentration of PFN1 was determined spectrophotometrically at an absorbance 
of 280 nm using a molar extinction coefficient of 18,450 M–1·cm–1. Aliquots of 
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PFN1 proteins were stored at –80 °C, typically at concentrations between 60–
600 μM. 
When PFN1 C71G was purified from inclusion bodies, BL21 (DE3) pLysS 
cells expressing C71G were cultured as described for PFN1 WT and C71G-
containing inclusion bodies were extracted as previously described (42). 
Inclusion bodies were solubilized in 50 mM Tris·HCl, pH 7.0, containing 5 mM 
EDTA, 5 mM DTT, and 3 M guanidinium hydrochloride (buffer C) at ambient 
temperature. The solubilized inclusion bodies were diluted in buffer C to a PFN1 
C71G concentration of ∼5 mg·mL–1. PFN1 C71G was re-folded in buffer A 
containing 0.5 M L-arginine at ambient tem- perature under conditions where the 
final concentrations of guanidinium hydrochloride and C71G were below 0.1 M 
and 0.2 mg·mL–1, respectively. The refolded protein was dialyzed in buffer A at 4 
°C and purified using a Sephacryl S-100 HR column as described for PFN1 WT. 
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V.e.3. Equilibrium Unfolding Experiments.  
For equilibrium unfolding experiments using tryptophan fluorescence, 
solutions of increasing urea concentration were prepared from a concentrated 
stock solution of 10.546 M urea in PBS using a Hamilton Microlab 500 titrator. 
PFN1 was mixed into the urea solutions to a final concentration of 2 μM with 1 
mM Tris(2-carboxyethyl)phosphine) (TCEP) and the samples were equilibrated 
for 15–30 min. The intrinsic tryptophan fluorescence of PFN1 was measured at 
25 °C with a T-format Horiba Fluorolog fluorimeter using an excitation 
wavelength of 295 nm. Three emission spectra (310 nm to 450 nm) were 
collected for each sample and averaged. The concentration of the urea in each 
sample was measured using an Abbe refractometer after data acquisition. Data 
were processed to obtain the center of mass (COM) of the emission spectrum. 
The COM was fit to a two-state transition model as previously described and the 
thermodynamic parameters, apparent ΔG° (the free energy of folding), m (the 
denaturant dependence of ΔG°), and Cm (the midpoint of the unfolding transition) 
were determined with the program Savuka (43, 44). Because the quantum yield 
of the native and unfolded states was within a factor of 2, the use of COM 
analysis is justified. We explicitly checked this by a rigorous global analysis using 
singular value decomposition and showed that the fit of the urea dependence 
basis vector gave thermodynamic parameters that were within the error of the 
COM and CD spectroscopy analyses, and no indications of non-two-state 
behavior. For equilibrium unfolding experiments using CD spectroscopy, PFN1 
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(10 μM) was equilibrated in various concentrations of urea as described above 
and CD spectra were acquired from 215 nm to 260 nm using a Jasco J-810 
spectropolarimeter. Three spectra were averaged and the mean residual 
ellipticity (MRE) at 220 nm was plotted as a function of urea concentration and fit 
to a two-state equilibrium unfolding model. 
For protein refolding experiments, a concentrated stock of PFN1 (100–250 
μM) denatured in urea (4–8.5 M) was diluted in urea/PBS to obtain a series of 
samples with decreasing concentrations of urea, 10 μM PFN1 and 1 mM TCEP. 
Samples were equilibrated for 30 min before acquisition of fluorescence emission 
spectra as described above. 
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V.e.4. DSF.  
Samples containing WT or mutant PFN1 (20 μM) in PBS with 20× SYPRO 
Orange (S6651; Invitrogen) were pipetted in quadruplicate into a 384-well plate 
and subjected to heat denaturation using a Bio-RadCFX384 Touch Real-Time 
PCR Detection System. The temperature was increased from 25 °C to 100 °C in 
0.3 °C increments and at each increment fluorescent intensities were acquired 
using HEX detector (excitation 515–535 nm, emission 560–580 nm). PFN1 
proteins were analyzed alone and in the presence of the poly-L-proline peptide 
(molecular weight 1,000–10,000, P2254; Sigma). Because this peptide was 
supplied from the manufacturer as a mixture of poly-L-proline species, the 
concentration is reported here in units of proline (molecular weight 115.13 g·mol–
1). For experiments with the poly-L-proline peptide, PFN1 was prepared with 4 
mM proline. The fluorescence intensities for the four replicates were averaged, 
normalized to the maximum fluorescence intensity, and plotted as a function of 
temperature to obtain melting curves, which were fit with a sigmoidal function in 
GraphPad Prism to determine the midpoint of transition or the apparent Tm. 
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V.e.5. Measuring PFN1 Turnover in Cells.  
Human SKNAS cells were cultured in DMEM (11965; Gibco) containing 
10% (vol/vol) FBS (F4135; Sigma-Aldrich) and 1% (wt/vol) penicillin and 
streptomycin (10378; Gibco) under standard culture conditions (37 °C, 5% 
CO2/95% air). SKNAS cells were transiently transfected with 0.5 μg of V5-PFN1 
plasmids (2) in 24-well plates using 1.75 μL NeuroMag (NM50500; OZ 
Biosciences) diluted in Opti-MEM (38915; Invitrogen). After 12 h of V5-PFN1 
expression, translation was inhibited with 30 μg·mL–1 cycloheximide (C7698; 
Sigma-Aldrich). Cells were lysed at specific time points during a 12.5-h time 
course following cycloheximide addition using RIPA buffer (BP-115-500; Boston 
BioProducts) supplemented with protease inhibitors (11836170001; Roche) and 
centrifuged at 19,357 × g for 15 min, after which the supernatant (containing 
soluble PFN1) was collected. The remaining pellet (containing insoluble PFN1) 
was washed once with RIPA lysis buffer, centrifuged again, and resolubilized 
with 8 M urea in volumes equal to their soluble counterparts. The protein 
concentration of the soluble fractions was determined using a bicinchoninic acid 
assay (23227; Thermo Scientific Pierce). Samples were processed and 
subjected to Western blot and densitometry analyses essentially as described 
(19). Western blots were probed using V5-specific (1:1,000, R96025; Invitrogen) 
and GAPDH-specific (1:20,000, G9545; Sigma) antibodies. Bands corresponding 
to soluble V5-PFN1 were normalized to the loading control, GAPDH, and then to 
the band corresponding to cycloheximide treatment for “0 h” for each protein. For 
 
 222 
each biological replicate, visible bands corresponding to insoluble V5-PFN1 were 
normalized to their respective 0 h PFN1 C71G band. Statistical significance was 
determined using a two-way ANOVA followed by Tukey’s post hoc analysis. 
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V.e.6. CD Spectroscopy.  
CD spectra of WT PFN1 or mutants (10 μM in PBS) were acquired from 
190 nm to 260 nm at a scan speed of 2 s per wavelength with a 1-mm cuvette at 
25 °C using a AVIV Biomedical CD spectrometer model 400. Data reflect an 
average of five scans that were blank subtracted. The resulting ellipticity curves 
were transformed to mean residue ellipticity as described (45). 
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V.e.7. Acidic Native PAGE.  
The method for acidic native PAGE analysis of basic proteins described 
by the Mario Lebendiker laboratory (wolfson.huji.ac.il/purification/) was used. 
Briefly, 29:1 acrylamide-bisacrylamide (BP1408-1; Fisher Scientific) native gels 
were cast with 7.5% (wt/vol) polyacrylamide in the resolving gel, pH 4.3, and 3% 
(wt/vol) polyacrylamide in the stacking gel, pH 6.8. The gel sample containing 
WT or mutant PFN1 (0.8 μg·μL–1) was prepared under native conditions using 
ice-cold acetate–KOH, pH 6.8 and 10% (vol/vol) glycerol with 0.025% (wt/vol) of 
methylene blue. PFN1 proteins (10 μg) were loaded onto the gel and subjected 
to reversed polarity electrophoresis under ice-cold conditions for 2 h at 100 V. 
The protein bands were visualized with Coomassie Brilliant Blue as described 
above for denaturing gels. 
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V.e.8. Analytical Size-Exclusion Chromatography.  
WT or mutant PFN1 (50 μL of PFN1 at 0.8 μg·μL–1) were subjected to 
analytical size-exclusion chromatography at 4 °C using a Superdex 75 column 
(17-5174-01; GE Healthcare) equilibrated with PBS and a flow rate of 0.5 
mL·min−1. For each trial (n = 2), elution profiles were acquired using absorbance 
at 280 nm and normalized to the peak value of WT PFN1. The area under peak 
was calculated using GraphPad Prism. 
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V.e.9. Protein Crystallization and X-Ray Structural 
Determination.  
PFN1 crystals were grown by hanging drop vapor diffusion after mixing 
the PFN1 protein with a 1:1 ratio of reservoir solution at 25 °C for WT and E117G 
and at 18 °C for M114T. Reservoir solution for WT contained 50 mM KH2PO4, 
36% (wt/vol) PEG 8,000 and 100 mM MES, pH 6.0. Reservoir solution for E117G 
contained 50 mM KH2PO4, 41% (wt/vol) PEG 8,000 and 100 mM MES, 
pH 6.0. Reservoir solution for M114T contained 750 mM sodium citrate, 200 mM 
NaCl, and 100 mM Tris, pH 7.5. 
E117G crystals were soaked in cryoprotectant composed of 25% (vol/vol) 
ethylene glycol and 75% (vol/vol) reservoir solution and M114T crystals were 
passed through mineral oil before mounting for data collection. Diffraction data 
were collected using a Rigaku 007 MicroMax HF rotating anode X-ray generator, 
under a nitrogen cryostream at 100 K (Oxford Cryosystems), on a Saturn944+ 
CCD detector. 
The data were processed using Xia2 (46) [running XDS (47)] for WT and 
M114T and HKL2000 (HKL Research) for E117G. All three structures were 
solved via molecular replacement with Phaser (48) using the profilin structure 
PDB ID code 1FIK (20) as the starting model followed by multiple rounds of 
manual model building performed with Coot (49). WT was refined with PHENIX 
(50) and E117G with REFMAC5 (51) using standard refinement protocols. 
M114T was refined with PHENIX using twin refinement with the twin law {h,-h-k,l} 
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applied through refinement, because the data were highly twinned with a twin 
fraction estimated to be 0.48. 
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V.e.10. Structural Analysis.  
SiteMap (Schrödinger, LLC) was used to identify and evaluate the 
mutation-site cavity volumes. Figures were generated using PyMOL 
(Schrödinger, LLC). 
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V.e.11. Poly-L-Proline Peptide Binding Experiments.  
The intrinsic tryptophan fluorescence of WT or ALS-PFN1 (2 μM) as a 
function of increasing concentrations of the poly-L-proline peptide described 
above at 25 °C was used to measure binding of PFN1 to poly-L- proline as 
previously described (52). The samples were excited at 295 nm and three 
emission spectra between 310 nm and 450 nm were collected for each sample 
and averaged. The fluorescence emission intensity at 323 nm was baseline-
corrected, normalized, plotted as a function of poly-L-proline and fit to a one-site 
total binding model in GraphPad Prism to yield apparent Kd values. 
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V.e.12. Inhibition of Spontaneous Actin Assembly.  
Gel-filtered monomeric rabbit muscle actin (3 μM, 5% pyrene-labeled) was 
converted to Mg–ATP–actin immediately before use in each reaction and mixed 
with 7 μL of different concentrations of PFN1 WT, and PFN1 mutants or control 
buffer and 3 μL of 20× initiation mix (40 mM MgCl2, 10 mM ATP, and 1 M KCl) in 
60-μL reactions. Actin polymerization was monitored over time at 365 nm 
excitation and 407 nm emission in a PTI fluorometer at 25 °C. Average relative 
rates of actin polymerization (n = 3) were determined based on the slopes of the 
assembly curves during the first 500 s of each reaction and plotted against 
increasing concentrations of PFN1 (mutants). Statistical significance was 
determined using a two-way ANOVA followed by Tukey’s post hoc analysis. 
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VI.a.1 Using A3A to understand the structural basis for substrate 
recognition in ssDNA deaminating APOBECs 
ssDNA deaminating APOBECs are essential components of the immune 
system. The A3 subfamily of human cytidine deaminases is renowned for 
providing a first line of defense against many exogenous and endogenous 
retroviruses while AID is responsible for somatically mutating immunoglobulins. 
However, the ability of these proteins to deaminate deoxycytidines in ssDNA 
makes APOBECs a double-edged sword. When APOBECs are over expressed, 
the resulting mis-regulated deaminase activity can contribute to genomic 
instability and cancer.  
The enzymology and biological consequences of APOBEC function have 
been extensively studied. However, as most studies focus on double-domain A3s 
(1-3), the mechanism by which APOBEC3s recognize and edit DNA remains 
largely elusive. The N-terminal domain of these double domain A3s are insoluble, 
thus they are very difficult to study in vitro (4). Studying the active C-terminal 
domain alone is not sufficient as it binds substrates only weakly (5) compared 
with full length and the N-terminal domain can influence the activity of double 
domain A3s  (6-9). In contrast to isolated CTDs of double-domain A3s, single 
domain A3s can bind substrate ssDNA with as low as 100 nanomolar Kd values 
(10, 11) . Challenges with double-domain A3s warrant alternative strategies to 
elucidate specificity and structures of A3 complexes. 
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A3A is a single-domain enzyme with the highest catalytic activity among 
the deaminases in the APOBEC superfamily (12) and a known inhibitor for HPV 
and the retroelement LINE-1(13, 14). When A3A is over expressed or mis-
regulated, it can also contribute to carcinogenesis (15). Since A3A is soluble in 
vitro as an intact protein, catalytically efficient, and is involved in viral restriction 
and cancer, A3A can be used as a critical benchmark to understand the function 
of the APOBEC super family. Therefore, I chose to focus on A3A to understand 
the structural basis for substrate recognition in ssDNA deaminating.  
As described in the Chapter III of this thesis, the crystal structure of A3A in 
complex with ssDNA not only visualizes the active site poised for catalysis by 
A3A, but also pinpoints the residues that confer specificity towards CC/TC motifs. 
The A3A–ssDNA complex structure also defines the 5’–3’ directionality and 
subtle conformational changes that clench the ssDNA within the binding groove, 
revealing the architecture and mechanism of ssDNA recognition that is likely 
conserved among all polynucleotide deaminases.  
Although our structure of A3A bound to ssDNA along with another A3 co-
crystal structure (16, 17) elucidated the structural basic of substrate specificity for 
TC, the molecular mechanism underlying substrate sequence specificity flanking 
the TC dinucleotide sequence remained unclear. In order to elucidate the 
substrate specificity of A3 that cannot be explained by these enzyme-substrate 
structures, I took a systematic approach to quantify the affinity for substrate as a 
function of sequence context, length, secondary structure, and solution pH, as 
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described in Chapter IV. The A3A ssDNA binding motif was identified as 
(T/C)TC(A/G), which correlated with enzymatic activity. A3A’s ability to bind RNA 
in a sequence specific manner was also validated. A3A was found to bind tighter 
to substrate binding motif within a hairpin loop compared to linear 
oligonucleotide, suggesting A3A affinity is modulated by substrate structure. 
Based on these findings and previously published A3A–ssDNA co-crystal 
structures, I proposed a new model with intra-DNA interactions for the molecular 
mechanism underlying A3A sequence preference.  
Crystal structure of DNA-bound A3A elucidates the architecture and 
mechanism of ssDNA recognition that is likely conserved among all 
polynucleotide deaminases, thereby opening the door for the design of 
mechanistic-based therapeutics. The signature sequence and substrate 
structural preferences identified for A3A leads to a new paradigm for identifying 
A3A’s involvement in mutation of endogenous or exogenous DNA. 
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VI.a.2. Nucleic acid-bound structures of APOBECs. 
In Chapter III, I describe the architecture and mechanism of A3A ssDNA 
substrate recognition, which is likely conserved among all polynucleotide 
deaminases. Since Chapter III was published, three other APOBEC-nucleic acid 
structures were solved. Figure VI.1 is a consolidation of key structures discussed 
in Chapter III and Chapter IV (Figure VI.1.A, B, and C), as well as the new 
structures since publication (Figure VI.1.D, E, and F). Comparison of APOBECs 
bound to poly nucleic acids with a substrate cytosine (Figure VI.2.A, B, and F) to 
those without (Figure VI.2.C, D, E, and F) reveal the potential for alternative poly 
nucleic acid binding sites outside of the canonical active site of these proteins. 
 A novel human A3F-CTD co-crystal structure was solved using non-
substrate Poly T ssDNA (Figure VI.1.D) (18). Detailed analysis of A3F-Poly T 
structure will be further examined in section VI.a.3. This structure also reveals a 
unique zinc coordinated dimer interface. As described in Chapter II, our apo A3A 
homodimer crystal structure was also coordinated by zinc. Further studies 
elucidating the role of zinc in modulating APOBEC oligomerization is necessary 
to determine the role of zinc beyond its function in the active site of APOBECs.  
The first ever A3H structure was recently published of a macaque A3H 
(macA3H) bound to dsRNA (Figure VI.1.E) (19). This is also the first structure of 
an APOBEC bound to RNA, albeit of unknown sequence (resolution was not high 
enough to identify the nucleotides of co-purified RNA). Sequence alignment with 
other active APOBEC domains reveal that the residues involved in macA3H-RNA  
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Figure VI.1. Solved structures of APOBEC-poly nucleic acid complexes. 
A. Our crystal structure of human A3A bound to the PolyT-1C ssDNA 
sequence 5’-TTTTTTTTCTTTTTT-3’ (PDB ID: 5KEG). 
B. Human A3B with active site A3A chimera bound to ssDNA 5’-TTTTCAT-3’ 
(PDB ID: 5TD5). 
C. Primate A3G-NTD bound to Poly T ssDNA sequence 5’-TTTTTTTTTT-3’ 
(PDB ID: 5K83). 
D. Human A3F-CTD bound to Poly T ssDNA sequence 5’-TTTTTTTTTT-3’ 
(PDB ID: 5W2M). Note ssDNA and Zinc binding site located outside active 
site. 
E. Macaque A3H bound to dsRNA of unknown sequence (PDB ID: 5W3V). 
F. MBP fused human AID bound to dsDNA sequence 5’-GTTCAAGGCCAG-
3’, 5’-CTGGCCTTGAAC-3’ and deoxycytidine monophosphate (PDB ID: 
5W0U). All protein structures shown in gray transparent surface view and 
cartoon. Zinc shown as marine sphere. Nucleic acid shown as orange sticks.  
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Figure VI.2. Active site view of APOBEC-poly nucleic acid complexes. 
A. PolyT-1C ssDNA with substrate deoxycytidine bound to the active site of 
human A3A (PDB ID: 5KEG). 
B. ssDNA with substrate deoxycytidine bound to active site of human A3B-
active site A3A chimera (PDB ID: 5TD5). 
C. Poly T ssDNA with only substrate deoxycytidine visible and bound to active 
site the Primate A3G-NTD(PDB ID: 5K83). 
D. Poly T ssDNA bound to “back side” of Human A3F-CTD (PDB ID: 5W2M).  
E. dsRNA of unknown sequence bound to the “top” of Macaque A3H(PDB ID: 
5W3V). 
F. deoxycytidine monophosphate bound to active site of MBP fused human 
AID. dsDNA also bound to “top” of protein (PDB ID: 5W0U). 
All protein structures shown in gray cartoon. Zinc shown as marine sphere. 
Nucleic acid shown as orange sticks.  
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Figure VI.3: macA3H RNA binding residues. 
Sequence alignment of human AID, the seven members of the APOBEC3 
subfamily active domains, and macA3H. Orange dots represent macA3H 
residues with side chain interactions with dsRNA, corresponding orange boxes 
to highlight the residue identity of other APOBEC3 at this position. Grey dots 
represent macA3H residues with backbone interactions with dsRNA, 
corresponding grey boxes to highlight the residue identity of other APOBEC3 
at this position. Catalytic glutamate denoted by orange star. Zinc coordinating 
residues denoted with green diamond. Identical residues highlighted in blue, 
residues 80-100% identical in light blue, 60-80% in teal.  Active site loops are 
denoted by red line.  Residues that make up the active site pocket are 
highlighted with red dashed boxes. 
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interactions are not conserved, other than in human A3H (Figure VI.3), 
suggesting this RNA binding mode may be A3H specific.  
The first AID structure was published as MBP-human AID fusion protein 
bound to dsDNA and deoxycytidine monophosphate (Figure VI.1.F and Figure 
VI.2.F) (20). However, AID does not bind to dsDNA in solution and interactions in 
the crystal structure are solely interactions with PO4 backbone. Authors suggest 
dsDNA-AID interaction is a crystallization artifact; dsDNA is stacking in the 
crystal lattice and is likely playing the role of neutralizing repulsion between the 
highly positively charged AID monomers. Despite major efforts from these 
authors, solving a structure of biologically relevant AID bound to substrate DNA 
remains elusive and is still necessary to elucidate the molecular mechanism for 
AID substrate recognition.  
To summarize, the nucleic acid bound structures of APOBEC superfamily 
members reveal both specific and nonspecific modes of binding, some being 
protein specific, while others may be shared within the family. 
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VI.a.3. Implications for the role of A3A homo dimer observed in 
apoA3A structure 
As described in the Chapter II of this thesis, cooperative oligomerization of 
A3A was found to regulate the specific binding of A3A to ssDNA. Additionally, as 
A3A forms multiple oligomeric states in solution. Our apo A3A crystal structure 
reveals A3A as a homodimer with symmetric domain swapping of N-terminal 
residues. Mutating the homodimer interface found in this structure resulted in a 
decrease in affinity for substrate as well as a decrease in Hill coefficient value 
relative to wildtype. These results suggest that the homodimer interface seen in 
our apo-A3A crystal structure mediates A3A cooperative protein-protein 
interactions that affect A3A activity.  
Considering these results, it is reasonable to expect a solved structure of 
A3A-substrate complex to have more than a 1:1 stoichiometry. However, our co-
crystal structure of A3A bound to ssDNA shown in Chapter III revealed a 
monomer in the asymmetric unit, with a 1:1 stoichiometry with ssDNA. The 
apparent discrepancy between the results in Chapter II and the co-complex seen 
in Chapter III may be explained by a new hypothesis for the mechanism for A3A 
substrate binding, in light of the third structure of an A3-substrate complex 
reported after the publication of Chapters II and III.  
Human A3F-CTD bound to a non-substrate Poly T ssDNA revealed a 
novel second non-specific polynucleotide binding site (Figure VI.1.D) (18). This 
novel binding site is located at the “backside” of APOBEC proteins relative to the 
	
	 247	
substrate binding site seen in our A3A-ssDNA structure (Figure VI.2.D). With 
more rigorous structural analysis combined with homology analysis between 
other active APOBEC domains suggest that (Figure VI.4), in contrast with the 
authors conclusions, that this second binding site may in fact be conserved 
through APOBEC proteins. 
The ssDNA used to obtain this co-crystal structure (a poly T 10-mer oligo) 
may not have bound to the active site of A3F-CTD because the sequence did not 
contain a substrate cytidine. The fluorescence anisotropy based binding assays 
described in Chapter II also used poly-T ssDNA as a background sequence for 
studying A3A substrate binding. Using the poly T sequence as a background for 
studying substrate specificity for A3A resulted in a considerable amount of 
background binding, as described in Chapter IV. Therefore, the non-specific 
binding we found in Chapter IV may be due to this second non-specific binding 
site. This second site can also explain the effect of ssDNA length on A3A binding 
affinity to DNA, with longer oligonucleotide binding stronger, as described in 
Chapter IV and previous reports on A3G substrate length dependence (21-23). 
Compilation of A3A-homodimer from Chapter II, A3A-ssDNA structure 
from Chapter III, A3F-CTD-ssDNA structure, and sequence homology studies 
reveal a new model for A3A binding to ssDNA (Figure V1.5 and V1.6). Figure 
VI.5 illustrates the potential for a homodimer of A3A bound to ssDNA in the 
active site as well as the distal nonspecific nucleic acid binding site.  Figure VI.6 
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Figure VI.4. A3F-CTD Poly T ssDNA binding residues. 
A. A3F-CTD backbone interactions with backbone PO4s.  
B. Sequence alignment of residues involved in backbone-backbone protein-
nucleic acid interactions with active APOBEC domains.  
C. Y333 residue side chain base stacking with deoxythymine base. 
D. Sequence alignment of residues involved in aromatic stacking protein-
nucleic acid interactions with active APOBEC domains. 
For A and C, residues 4A away from ssDNA are in green sticks. Hydrogen 
bonds represented as gray dashes. ssDNA represented as orange sticks. 
Oxygen and nitrogen colored as red and blue, respectively.  
For B and D, Sequence alignment of human AID, the seven members of the 
APOBEC3 subfamily active domains, and macA3H. Orange dots represent 
A3F-CTD residues with side chain interactions with ssDNA, corresponding 
orange boxes to highlight the residue identity of other APOBEC3 at this 
position. Grey dots represent A3F-CTD residues with backbone interactions 
with ssDNA, corresponding grey boxes to highlight the residue identity of other 
APOBEC3 at this position. Identical residues highlighted in blue, residues 80-
100% identical in light blue, 60-80% in teal.  
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Figure VI.5: Compilation of A3 apo and bound structures. 
A.  Our co-crystal structure of A3A-ssDNA complex aligned with A3F-CTD 
ssDNA structure. A3A shown as gray cartoon, ssDNA bound to A3A shown in 
green sticks. PolyT ssDNA from A3F-CTD-ssDNA structure depicted as 
orange sticks. Zinc shown as marine sphere.  
B. compiled structure in A. aligned to homodimer in our apo-A3A crystal 
structure. A3A from complex structure shown as gray surface. DNA depicted 
as described for A. 
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Figure VI.6: Proposed model of A3 homodimer cooperatively binding to 
ssDNA. 
A. Compiled structure as in Figure VI.6. ssDNA from solved crystal structures 
depicted in light green sticks. Model of directionality of ssDNA binding shown 
with green arrow. 
B. Compiled structures seen in A, with homologous residues highlighted in 
A3A surface.  
C. 90º rotation of B. with poly T ssDNA from A3F-CTD structure shown in 
orange sticks.  
D. Figure C. with Model of directionality of ssDNA binding shown with green 
arrow. 
Model of directionality of ssDNA binding shown with green arrow. 
A3A from complex structure shown as gray surface. Identical residues 
highlighted in blue, residues 80-100% identical in light blue, 60-80% in teal. 
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illustrates the potential for a homodimer of a A3A binding to two strands of single 
stranded nucleic acid. Note the antiparallel directionality that results from this 
model (Figure VI.6A). Interestingly, this model captures many homologous 
APOBEC residues within in the path of nucleic acid binding (Figure VI.6B, C, 
and D). Additionally, this model requires two A3A proteins to bind one strand of 
single stranded nucleic acid simultaneously (Figure VI.6 D) and would elucidate 
the structural mechanism for cooperative binding observed for A3A, as described 
in Chapter II, A3F and AID (18, 20). Crystallographic, mutational, and 
biochemical studies are necessary to determine the biological relevance of this 
model.   
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VI.a.4. Applications for identifying APOBEC signature 
sequences in a quantitative manner  
The dinucleotide motif, TC, was previously studies identified as A3A 
signature sequence (17, 24, 25). I confirmed and expanded on A3A’s signature 
sequence to the 4-mer motif, (T/C)TC(A/G). The comprehensive identification of 
A3A signature sequences found in chapter IV enables a more accurate 
evaluation of A3A activity based on sequence analysis. Previous studies used 
only a single A3A signature sequence to implicate A3A’s role in viral restriction or 
cancer progression. Since I have identified four almost equivalent substrate 
signature sequences, TTCA, TTCG, CTCA, and CTCG, I propose using a set of 
sequences rather than just one as a more accurate method to identify A3A’s 
involvement in mutagenesis. 
The quantitative and systematic approach I took to determine A3A’s 
signature sequence can also be applied to identifying the signature sequences of 
other APOBECs. To date, no other study has determined any APOBEC signature 
sequence in a comprehensive and quantitative manner. Thus, the signature 
sequences previously identified may not represent the actual signature sequence 
for these enzymes. Additionally, the signature sequence of many other 
APOBECs are unknown outside their dinucleotide sequence motif. Further 
determination of the sequence specificity of other APOBECs will be a strong 
foundation for a more accurate identification of APOBECs role in cancer, viral 
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restriction and other function in the cell that rely on or are effected by 
modifications in ssDNA or RNA. 
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VI.a.5. pH dependence of APOBEC activity 
In chapter IV, a systematic measurement of A3A affinity for signature 
sequence in a broad range of pH values was determined in order to verify and 
quantify the pH dependence of A3A for substrate ssDNA (15, 25).  This pH 
dependency may relate to the cellular compartmentalization of maximal activity.  
A3A was found to have an increase in affinity with a decrease in pH value. The 
structural basis for the pH dependence of A3A as described in chapter III was 
elucidated with analysis of our A3A-DNA co-crystal structure. The bound A3A 
structure shows that the active site His29 in loop 1 of A3A can hydrogen bond 
with the ssDNA backbone and sugar of -1 and 0 nucleotides. This hydrogen bond 
network could only occur at pH values of 6.5 and below, when the histidine is 
protonated. Thus, the protonated state of histidine may be responsible for 
change in affinity seen at different pH values described in chapter IV and 
maximum catalytic activity seen at pH 6.0 in previous studies (15).  
The activity of A3G was also been shown to be pH dependent. Activity 
experiments with A3G-CTD identified an increase in cytidine deamination with 
decrease pH value (2). These authors suggested this pH dependency is due to 
the His216, also located in in loop 1, of the active site of A3G-CTD (2). Thus, 
active site histidines in A3A and A3G may be an inter-protein regulation 
mechanism of enzymatic activity that may be conserved and define specificity 
within the APOBEC super family. Furthermore, A3A and A3G maximum activity 
occurring in the acidic pH range warrants further studies on their role in 
	
	 255	
endosomal related functions, such as foreign DNA sensing and potential 
exosomal related functions, such as cell-cell signaling, embryonic 
morphogenesis, the regulation of host-pathogen interactions, as well as in the 
progression of neurodegenerative pathologies and cancer. 
Through sequence analysis of other ssDNA deaminating APOBECs, I 
found A3H as the only another APOBEC enzyme that has a histidine located 
within its active site (Figure VI.7A). Unlike A3G and A3A, with histidine in loop 1 
of their active sites, the active site histidine of A3H is located in loop 7. Homology 
model of A3H shows that the active site histidine is located in relatively the same 
area as the histidine seen in A3A and A3G, although in this model, A3H active 
site histidine is flipped away from the active site (Figure VI.7B). I propose that 
upon substrate binding, A3H active site histidine could flip back towards the 
active site to make hydrogens bonds with substrate backbone, similar to what 
was seen for A3A.  
A3H is proposed to be the least stable and least active of the APOBECs, 
thus elucidating A3H activity and substrate specificity has remained elusive. 
Studying A3H activity and specificity in a quantitative and systematic way, as 
described in chapter IV for A3A, may reveal conditions in which A3H is more 
active than previously reported. Further studies testing A3H activity and 
specificity is warranted to determine if A3H is also regulated by pH. 
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Figure VI.7 Active site histidines in APOBEC enzymes.  
A. Sequence alignment of active site loops of all members of the APOBEC 
super family. B. Solved structures of A3A and A3G-CTD and homology model 
of A3H. Surface depicted in gray, Z1 domains shown as red cartoon (A3A and 
A3G-CTS), Z3 domain shown as green cartoon (A3H). Active site histidine 
shown as orange stick. Nitrogen and oxygen of histidine base colored blue 
and red respectively. Active site Zinc shown as gray spheres. 
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VI.a.6. Implications of deamination of RNA by APOBEC 
Chapter IV describes for the first time A3A’s ability to bind RNA in a highly 
specific and structural context-dependent manner. Previous reports suggested 
that A3A binds only weakly to RNA and is not an RNA deaminase, however 
these experiments were performed with unstructured RNA (23). Our results on 
A3A binding to hairpin RNA and not linear ssRNA, along with a recent study  
describing A3A preference for deaminating cytidines in the loop region of stable 
RNA hairpins demonstrates that A3A’s RNA deamination activity is highly 
dependent on sequence context and secondary structure (26) .  
 Analysis of our A3A-ssDNA structure from Chapter III also illustrates a 
potential structural basis for A3A binding and deaminating RNA. A3A can 
conceivably bind RNA in the same manner as substrate DNA. The extra oxygen 
of the cytidine sugar could be easily accommodated by the highly conserved 
residue Tyr130 and the zinc coordinating His70 (Figure VI.8A and B). Other 
RNA ribose oxygens in close proximity to A3A are at the -1 and -2 position and 
could also be accommodated for by residues Tyr132, Gly27, and His29 (Figure 
VI.8C and D).  A crystal structure of A3A bound to RNA is essential for 
determining the mechanism of A3A deamination of RNA as well as providing a 
foundation for using structural analysis to identify other A3s with the potential to 
deaminate RNA. A3As ability to edit RNA opens up a new dimension of potential 
substrates that would augment the biological role of this enzyme. 
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Figure	VI.8.	Potential	structural	mechanism	for	A3A	binding	RNA		
A.	Our	A3A-PolyT-1C	co	crystal	structure	(PDB	ID_	5KEG):	and	B.	A3A-ATCG	structure	
(PDB	ID:	5SWW)	illustrating	substrate	cytidine	and	A3A	residues	near	where	the	extra	
Oxygen	would	be	in	an	RNA	cytidine	substrate.		
C.	Residues	near	-1T	and	D.	near	-2A	oxygen	in	PDB	5SWW.	
A3A	residues	in	proximity	to	extra	oxygen	on	RNA	ribose	are	shown	as	purple	sticks.	
DNA	shown	in	orange.	Location	of	extra	oxygen	depicted	in	green.	catalytic	zinc	in	
gray-blue	spheres,	active	site	oxygen	shown	in	red	sphere.	Oxygen	and	Nitrogens	are	
colored	red	and	blue	respectively.			
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VI.b.1. Elucidating the structural basis for mutation-induced 
destabilization of profilin 1 in ALS 
Profilin-1 is a small protein that binds monomeric actin to enhance actin 
polymerization, a critical process for axon outgrowth in motor neurons. Mutations 
in the PFN1 gene were recently associated with both familial and sporadic forms 
of ALS (12, 27). Although ALS-linked mutations have been shown to induce 
PFN1 aggregation, the effect of these mutations on protein stability and structure 
has not been studied (12). Chapter V focuses on determining what effect these 
disease-causing mutants have on the structure and stability of PFN1 in order to 
elucidate the mechanism of pathogenicity of these single point mutants.  
To visualize the effects disease causing single point mutants have on the 
structure of PFN1, I solved the crystal structures for three PFN1 proteins, 
including the WT protein. Analysis of these crystal structures revealed that the 
M114T mutation creates a cleft that extends into the interior of PFN1 compared 
the WT PFN1 structure. Additionally, I developed a model that illustrates the 
most severely destabilizing C71G mutation creates a cavity near the core of the 
PFN1 protein, proximal to the cleft formed by M114T. This model is based on 
studied on other proteins demonstrating that single point mutants which create 
non-surface exposed cavities can severely destabilize a protein’s native 
conformation (28, 29). The structure of E117G, a variant predicted to have low 
pathogenicity, closely resembled WT PFN1 structure, thus reconciling the 
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occurrence of this mutation in control populations in previous studies (12).  
Overall, Chapter V implicates a destabilized form of PFN1 in ALS pathogenesis. 
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VI.b.2. Characterizing the conformation and local stability of 
PFN1-ALS mutants in solution. 
In Chapter V, the effects of two of the four ALS associated mutant PFN1 
mutants on PFN1 structure were elucidated. Although many crystal trials were 
performed for the remaining two mutants, structures of G118V and C71G remain 
elusive. To characterize PFN1 mutants not conducive for crystallographic 
studies, I propose studying the low-energy native states of these mutants in 
solution using hydrogen exchange (HX) coupled with high-resolution mass 
spectrometry (MS). This approach may also be used to study M114T in 
conjunction with the structural analysis described in Chapter V. Specifically, 
results from HX-MS could determine if the cleft revealed through our structural 
analysis reflect those found for PFN1 M114T in solution. Furthermore, with 
native-state HX-MS one could characterize the local stability of PFN1-ALS 
mutants in solution through characterization of their high-energy states. Since 
partial unfolding of a protein can cause it to aggregate, identifying changes in the 
local stability of these mutants may help explain why these mutants are more 
prone to aggregation. 
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VI.b.3. Elucidating the role of single point mutations on the 
function of PFN1. 
PFN1 is best known for its role in actin dynamics in the context of 
endocytosis, membrane trafficking, cell motility, and neuronal growth and 
differentiation (30). In addition to binding monomeric or G-actin, PFN1 also binds 
to a host of different proteins through their poly- L-proline motifs and to lipids 
such as phosphatidylinositol 4,5- bisphosphate (30, 31). Beyond the effects of 
single point mutants on protein stability, determining PFN1 disease causing 
mutants effects on ligand binding could further elucidate mechanisms that 
contribute to the mutations pathogenicity. 
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VI.b.4. Designing small molecule therapies to stabilize PFN1 
disease causing mutants.  
Data described in Chapter V identify misfolded and destabilized PFN1 as 
a potential upstream trigger of the adverse events that culminate in ALS, opening 
up new avenues for therapeutic approaches for ALS. One approach to designing 
therapies for PFN1 associated ALS is to develop specific pharmacological 
chaperones for each ALS causing mutant of PFN1. For example, a small 
molecule that fills the cleft formed by the M114T mutation or the putative cavity 
formed by C71G mutation could be designed to stabilize PFN1. Stabilizing ALS-
PFN1 has the potential to restore the normal structure and function of the protein, 
thereby preventing the pathogenic cascade leading to ALS. 
Another therapeutic approach was developed based on the stabilizing 
effects of poly-L-proline on mutant PFN1 shown in Chapter V. We hypothesize 
that designing small-molecules that bind to allosteric regions of mutant PFN1 
could stabilize PFN1. An allosteric stabilizer of PFN1 may allow for a therapy that 
could be used for any PFN1 ALS associated mutant. 
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